ingest/c2m2s/GlyGen/glygen_cfde_2025_dec_data_submission/glygen_cfde_2025_sept_data_submission/protein.tsv:P47031	IML2_YEAST	Inclusion body clearance protein IML2	["D6VWA1", "Increased minichromosome loss protein 2"]	NCBI:txid559292
ingest/c2m2s/GlyGen/glygen_cfde_2025_dec_data_submission/glygen_cfde_2025_sept_data_submission/protein.tsv:Q55F80	Q55F80_DICDI	Viral A-type inclusion protein	[]	NCBI:txid44689
ingest/c2m2s/GlyGen/glygen_cfde_2025_dec_data_submission/glygen_cfde_2025_sept_data_submission/protein.tsv:Q69ZR9	TASOR_MOUSE	Protein TASOR	["E9PUH2", "Q9CUD3", "Transgene activation suppressor protein"]	NCBI:txid10090
ingest/c2m2s/GlyGen/glygen_cfde_2025_dec_data_submission/glygen_cfde_2025_sept_data_submission/protein.tsv:Q9UK61	TASOR_HUMAN	Protein TASOR	["Q9UPP7", "Q9H2F7", "Transgene activation suppressor protein", "Retinoblastoma-associated protein RAP140", "A1L3A4", "CTCL tumor antigen se89-1", "B5ME28"]	NCBI:txid9606
ingest/c2m2s/HMP/datapackage/merged/data/file.tsv:tag:hmpdacc.org,2022-04-04:	SRR6697898_SRS2933504_summary_stats.json	tag:hmpdacc.org,2022-04-04:	MOMSPI	drs://drs.hmpdacc.org/1Fn14Lgbtb34X		1057	1057	851de0a741d4a7cc2d72e9e39b17d7b76d920e228132055651abe1f947d6beb3	9373eaf701845dbecb8c86a9bf0f7255	SRR6697898_SRS2933504_summary_stats.json	format:3464		data:2048	OBI:0002763					
ingest/c2m2s/HMP/datapackage/merged/data/file.tsv:tag:hmpdacc.org,2022-04-04:	SRR6698686_SRS2934224.filtered.fastq.bz2	tag:hmpdacc.org,2022-04-04:	MOMSPI	drs://drs.hmpdacc.org/LgBTh4K9pKDw		2700058	22137780	906f7c4ff87370bda15a0e018d0bcc9ed949ff80b25d67d7c494a9c3e884e253	62fa8bf9383254f8f3b8d0a1ac22bbe7	SRR6698686_SRS2934224.filtered.fastq.bz2	format:1930		data:3494	OBI:0002763					
ingest/c2m2s/HMP/datapackage/merged/data/file.tsv:tag:hmpdacc.org,2022-04-04:	CSM67UB9_ecs.tsv.bz2	tag:hmpdacc.org,2022-04-04:	IBDMDB	drs://drs.hmpdacc.org/i6rLBLgbtiNg		32360	304050	a6c5cf83826523c3105ee0f2af813d6b307ba05964c4f6a21b065288e98a0420	18299016dc32dc01c2dee4ad75a61bfa	CSM67UB9_ecs.tsv.bz2	format:3475		data:0907	OBI:0002760					
ingest/c2m2s/HMP/datapackage/merged/data/project.tsv:tag:hmpdacc.org,2022-04-04:	HHS			HHS	Healthy Human Subjects	The Healthy Human Subjects project is part of phase 1 of the Human Micrbiome Project and involved characterization of the normal microbiota from 300 healthy adults. It entailed sampling from 18 body sites in women and 15 in men (excluding three vaginal sites) distributed among five major body areas. The samples were subjected to 454 pyrosequencing for 16S rRNA gene analysis to characterize the complexity of microbial communities. For a subset of the samples, Illumina whole metagenome sequencing was done for taxonomic profiling, metabolic profiling, gene finding, and gene annotation. Numerous additional analyses were performed on the data.
ingest/c2m2s/HMP/datapackage/merged/data/project.tsv:tag:hmpdacc.org,2022-04-04:	MOMSPI			MOMSPI	Multi-Omic Microbiome Study-Pregnancy Initiative	This project characterized the microbiomes of pregnant women to gauge microbiome effects on risk of preterm birth (PTB). The project followed 1,527 women longitudinally through pregnancy and involved the collection of 206,437 samples, including maternal vaginal, buccal, rectal, skin and nares swabs, blood, urine, and birth products, as well as infant cord and cord blood, meconium and first stool, buccal, skin and rectal swabs. Subsets of these specimens underwent 16S rRNA gene taxonomic analysis, metagenomic and metatranscriptomic sequencing, cytokine profiling, lipidomics analysis, and bacterial genome analysis.
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/collection.tsv:https://druggablegenome.net/cfde_idg_tcrd_diseases	DISEASE_DOID_3429	https://druggablegenome.net/cfde_idg_tcrd_diseases..collection_DISEASE_DOID_3429	2023-06-07	tcrd_disease_DOID_003429_collection	DiseasePage Collection: DOID:3429	DiseasePage Collection: Myositis, Inclusion Body (DOID:3429, FILE=tcrd_disease_DOID_003429.json)	
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/collection.tsv:https://druggablegenome.net/cfde_idg_tcrd_diseases	DISEASE_DOID_11259	https://druggablegenome.net/cfde_idg_tcrd_diseases..collection_DISEASE_DOID_11259	2023-06-07	tcrd_disease_DOID_011259_collection	DiseasePage Collection: DOID:11259	DiseasePage Collection: cytomegalic inclusion disease (DOID:11259, FILE=tcrd_disease_DOID_011259.json)	
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/compound.tsv:338	Salicylic acid	nan	["salicylic acid", "2-Hydroxybenzoic acid", "69-72-7", "o-hydroxybenzoic acid", "2-Carboxyphenol", "o-Carboxyphenol", "Rutranex", "Salonil", "Retarder W", "Keralyt", "Duoplant", "Freezone", "Saligel", "Ionil", "Psoriacid-S-stift", "Benzoic acid, 2-hydroxy-", "Stri-Dex", "Salicylic acid soap", "Salicylic acid collodion", "Verrugon", "Phenol-2-carboxylic acid", "Acidum salicylicum", "Trans-Ver-Sal", "Orthohydroxybenzoic acid", "2-Hydroxybenzenecarboxylic acid", "Acido salicilico", "Ionil-Plus", "Salicylic acid, tech.", "Kyselina salicylova", "Clear away wart remover", "Duofil wart remover", "Domerine", "Sebucare", "Duofilm", "Sebulex", "Salicyclic acid", "Ionil plus", "Dr. Scholl's corn removers", "Kyselina salicylova [Czech]", "Dr. Scholl's callus removers", "Dr. Scholl's wart remover kit", "Kyselina 2-hydroxybenzoova", "Occlusal", "Acido salicilico [Italian]", "Advanced pain relief corn removers", "Caswell No. 731", "2-hydroxy-benzoic acid", "Kyselina 2-hydroxybenzoova [Czech]", "Advanced pain relief callus removers", "Acido o-idrossibenzoico [Italian]", "NSC 180", "Salicylic acid & Sulfur Soap", "CCRIS 6714", "HSDB 672", "AI3-02407", "UNII-O414PZ4LPZ", "MFCD00002439", "EPA Pesticide Chemical Code 076602", "BRN 0774890", "CHEBI:16914", "CHEMBL424", "O414PZ4LPZ", "MLS000069653", "NSC180", "Salicylic acid inclusion complex", "K 537", "NSC-180", "ATA fraction 10, ammonium salt", "NCGC00159447-05", "SMR000059163", "Mediplast pads", "Akurza Lotion", "Hydrisalic Gel", "Akurza Cream", "Salex Lotion", "Salex Cream", "DSSTox_CID_6368", "DuoPlant Gel", "DHS Sal Shampoo", "DSSTox_RID_78106", "P&S Shampoo", "DSSTox_GSID_26368", "Salicylic acid [USAN:JAN]", "Acido o-idrossibenzoico", "Durasal", "salicylicum acidum", "CAS-69-72-7", "Propa pH Peel-Off Acne Mask", "NSC629474", "phenol derivative, 7", "Salicylic acid (TN)", "Benzoic acid, 2-hydroxy-, ion(1-)", "EINECS 200-712-3", "Salicylic acid [USP:JAN]", "Azurechelin", "Salicylic acid (6CI,8CI)", "salicylic-acid", "Anti-blemish", "Salicylic acid rs", "hydroxy-benzoic acid"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/compound.tsv:4201	Minoxidil	nan	["minoxidil", "38304-91-5", "Rogaine", "Loniten", "Regaine", "Minoximen", "Theroxidil", "Lonolox", "6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide", "2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide", "C9H15N5O", "U-10858", "3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine", "CHEBI:6942", "6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide", "Tricoxidil", "6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine", "Alopexil", "Alostil", "MFCD00063409", "Minodyl", "MLS000028566", "Normoxidil", "Minossidile [Italian]", "Minoxidilum [INN-Latin]", "NCGC00015673-08", "Minoxidilum", "SMR000058963", "6-amino-2-imino-4-(piperidin-1-yl)-1,2-dihydropyrimidin-1-ol", "CAS-38304-91-5", "Apo-Gain", "U10858", "DSSTox_CID_20685", "DSSTox_RID_79541", "6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide", "DSSTox_GSID_40685", "RiUP", "6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide", "2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate", "Neoxidil", "Avacor and Mintop", "SMR000326812", "Loniten (TN)", "Rogaine (TN)", "Riup (TN)", "2,4-Diamino-6-piperidinopyrimidine 3-oxide", "SR-01000075331", "SR-05000001479", "3-oxido-6-piperidin-1-ylpyrimidin-3-ium-2,4-diamine", "U-10,858", "Kopdil", "Regaine For Men", "Minoxidil,(S)", "Regaine For Women", "UNII-5965120SH1", "Prestwick_521", "3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine", "TM-160", "Men''''s Rogaine", "Women''''s rogaine", "6-amino-2-imino-4-(piperidin-1-yl)pyrimidin-1(2H)-ol", "Rogaine Extra Strength", "pyrimidin-1(2H)-ol", "Spectrum_000969", "Tocris-0583", "Minoxidil Extra Strength", "regid855572", "Opera_ID_1150", "Prestwick0_000020", "Prestwick1_000020", "Prestwick2_000020", "Prestwick3_000020", "Spectrum2_001053", "Spectrum3_000509", "Spectrum4_000063", "Spectrum5_001299", "Lopac-M-4145", "M1389", "CHEMBL802", "M 4145", "Minoxidil (JAN/USP/INN)", "CBiol_001798", "Lopac0_000786", "SCHEMBL29698", "BSPBio_000059", "BSPBio_001385", "BSPBio_002037", "KBioGR_000105", "KBioGR_000585", "KBioSS_000105", "KBioSS_001449", "MLS000859953", "MLS001077294", "DivK1c_000160", "SCHEMBL232565", "SPECTRUM1500415", "SPBio_001006", "SPBio_001980", "BPBio1_000065", "CHEMBL609587"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/compound.tsv:4634	Oxybutynin	nan	["oxybutynin", "5633-20-5", "Ditropan", "Oxytrol", "Oxibutyninum", "Oxybutyninum", "Oxybutynine", "Oxibutinina", "Oxybutynine [INN-French]", "Oxybutyninum [INN-Latin]", "Oxybutinin", "Oxibutinina [INN-Spanish]", "(RS)-oxybutynin", "4-Diethylamino-2-butinyl alpha-cyclohexylmandelat", "Ditropan Xl", "Oxybutynin (Ditropan)", "4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate", "4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate", "4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate", "CHEMBL1231", "CHEBI:7856", "4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester", "5633-20-5 (free)", "Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester", "MFCD00865252", "Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester", "kentera", "Cystrin", "4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate", "Oxybutynin Base", "Anturol", "transdermal patch", "Lyrinel XL", "Oxytrol for Women", "Oxybutynin [USAN:INN:BAN]", "CCRIS 1923", "Oxybutynin transdermal", "oxybutynin topical gel", "HSDB 3270", "Oxybutynin transdermal patch", "Anturol (TN)", "Oxytrol (TN)", "Oxybutynin (USAN/INN)", "Prestwick0_000287", "Prestwick1_000287", "Prestwick2_000287", "Prestwick3_000287", "SCHEMBL2992", "Lopac0_000923", "BSPBio_000194", "GTPL359", "MLS006010052", "SPBio_002413", "BPBio1_000214", "DTXSID0023406", "OXYBUTYNIN, Oxybutynin chloride", "CHEBI:144551", "HMS3884K08", "BCP12179", "HY-B0267", "AB7701", "BDBM50165019", "s1754", "AKOS015896242", "Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester", "AC-2153", "CCG-205005", "DB01062", "KS-5221", "MCULE-3407007074", "SDCCGSBI-0050898.P003", "MRF-0000601", "(+/-)-OXYBUTYNIN(Hydrochloride form)", "NCGC00015767-03", "NCGC00015767-04", "NCGC00015767-06", "NCGC00015767-07", "NCGC00015767-09", "NCGC00015767-10", "NCGC00015767-21", "NCGC00089795-02", "O222", "SMR001550466", "SBI-0050898.P002", "AB0013281", "FT-0603679", "SW196787-3", "C07360", "D00465", "27815-EP2269989A1", "27815-EP2275420A1", "27815-EP2280008A2", "27815-EP2298767A1", "27815-EP2314587A1", "633O205", "A831004", "L000923", "Q1060922", "BRD-A65013509-003-03-8", "BRD-A65013509-003-13-7"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/disease.tsv:DOID:11573	listeriosis	A primary bacterial infectious disease that results_in infection, has_material_basis_in Listeria monocytogenes, which is transmitted_by ingestion of contaminated food or raw milk or transmitted_by congenital method. Ingestion of Listeria by pregnant women has_symptom nausea, has_symptom vomiting, has_symptom diarrhea, has_symptom fever, has_symptom malaise, has_symptom back pain, and has_symptom headache. Maternal infection with Listeria can result in chorioamnionitis, premature labor, spontaneous abortion, or stillbirth.	["Infection by Listeria monocytogenes","Listeria infection"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/disease.tsv:DOID:12217	Lewy body dementia	A dementia that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.	["Dementia with Lewy bodies","Diffuse Lewy body disease","Lewy body disease","Senile dementia of the Lewy body type"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/disease.tsv:DOID:2272	vulvovaginal candidiasis	A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.	["Candidal vulvovaginitis","Candidal: cervix","Candidiasis of vulva and vagina","Monilial vulvovaginitis","Vulvovaginal Candidiasis"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/disease.tsv:DOID:3016	breast malignant phyllodes tumor	A breast cancer that is characterized by a prominent infiltrative border, unequivocal sarcomatous areas, and stromal overgrowth and arises_from the stroma, lined by an epithelial and myoepithelial bilayer, forming a leaflike structure. They tend to grow rapidly and present in middle-aged women (40s-50s).	["DOID:1632","DOID:3018","breast malignant phyllodes tumour","malignant cystosarcoma phyllodes","malignant Mammary Phyllodes tumor","malignant Mammary Phyllodes tumour","malignant Phyllodes neoplasm","malignant phyllodes tumor","malignant phyllodes tumor of breast","malignant phyllodes tumour","malignant phyllodes tumour of breast","Phyllodes breast neoplasm","phyllodes breast tumor","phyllodes breast tumour","Phyllodes tumor, malignant"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/disease.tsv:DOID:3429	inclusion body myositis	A myositis that is characterized by late onset of skeletal muscle inflammation, weakness, and atrophy with cytoplasmic granules and vacuoles in the muscle.	[]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/disease.tsv:DOID:5426	primary ovarian insufficiency	An ovarian disease where ovaries do not produce estrogen despite high levels of circulating gonadotropins in women under 40.	["hypergonadotropic hypogonadism","premature menopause","premature ovarian failure","premature ovarian insufficiency","primary ovarian insufficiency"]
ingest/c2m2s/IDG/IDG_C2M2_2024-01-09_datapackage_validated/merged-datapackage_cba63847d02e8ee1ccf150a98ebe814be895333c/data/disease.tsv:DOID:9478	postpartum depression	An endogenous depression that involves intense, sustained and sometimes disabling depression experienced by women after giving birth.	["Maternity blues","postnatal depression"]
ingest/c2m2s/LINCS/datapackage/compound.tsv:2730	Chlorpyrifos		["chlorpyrifos", "2921-88-2", "Dursban", "Chlorpyriphos", "Lorsban", "Trichlorpyrphos", "Brodan", "Coroban", "Chlorpyrifos-ethyl", "Piridane", "Equity", "Lentrek", "Pyrinex", "Stipend", "Lock-On", "Chloropyrifos", "Killmaster", "Bonidel", "Danusban", "Geodinfos", "Spannit", "Tafaban", "Dowco 179", "Durmet", "Radar", "Terial", "Zidil", "Suscon blue", "Suscon green", "suSCon", "Dursban F", "Dursban R", "Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester", "Dursban 4E", "O,O-Diethyl O-3,5,6-trichloro-2-pyridyl phosphorothioate", "Chlorpyriphos-ethyl", "Ethyl chlorpyriphos", "Dursban 10CR", "Chlorpyrifos (Dursban)", "Chlorpyrifos ethyl", "Detmol U.A.", "Empire 20", "Chlorpyrifos [BAN]", "Chloropyriphos", "Chlorpyrofos", "Chlorpyrophos", "Pageant", "Silrifos", "m-Chlorpyrifos", "XRM 429", "OMS-0971", "XRM 5160", "Dursban 2E", "ENT 27311", "Clorpyrifos", "ENT-27311", "O,O-Diethyl O-(3,5,6-trichloro-2-pyridinyl)phosphorothioate", "NSC-755891", "Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridyl) ester", "Bonidel; CPF Zamba; Chlora;", "MLS001065609", "JCS58I644W", "O,O-Diaethyl-O-3,5,6-trichlor-2-pyridylmonothiophosphat", "O,O-diethyl O-(3,5,6-trichloropyridin-2-yl) thiophosphate", "DTXSID4020458", "CHEBI:34631", "2-Pyridinol, 3,5,6-trichloro-, O-ester with O,O-diethyl phosphorothioate", "Chlorpyrifos (BAN)", "Dhanusban", "o,o-Diethyl-o-(3,5,6-trichloro-2-pyridyl)phosphorothioate", "SMR000568474", "Grofo", "Detmol ua", "Radar (fungicide)", "Dursban 44", "Lorsban 50SL", "DTXCID80458", "Terial 40L", "O,O-Diethyl O-(3,5,6-Trichloro-2-pyridyl) phosphorothioate", "Caswell No. 219AA", "O,O-diethyl O-(3,5,6-trichloropyridin-2-yl) phosphorothioate", "diethoxy-sulfanylidene-[(3,5,6-trichloro-2-pyridinyl)oxy]phosphorane", "Chlorpyriphos [ISO-French]", "CAS-2921-88-2", "CCRIS 7144", "HSDB 389", "Chlorpyrifos [ANSI:BSI:ISO]", "EINECS 220-864-4", "EPA Pesticide Chemical Code 059101", "BRN 1545756", "pridane", "UNII-JCS58I644W", "Warhawk", "Bolton", "Detmol", "Tricel", "Nufos", "AI3-27311", "diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxy-?^{5}-phosphane", "Zodiac (TN)", "Chlorpyrifos (ethyl)", "Spectrum_001897", "O,O-Diethyl O-(3,5,6-trichloro-2-pyridyl) phsophorothioate", "SpecPlus_000518", "diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxyphosphorane", "O,O-Diaethyl-O-3,5,6-trichlor-2-pyridylmonothiophosphat [German]", "Spectrum2_001230", "Spectrum3_000849", "Spectrum4_000689", "Spectrum5_002014", "CHLORPYRIFOS [MI]", "CHLORPYRIFOS [ISO]", "CHLORPYRIFOS [HSDB]", "cid_2730", "Dursban, analytical standard", "BIDD:PXR0044", "SCHEMBL21680", "BSPBio_002437", "CHLORPYRIFOS [MART.]", "KBioGR_001157", "KBioSS_002427", "SPECTRUM330058", "DivK1c_006614", "SPBio_001080", "CHEMBL463210", "BDBM74063", "KBio1_001558", "KBio2_002421", "KBio2_004989", "KBio2_007557", "KBio3_001937", "SBPBAQFWLVIOKP-UHFFFAOYSA-", "OMS 971", "HMS3039C03", "HMS3264O03", "O,O-Diethyl-O-(3,5,6-trichloro-2-pyridyl)phosphorothiolate", "Pharmakon1600-00330058", "HY-B0815", "O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) phosphorothioate", "Tox21_202383", "Tox21_300148", "AC-993", "CCG-39144", "MFCD00041800", "NSC755891", "AKOS015891656", "Chlorpyrifos 100 microg/mL in Acetone", "ENT 27,311", "KS-5372", "NSC 755891", "Chlorpyrifos 1000 microg/mL in Acetone", "Chlorpyrifos 1000 microg/mL in Toluene", "NCGC00091472-01", "NCGC00091472-02", "NCGC00091472-03", "NCGC00091472-04", "NCGC00091472-05", "NCGC00091472-06", "NCGC00091472-07", "NCGC00091472-08", "NCGC00091472-09", "NCGC00253974-01", "NCGC00259932-01", "Chlorpyrifos 10 microg/mL in Cyclohexane", "Chlorpyrifos 100 microg/mL in Cyclohexane", "SBI-0052543.P002", "Chlorpyrifos 100 microg/mL in Acetonitrile", "CS-0012832", "FT-0698165", "D07688", "H10426", "AB00053051_06", "Chlorpyrifos, PESTANAL(R), analytical standard", "A819822", "Q414915", "SR-01000854727", "J-017440", "SR-01000854727-2", "BRD-K08303368-001-02-7", "BRD-K08303368-001-06-8", "Chlorpyrifos, certified reference material, TraceCERT(R)", "O,O-Diethyl O-3,5,6-trichloro-2-pyridylphosphorothioate", "diethoxy-thioxo-[(3,5,6-trichloro-2-pyridyl)oxy]phosphorane", "O,O-Diethyl o-(3,5,6-trichloro-2-pyridinyl) thiophosphate #", "diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxy--phosphane", "ethyl 3,5,6-trichloropyridin-2-yl ethoxy(sulfanylidene)phosphonite", "O,O-DIETHYL O-3,5,6-TRICHLOROPYRIDIN-2-YL PHOSPHOROTHIOATE", "diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxy-lambda5-phosphane", "diethoxy-sulfanylidene-[3,5,6-tris(chloranyl)pyridin-2-yl]oxy--phosphane", "diethoxy-sulfanylidene-[3,5,6-tris(chloranyl)pyridin-2-yl]oxy-$l^{5}-phosphane"]
ingest/c2m2s/LINCS/datapackage/compound.tsv:4201	Minoxidil		["minoxidil", "38304-91-5", "Rogaine", "Loniten", "Minoximen", "Regaine", "Theroxidil", "Alopexil", "Alostil", "Tricoxidil", "Lonolox", "Normoxidil", "Prexidil", "Minodyl", "Pierminox", "RiUP", "Mintop", "2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide", "U-10858", "6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide", "3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine", "CHEBI:6942", "6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide", "U-10,858", "6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine", "NSC-757106", "MLS000028566", "DTXSID9040685", "Minossidile [Italian]", "Minoxidilum [INN-Latin]", "NCGC00015673-08", "Minoxidilum", "SMR000058963", "6-amino-2-imino-4-(piperidin-1-yl)-1,2-dihydropyrimidin-1-ol", "CAS-38304-91-5", "Apo-Gain", "U10858", "6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide", "2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate", "DTXCID7020685", "Neoxidil", "Avacor and Mintop", "SMR000326812", "Loniten (TN)", "Rogaine (TN)", "Riup (TN)", "2,4-Diamino-6-piperidinopyrimidine 3-oxide", "SR-01000075331", "SR-05000001479", "MFCD00063409", "3-oxido-6-piperidin-1-ylpyrimidin-3-ium-2,4-diamine", "Kopdil", "Regaine For Men", "Minoxidil,(S)", "Regaine For Women", "Prestwick_521", "3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine", "TM-160", "Men''''s Rogaine", "Women''''s rogaine", "Rogaine Extra Strength", "pyrimidin-1(2H)-ol", "Spectrum_000969", "Tocris-0583", "MINOXIDIL [INN]", "MINOXIDIL [JAN]", "MINOXIDIL [MI]", "Minoxidil Extra Strength", "MINOXIDIL [HSDB]", "MINOXIDIL [INCI]", "MINOXIDIL [USAN]", "regid855572", "Opera_ID_1150", "Prestwick0_000020", "Prestwick1_000020", "Prestwick2_000020", "Prestwick3_000020", "Spectrum2_001053", "Spectrum3_000509", "Spectrum4_000063", "Spectrum5_001299", "Lopac-M-4145", "MINOXIDIL [VANDF]", "M1389", "CHEMBL802", "MINOXIDIL [MART.]", "M 4145", "MINOXIDIL [USP-RS]", "MINOXIDIL [WHO-DD]", "Minoxidil (U-10858)", "Minoxidil (JAN/USP/INN)", "CBiol_001798", "Lopac0_000786", "SCHEMBL29698", "BSPBio_000059", "BSPBio_001385", "BSPBio_002037", "KBioGR_000105", "KBioGR_000585", "KBioSS_000105", "KBioSS_001449", "6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide", "MLS000859953", "MLS001077294", "DivK1c_000160", "SCHEMBL232565", "SPECTRUM1500415", "SPBio_001006", "SPBio_001980", "BPBio1_000065", "CHEMBL609587", "GTPL4254", "Minoxidil, >=99% (TLC)", "SGCUT00112", "MINOXIDIL [ORANGE BOOK]", "6-amino-2-imino-4-(piperidin-1-yl)pyrimidin-1(2H)-ol", "CHEMBL1372483", "MINOXIDIL [EP MONOGRAPH]", "BCBcMAP01_000193", "BDBM81463", "CHEBI:92128", "HMS500H22", "KBio1_000160", "KBio2_000105", "KBio2_001449", "KBio2_002673", "KBio2_004017", "KBio2_005241", "KBio2_006585", "KBio3_000209", "KBio3_000210", "KBio3_001537", "MINOXIDIL [USP MONOGRAPH]", "NINDS_000160", "BCPP000162", "Bio1_000084", "Bio1_000573", "Bio1_001062", "Bio2_000105", "Bio2_000585", "HMS1361F07", "HMS1568C21", "HMS1791F07", "HMS1920P03", "HMS1989F07", "HMS2089L08", "HMS2091F20", "HMS2095C21", "HMS2233E04", "HMS2235N21", "HMS3259P21", "HMS3262M14", "HMS3266O06", "HMS3371E15", "HMS3372M19", "HMS3402F07", "HMS3411G16", "HMS3675G16", "HMS3712C21", "Pharmakon1600-01500415", "ACT04612", "BCP01409", "CAS_4201", "HY-B0112", "NSC_4201", "to_000070", "Tox21_110193", "Tox21_500786", "BDBM50237593", "CCG-40112", "HB1094", "NSC757106", "s1383", "STL453211", "AKOS015920078", "AKOS016339636", "Tox21_110193_1", "6-amino-2-imino-4-(piperidin-1-yl)", "AC-5271", "BCP9000929", "CCG-220020", "CS-1867", "DB00350", "GS-3605", "KS-5164", "LP00786", "NC00686", "SDCCGSBI-0050764.P005", "IDI1_000160", "IDI1_033855", "SMP1_000192", "NCGC00015673-01", "NCGC00015673-02", "NCGC00015673-03", "NCGC00015673-04", "NCGC00015673-05", "NCGC00015673-06", "NCGC00015673-07", "NCGC00015673-09", "NCGC00015673-10", "NCGC00015673-11", "NCGC00015673-13", "NCGC00015673-20", "NCGC00018278-01", "NCGC00018278-02", "NCGC00018278-03", "NCGC00018278-04", "NCGC00024666-01", "NCGC00024666-02", "NCGC00024666-03", "NCGC00024666-04", "NCGC00024666-05", "NCGC00024666-06", "NCGC00024666-07", "NCGC00024666-08", "NCGC00179672-01", "NCGC00261471-01", "16317-69-4", "BD164673", "SBI-0050764.P004", "2,6-Diamino-4-piperidinopyrimidine 1-Oxide", "5965120SH1", "AB00513797", "EU-0100786", "FT-0620793", "D00418", "EN300-121204", "H10337", "O10620", "6-(1-Piperidinyl)-2,4-pyrimidinediamine3-oxide", "AB00052047-08", "AB00052047_09", "AB00052047_10", "AB00513797-02", "A824098", "Q424165", "Q-201408", "SR-01000075331-1", "SR-01000075331-3", "SR-01000075331-5", "SR-05000001479-1", "SR-05000001479-2", "2,4-DIAMINO-6-PIPERIDINOPYRIMIDINE 3-OXIDE.", "3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine", "BRD-K06902185-001-05-2", "BRD-K06902185-001-10-2", "BRD-K14888893-001-02-3", "Minoxidil, British Pharmacopoeia (BP) Reference Standard", "Z1541638524", "Minoxidil, European Pharmacopoeia (EP) Reference Standard", "2-azanylidene-3-oxidanyl-6-piperidin-1-yl-pyrimidin-4-amine", "6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidino-pyrimidine", "Minoxidil, United States Pharmacopeia (USP) Reference Standard", "Minoxidil for system suitability, European Pharmacopoeia (EP) Reference Standard"]
ingest/c2m2s/LINCS/datapackage/compound.tsv:4634	Oxybutynin		["oxybutynin", "5633-20-5", "Ditropan", "Oxytrol", "Oxibutyninum", "kentera", "Oxybutyninum", "Oxybutinin", "Oxybutynine", "Oxibutinina", "Oxybutynine [INN-French]", "Oxybutyninum [INN-Latin]", "Oxibutinina [INN-Spanish]", "4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate", "4-Diethylamino-2-butinyl alpha-cyclohexylmandelat", "Ditropan Xl", "Oxybutynin (Ditropan)", "4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate", "4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate", "CHEMBL1231", "CHEBI:7856", "4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester", "K9P6MC7092", "5633-20-5 (free)", "Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester", "Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester", "Cystrin", "Oxybutynin Base", "Anturol", "4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate", "transdermal patch", "(R)-4-(Diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate", "Lyrinel XL", "Oxytrol for Women", "Oxybutynin [USAN:INN:BAN]", "CCRIS 1923", "Oxybutynin transdermal", "oxybutynin topical gel", "HSDB 3270", "Oxybutynin transdermal patch", "Oxybutinyn", "UNII-K9P6MC7092", "(RS)-oxybutynin", "Anturol (TN)", "Oxytrol (TN)", "MFCD00865252", "OXYBUTYNIN [MI]", "OXYBUTYNIN [INN]", "Oxybutynin (USAN/INN)", "Prestwick0_000287", "Prestwick1_000287", "Prestwick2_000287", "Prestwick3_000287", "OXYBUTYNIN [HSDB]", "OXYBUTYNIN [USAN]", "OXYBUTYNIN [VANDF]", "OXYBUTYNIN [MART.]", "SCHEMBL2992", "OXYBUTYNIN [WHO-DD]", "Lopac0_000923", "BSPBio_000194", "GTPL359", "MLS006010052", "OXYBUTYNIN [EMA EPAR]", "SPBio_002413", "BPBio1_000214", "DTXSID0023406", "OXYBUTYNIN [ORANGE BOOK]", "OXYBUTYNIN, Oxybutynin chloride", "CHEBI:144551", "HMS3884K08", "BCP12179", "HY-B0267", "AB7701", "BDBM50165019", "s1754", "AKOS015896242", "Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester", "AC-2153", "CCG-205005", "DB01062", "KS-5221", "SDCCGSBI-0050898.P003", "MRF-0000601", "(+/-)-OXYBUTYNIN(Hydrochloride form)", "NCGC00015767-03", "NCGC00015767-04", "NCGC00015767-06", "NCGC00015767-07", "NCGC00015767-09", "NCGC00015767-10", "NCGC00015767-21", "NCGC00089795-02", "SMR001550466", "SBI-0050898.P002", "FT-0603679", "SW196787-3", "C07360", "D00465", "EN300-6478839", "A831004", "L000923", "Q1060922", "BRD-A65013509-003-03-8", "BRD-A65013509-003-13-7", "Z2588038990", "4-(Diethylamino)-2-butynyl .alpha.-phenylcyclohexaneglycolate", "4-(Diethylamino)-2-butynyl cyclohexyl(hydroxy)phenylacetate #", "4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)(phenyl)acetate", "4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate", "rac-4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate", "(R)-4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate", "(2R)-2-cyclohexyl-2-hydroxy-2-phenylacetic acid 4-(diethylamino)but-2-ynyl ester", "alpha-cyclohexyl-alpha-hydroxybenzeneacetic acid 4-(diethylamino)-2-butynyl ester", "Benzeneacetic acid, a-cyclohexyl-a-hydroxy-,4-(diethylamino)-2-butynyl ester", "Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butyn-1-yl ester", "119579-36-1"]
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000049	http://dx.doi.org/10.21228/M8W88R			Biomarkers of Exposure to ARsenic (BEAR) study	The BEAR study has been established to assess the health effects associated with prenatal arsenic exposure during neonatal and early life. The study area is in Gómez Palacio, Durango, Mexico where women are exposed to levels of iAs in drinking water up to 236.0 ?g As/L.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000069	http://dx.doi.org/10.21228/M8KS37			Effect of diet and age on ovarian metabolome	The long-term goal of this research is to understand the effects of the Western diet on female reproductive function and aging, to characterize the resultant health consequences and to determine the value of dietary intervention. In the past 100 years, dietary patterns in Western societies have changed remarkably. The consumption of saturated fatty acids (SFA), omega-6 (n-6) unsaturated fatty acids and refined carbohydrates has risen sharply, whereas consumption of fruits, vegetables and omega-3 fatty acids (n-3) has declined. This dietary pattern is associated with post-prandial oxidative stress and inflammation, both of which are implicated in numerous disease processes. The key rationale for this pilot grant application stems from studies reporting a decline in reproductive function in women that is coincident with changing patterns of Western diet, observations of Western diet-associated infertility in rodents, and adverse effects of diet on ovarian reserve in monkeys. Recently, ovarian-metabolomic profiling has been used to characterize oxidative and inflammatory pathways in the non-diseased ovary. Using this technology, it has also been reported that aging women, and those with reduced ovarian reserve, have altered follicular fluid levels of carbohydrates and reproductive hormones compared to normal ovarian reserve women. Therefore, this methodology is ideal for determining differences in global metabolomic profiles among ovaries derived from subjects of differing nutritional backgrounds. The proposed study will compare the effects of chronic exposure to a typical Western diet with a prudent diet on ovarian metabolome and metabolites associated with oxidative stress pathways. The central hypothesis is that ovaries from monkeys exposed to markedly divergent nutritional backgrounds will differentiate from each other with respect to their metabolome and with respect to metabolites indicative of oxidative stress. We will address this with three Specific Aims designed to: 1) determine whether the metabolome of ovarian tissue from cynomolgus monkeys (Macaca fascicularis) differentiates by nutritional background; 2) determine if metabolomic profiles of ovarian tissue will differentiate by age in pedigreed, known-age domestic vervet monkeys (Chlorocebus aethiops sabaeus) and 3) investigate whether the effects of diet or age on ovarian tissue metabolome is reflected by changes in serum metabolites. Archived ovarian tissue from two well-established nonhuman primate models of women?s health (Macaca fascicularis and Chlorocebus aethiops sabaeus) will be used for this study.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000097	http://dx.doi.org/10.21228/M8HS3M			Sex, Steroids, Sleep and Metabolic Dysfunction in Women	Sex obstructive sleep apnea studies
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000188	http://dx.doi.org/10.21228/M8ZK5B			Nicotine alters brain oxidative metabolism	Nicotine addiction through the use of cigarettes is the most common form of chemical dependency in the United States. Despite global warnings and awareness of the detrimental effects of smoking on health, smoking-derived nicotine dependence makes it very difficult to relinquish the habit. Unfortunately, nicotine exposure makes females more susceptible to ischemic neurodegeneration. Moreover, this susceptibility is enhanced when combined with oral contraceptives. Usually, women initiate nicotine usage during their adolescence, the period of life when one also is likely to get sexually active and also likely to use oral contraceptives. The underlying mechanisms responsible for the exacerbated neurodegeneration due to the long exposure of nicotine and oral contraceptives are not known. Our published studies showed that nicotine toxicity is exacerbated by oral contraceptives via altered mitochondrial function and increased reactive oxygen species production in the hippocampus of female rats. This mitochondrial dysfunction involved a defect on the enzymatic activity of the terminal enzyme of the electron transport chain (complex IV) as a consequence of an impaired biogenesis. However, how this mitochondrial impairment impacts the overall brain metabolism remains to be investigated. To understand the overall effect of nicotine on the brain metabolism and the mechanisms responsible for the enhanced toxicity of nicotine when combined with oral contraceptives, we propose two specific aims. We will investigate the metabolomic profile of brains (hippocampus) of female rats treated with nicotine alone or in combination with oral contraceptives. We will also determine the effect on the activity and steady-state levels of key regulatory metabolic enzymes. We will use an established rat animal model mimicking conditions of nicotine exposure produced by cigarette smoking and simulating conditions of oral contraceptives usage taking in consideration hormonal cycles in women. Discerning the exact effects of nicotine and its combination with oral contraceptives on overall brain metabolisms at different ages will open a new window for future therapeutic intervention. This intervention will reduce their susceptibility to neurodegenerative conditions in women trying to give up nicotine addiction.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000233	http://dx.doi.org/10.21228/M8J590			LC-MS Based Approaches to Investigate Metabolomic Differences in the Urine and Plasma of Young Women after Drinking Cranberry Juice or Apple Juice	The present study aimed to investigate overall metabolic changes caused by cranberry juice or apple juice consumption using a global LC-MS based metabolomics approach.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000273	http://dx.doi.org/10.21228/M8H30K			Methylation in mouse liver	We are interested in knowing whether elevated total homocysteine affects the level of DNA methylation liver cells and Bone Marrow in our inducible mouse model of hyperhomocysteinemia. To answer this question, we will use our Tg-hCBS Cbs-/- mouse. This mouse lacks the endogenous mouse CBS gene and instead contains a human CBS cDNA transgene that is under control of a zinc inducible MT-1 promoter. We will send you DNA isolated from the livers and Bone Marrow of twelve animals, six of which that were uninduced and six that were induced by treatment with zinc water.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000279	http://dx.doi.org/10.21228/M8VC8G			Non targeted meatbolomic profiling of transgenic- humanized amylin producing rats	Non targeted metabolomic analysis on samples from rats expressing human amylin.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000300	http://dx.doi.org/10.21228/M88C86			Plasma Metabolomic Profiles Reflective of Glucose Homeostasis in Non-Diabetic and Type 2 Diabetic Obese African-American Women	Insulin resistance progressing to type 2 diabetes mellitus (T2DM) is marked by a broad perturbation of macronutrient intermediary metabolism. Understanding the biochemical networks that underlie metabolic homeostasis and how they associate with insulin action will help unravel diabetes etiology and should foster discovery of new biomarkers of disease risk and severity. We examined differences in plasma concentrations of >350 metabolites in fasted obese T2DM vs. obese non-diabetic African-American women, and utilized principal components analysis to identify 158 metabolite components that strongly correlated with fasting HbA1c over a broad range of the latter (r?=??0.631; p<0.0001). In addition to many unidentified small molecules, specific metabolites that were increased significantly in T2DM subjects included certain amino acids and their derivatives (i.e., leucine, 2-ketoisocaproate, valine, cystine, histidine), 2-hydroxybutanoate, long-chain fatty acids, and carbohydrate derivatives. Leucine and valine concentrations rose with increasing HbA1c, and significantly correlated with plasma acetylcarnitine concentrations. It is hypothesized that this reflects a close link between abnormalities in glucose homeostasis, amino acid catabolism, and efficiency of fuel combustion in the tricarboxylic acid (TCA) cycle. It is speculated that a mechanism for potential TCA cycle inefficiency concurrent with insulin resistance is “anaplerotic stress” emanating from reduced amino acid-derived carbon flux to TCA cycle intermediates, which if coupled to perturbation in cataplerosis would lead to net reduction in TCA cycle capacity relative to fuel delivery.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000317	http://dx.doi.org/10.21228/M87G7J			Metabolomic Profiling in Early Pregnancy using Pre-Diagnostic Sera from Women Who Developed Placental Abruption	Placental abruption is an ischemic placental disorder that results from the premature separation of the placenta from the wall of the uterus before delivery of the fetus. This disorder is associated with pre-term delivery, fetal death, maternal hemorrhagic shock, and renal failure. Several physiologic disturbances, such as oxidative stress, carbohydrate/fatty acid metabolism, and mitochondrial dysfunction, have been associated with ischemic placental disorder as well as with placental abruption. This preliminary study proposes to identify metabolites associated with incident placental abruption using existing serum and clinical data from a previously studied cohort. Metabolomics analysis will be carried out on maternal serum (51 cases and 51 controls) collected in early pregnancy (early second trimester).
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000325	http://dx.doi.org/10.21228/M8788V			Armpit Biodiversity Metabolites and Odors	Diverse communities of microscopic organisms (microbiota) live on the skin, and their collective genomes are referred to as the skin microbiome. The skin microbiota aid in the skin’s barrier function and help mature our immune system as well as produce odor by metabolizing sweat and other secretions produced by our bodies. Only now with the advancement of high throughput sequencing technologies has it become possible to sample the intrinsic variation of the microbiota that inhabits the outer surface of the body. This project will sample DNA from microbes (single celled organisms) that live on the human skin, investigate microbial gene regulation, skin surface metabolites, microbial odor production, and begin to assess the human perception of pleasantness of these microbial associated odors.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000341	http://dx.doi.org/10.21228/M8989V			Metabolomics Analysis of Triple Negative Breast Cancer Cell Lines	To date there are no clinically approved targeted therapies for triple negative breast cancer (TNBC). In addition to the absence of estrogen, progesterone, and HER2/neu receptors, TNBCs possess characteristics that make them some of the most aggressive forms of breast cancer (BCa). In terms of epidemiology, breast cancers with the triple negative profile present at a higher prevalence in premenopausal women under the age of 40, usually with a BMI greater than 30, and have higher incidences of mutations in BRCA1 or BRCA2 genes. Additionally, several studies have shown a higher prevalence in African American women, demonstrating a health disparity. In spite of this knowledge and the fact that most people respond to initial chemotherapeutic treatment, lasting treatment modalities used for the cure and maintenance of other BCa subtypes generally fail to significantly increase disease-free survival or diminish the rates of recurrence within the first five years after initial detection of TNBC. Our ultimate goal is to identify novel biomarkers which may be leveraged for initiating prevention strategies in high risk populations, earlier detection, or targeted treatment of this disease.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000343	http://dx.doi.org/10.21228/M8JS49			Follicular fluid lipidomics reveals lipid alterations by LH addition during IVF cycles	Ovulation induction protocols are key components for performing assisted reproduction treatments successfully. The objective of the present study was to estimate how LH addition to controlled ovarian stimulation protocols may affect the follicular fluid lipid profile of women undergoing in vitro fertilization treatment. We conducted the study using 28 self-paired samples, 14 per group. The patients received FSH during their first cycle of ovarian stimulation (FSH group). If treatment did not result in pregnancy, the same patients returned for a new cycle and received stimulus with the addition of LH to the previous protocol (Low-dose-LH group). Lipidomics analysis was performed by UPLC-MSE mass spectrometry. Potential lipid biomarkers were identified by the software Progenesis QI. Statistical analysis was performed using the SPSS 18.0 and MetaboAnalyst 2.0 software.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000348	http://dx.doi.org/10.21228/M82K58			Metabolic features of chronic fatigue	More than 2 million people in the United States have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). We performed targeted, broad-spectrum metabolomics to gain insights into the biology of CFS. We studied a total of 84 subjects using these methods. Forty-five subjects (n = 22 men and 23 women) met diagnostic criteria for ME/CFS by Institute of Medicine, Canadian, and Fukuda criteria. We targeted 612 metabolites in plasma from 63 biochemical pathways by hydrophilic interaction liquid chromatography, electrospray ionization, and tandem mass spectrometry in a single-injection method. Our data show that despite the heterogeneity of factors leading to CFS, the cellular metabolic response in patients was homogeneous, statistically robust, and chemically similar to the evolutionarily conserved persistence response to environmental stress known as dauer.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000388	http://dx.doi.org/10.21228/M8WP4C			Regulation of Metabolism by LSR	Breast cancer is a global crisis, accounting for nearly one quarter of all cancers in women. In the U.S., African-American (AA) women suffer disproportionately from breast cancer mortality compared to other racial/ethnic groups. Both social (socioeconomic factors, diet, obesity) and biological hypotheses (gene polymorphisms, gene expression profiling) have been advanced to explain these discrepancies, but the differences remain poorly understood. Multiple aspects of tumor aggressiveness have been identified in the AA population, including a high proportion of basal-like tumors. Basal-like tumors are clinically the most aggressive, characterized by enhanced cancer stem cell-like features. Currently, no effective molecular therapies exist for these highly aggressive cancers and patient survival is poor. Escalating this disparity is the disease promoting effects of obesity and metabolic syndrome, which are significantly higher in AA women. Obesity and its associated inflammation have been attributed to poor patient outcomes, resistance to chemotherapeutics, and/or cancer risk. A meta-analysis of 43 studies of obesity and breast cancer revealed that obese patients were 33% more likely than non-obese patients to die of breast cancer. Yet apart from correlative studies, no reports have combined these factors with cancer disparities to ascertain their molecular interactions and physiology on breast tumorigenesis. We tested the integration these factors, with focus on a specific molecule, Lipolysis Stimulated Lipoprotein Receptor (LSR), in the promotion of aggressive cancer behaviors. LSR is a cell surface molecule that regulates post-prandial lipid uptake in the liver, is sensitive to high fat diets, and is regulated by metabolic cues, including leptin. By testing each of these factors as well as their dynamic interactions on breast cancer tumorigenesis, we will gain valuable insight into biological mechanisms that influence cancer risk/disparities, response to therapy, and ultimately patient outcome. We recently reported LSR is overexpressed in breast tumors, directs aggressive breast cancer cell behaviors including proliferation and migration, and enhances cancer stem cell-like and chemotherapeutic resistance features in breast cancer cells.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000421	http://dx.doi.org/10.21228/M8N316			Exploratory research on first and second trimester urinary metabolic profiles and fetal growth restriction	From 2010 to 2012, women were recruited into The Infant Development and the Environment Study (TIDES) from obstetrical clinics affiliated with academic medical centers in four U.S. cities. Using previously collected first and second trimester urine samples from this prospective cohort of nearly 800 pregnancies, we designed a nested case control study aimed to determine whether maternal metabolic abnormalities/differences are associated with FGR. To find the patients with fetal growth restriction (FGR), we reviewed de-identified questionnaires and de-identified previously collected data, and performed a growth potential formula considering gestational age, infant sex, maternal and paternal height, and interaction of gestational age with maternal weight. Using a case:control ratio of 1:2, matched on study site, maternal age (± 2 years), parity, and infant's sex, 53 cases were matched to 106 controls for a total of 159 patients, and 318 samples (one in each ttrimester). The samples were analyses by NMR spectroscopy, using Bruker IVDr platform.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000457	http://dx.doi.org/10.21228/M8060Z			Metabolomic Mechanisms of Dietary Salt Effects on Blood Pressure	Enhanced sensitivity of blood pressure to salt intake is observed in approximately 50% of hypertensive patients, reaching 75% in African American hypertensive patients. We recently discovered a novel role of abnormal cellular intermediary metabolism in hypertension in the Dahl salt-sensitive (SS) rat, the most commonly used polygenic, hereditary model of human salt-sensitive hypertension. We propose to test the hypothesis that blood pressure sensitivity to dietary salt intake in human is associated with metabolite changes in the urine. Leveraging the expertise and resources at the Mayo Clinic Metabolomics Resources Core, we propose to perform targeted LC/MS analysis and NMR spectra generation in urine samples obtained from a subset of subjects from the Dietary Approaches to Stop Hypertension – Sodium (DASH2) clinical trial and kidney tissue extract and urine samples from SS rats and a newly generated transgenic rat that overexpresses fumarase (SS.Fh1+). The study will be the first to systematically characterize urinary metabolite profiles associated with blood pressure response to salt in humans. The study is anticipated to generate new insight into the mechanisms (particularly renal mechanisms) underlying salt-sensitive hypertension. Findings of the proposed study could lead to an expanded clinical study as well as mechanistic studies in animal models.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000463	http://dx.doi.org/10.21228/M86P5J			Changes in metabolites and lipid mediators associated with supervised exercise training for peripheral artery disease	Peripheral artery disease (PAD) is a leading cause of cardiovascular related morbidity and mortality, affecting over 8.5 million men and women in the United States and greater than 200 million individuals worldwide. The mainstay of treatment to improve lower limb symptoms is supervised walking therapy, which does not affect plaque morphology or alter conduit artery blood flow, but rather ameliorates endothelial dysfunction, enhances skeletal muscle metabolism and mitochondrial function, and suppresses inflammatory activation. In this pilot feasibility project we will employ metabolic and lipidomic techniques to measure the effects of supervised exercise therapy on primary metabolism, complex lipids, and lipid mediators, and correlate these effects with individual, subject-level measures of the response to exercise therapy among subjects with PAD. The overarching theme of this work is to identify metabolites, complex lipids, and lipid mediators that are associated with the inter-individual variability in the response of subjects with PAD to supervised exercise therapy. This knowledge will significantly enhance our understanding of the pathophysiology of lower extremity symptoms in PAD, as well as the manner in which supervised exercise therapy improves walking intolerance. It will identify novel therapeutic targets and pathways for pharmacologic manipulation in the treatment of PAD. Aside from having the potential to generate multiple high-impact publications, it will serve as the basis for a planned NIH R01 submission by the PI at the conclusion of the award period.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000505	http://dx.doi.org/10.21228/M8CW9P			Subfertility Study	Assess the relative efficacy of a very low energy diet (VLED) using liquid meal replacement vs. standard of care dietary counseling and education (DCE) on the metabolic effects of weight reduction in the obese, subfertile population and assess ovulation and time to conception in these women.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000620	http://dx.doi.org/10.21228/M8J098			Comparison of 1d NOESY presat and optimized PURGE for urine analysis	The pulse sequence commonly used for NMR metabolomics, 1D NOESY presat, and an optimized PURGE pulse sequence, are compared with 10 urine samples.These 10 urine samples came from quality control pooled Mormon women urine (OH2050F) and were frozed at -80°C before analysis. All 10 samples were technical replicate, coming from the same pool and sumitted to the same treatment before NMR analysis.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000634	http://dx.doi.org/10.21228/M8QM3R			Multiplatform plasma metabolic and lipid fingerprinting of breast cancer: a pilot control-case study in Colombian Hispanic women.	In this pilot study, a metabolomic approaches was performed to establish a plasma metabolic fingerprint of Colombian Hispanic women with breast cancer. Data from NMR, GC-MS and LC-MS were combined and compared.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000652	http://dx.doi.org/10.21228/M8D38P			Mayo Pilot and Feasibility: Mechanisms for Insulin Resistance in Polycystic Ovary Syndrome	Polycystic Ovary Syndrome (PCOS), a condition of androgen excess, infrequent ovulation, and insulin resistance is the most common endocrine disorder among premenopausal women. Little is known about the exact mechanisms of insulin resistance in PCOS and how metformin can improve insulin sensitivity, increase the frequency of ovulation and lower androgens in PCOS. Preliminary data from metabolomic analyses of amino acids demonstrate increased concentrations of lysine and its metabolite, a-aminoadipic acid (AAA), in PCOS versus obese controls. Interestingly, greater AAA concentrations predicted the development of type 2 diabetes in the Framingham epidemiologic cohort, experimentally lowers glucose in animal models and increases insulin secretion in vitro. To date, the mechanism for increased circulating concentrations of lysine and AAA in insulin-resistant individuals is not known. Building upon these findings, we have initiated a project to simultaneously study lysine and AAA kinetics for the first time in insulin-resistant individuals using stable isotope tracer methodology. We will evaluate: 1) whether lysine and AAA kinetics are altered in PCOS versus healthy controls; 2) the effect of hyperinsulinemia on lysine and AAA kinetics in PCOS versus controls; 3) whether treatment to improve insulin sensitivity changes lysine and AAA kinetics in PCOS. The long-term goal is to target pathways for the treatment of PCOS and the prevention of type 2 diabetes in PCOS and other insulin-resistant individuals at greater risk for type 2 diabetes.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000666	http://dx.doi.org/10.21228/M8KQ3J			GC6-74 matabolomic of tuberculosis.	Within the GC6-74 cohorts, 4,462 HIV-negative healthy household contacts of 1,098 index TB cases were recruited from 2006 to 2012 at four African sites included in this study i.e. SUN (Stellenbosch University, South Africa), MRC (Medical Research Council Unit, The Gambia), AHRI (Armauer Hansen Research Institute, Ethiopia) and MAK (Makerere University, Uganda). The study had an exclusion period of 3 months, such that participants, who were diagnosed with active TB within 3 months of enrolment, were excluded from analysis to prevent inclusion of participants who had incipient or asymptomatic clinical TB disease at enrolment. Additional exclusion criteria were positive HIV rapid test, current or previous anti-retroviral treatment, history of TB, pregnancy, participation in drug and/or vaccine clinical trials and chronic disease diagnosis or immunosuppressive therapy within the past 6 months, and living in the study area for less than 3 months. A total of 97 individuals who developed active TB within the two year follow-up period were included in this study and matched at a ratio of 1:4 with participants who remained healthy during the 2-year follow-up period (controls); matching, by site, age class, sex, and wherever possible year of recruitment. Initial samples collected upon enrolment were termed baseline (BL) samples. Further samples were taken 6 and 18 months post-exposure, provided that the participant had remained TB free at the time of sample collection. Metabolic profiling was carried out for each study site, using either serum or plasma samples. For a small number of samples, an insufficient amount of plasma was available, so the sample was diluted using RPMI buffer.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000695	http://dx.doi.org/10.21228/M8V100			Global Metabolomics of the Placenta Reveals Distinct Metabolic Profiles between Maternal and Fetal Placental Tissues Following Delivery in Non-Labored Women	We evaluated the metabolic alterations in maternal and fetal placental tissues from non-labored women undergoing cesarean section using samples collected from 5 min to 24 h following delivery. Using 1H-NMR, we identified 14 metabolites that significantly differed between maternal and fetal placental tissues (FDR-corrected p-value < 0.05), with 12 metabolites elevated in the maternal tissue, reflecting the flux of these metabolites from mother to fetus. In the maternal tissue, 4 metabolites were significantly altered at 15 min, 10 metabolites at 30 min, and 16 metabolites at 1 h postdelivery, while 11 metabolites remained stable over 24 h. In contrast, in the fetal placenta tissue, 1 metabolite was significantly altered at 15 min, 2 metabolites at 30 min, and 4 metabolites at 1 h postdelivery, while 22 metabolites remained stable over 24 h. Our study provides information on the metabolic profiles of maternal and fetal placental tissues delivered by cesarean section and reveals that there are different metabolic alterations in the maternal and fetal tissues of the placenta following delivery.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000696	http://dx.doi.org/10.21228/M8Q96S			Pregnancy Eating and Postpartum Diapers (PEAPOD)	This was a pilot study (n=27), to assess the feasibility, acceptability, and preliminary efficacy of implementing a randomized controlled trial of a diet intervention in pregnancy designed to test the effect of maternal diet on the maternal and infant gut microbiome. Our specific aims were to: 1) test feasibility of enrollment and implementation; 2) assess acceptability of weekly food deliveries; and 3) estimate the preliminary effect size of the intervention relative to the usual care group on (a) maternal gut butyrate composition measured in three maternal stool samples collected at two time points during pregnancy (pre- and post-diet intervention phase) and also collected at 6 weeks postpartum; and (b) infant gut butyrate composition measured in infant stool samples collected at 6 weeks of age. The overall goal of PEAPOD was to gather pilot data to effectively refine the intervention so that it can be tested in a larger, longer study using a factorial design. For this pilot, we employed a 2-arm RCT with a total sample size of 27 mother-child pairs. We enrolled women in mid-pregnancy who were intending to breastfeed, randomized them to the diet intervention (n=13) or to a usual care group (n=14) and followed them to 6 weeks postpartum. Data collection included surveys of detailed maternal dietary information, as well as collection of maternal blood, urine, and stool at three time points (25 and 36 weeks gestation, and 6 weeks postpartum), and an infant stool sample at 6 weeks of age along with information about infant feeding practices. The diet intervention was initiated at 32 weeks gestation and continued until birth of the baby; thus the 25 week gestation biospecimens are pre-intervention and the 36 week gestation biospecimens are after 4 weeks of receiving the diet intervention. We chose to collect the second set of biospecimens at 36 weeks gestation to avoid missing post-intervention samples in instances where women delivered preterm. We partnered with the hospital catering service and the diet intervention including either legumes (e.g. minestrone with white beans) or whole grains (e.g. beef barley), and 5 pieces of fresh fruit (e.g. apples, oranges). In addition, in the first week, participants received a collection of non-perishable high fiber foods (whole wheat breakfast cereal, oatmeal, dried fruit, and canned beans) as well as upscale olive oil and vinegar from a local store along with recipes for salad dressing, side dishes, and some general information about the health benefits of the Mediterranean diet. We anticipated that participants would likely share the food with their families but our intent was to provide enough supplementary food to increase the fiber consumption of the pregnant women.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000702	http://dx.doi.org/10.21228/M8XT3P			School Inner-City Asthma Intervention Study	SICAS 1: Allergic asthma is the most common chronic disease of childhood in the United States. Asthma is also the number one cause of school absences in America. The role of indoor allergen exposure in homes and asthma development and morbidity has been extensively studied. Because children spend a significant amount of time in school, the school classroom environment may be as significant a source of allergen exposure and consequent asthma morbidity as allergen exposure in the home. However, little is known about the role of allergen exposure in schools and asthma morbidity. We hypothesize that exposure to common indoor allergens in the classroom will increase the risk of asthma morbidity in inner-city children with asthma, even after controlling for home allergen exposures. In a longitudinal study of 300 elementary school-aged children with asthma from multiple classrooms in close to 40 inner-city schools, we will examine the following specific aims: 1) to test whether elevated levels of allergens in the classroom increase the risk of asthma morbidity, even after controlling for allergen exposure in the home; and 2) to test whether the risk of increased asthma morbidity in relation to elevated classroom levels of a specific allergen will be highest for those specifically sensitized to that allergen. An understanding of exposure risk factors specific to the school classroom is critical, because the school classroom environment could potentially be considered as an effective target for prevention of inner-city asthma morbidity by reducing exposures to many symptomatic children through school- based interventions. While the potential importance of the classroom environment to the health of asthmatic children has been recognized nationally, study of this area has lacking. This unique application will build on significant collaborations between the Channing Laboratory at the Brigham and Women's Hospital, Children's Hospital Boston, the Harvard School of Public Health, the University of Massachusetts Amherst, and the Boston Public School System. Our multidisciplinary research group has significant expertise in asthma epidemiology and environmental epidemiology (Drs. Phipatanakul and Gold), environmental assessment (Drs. Phipatanakul, Gold, Muilenberg, and Rogers), and statistics (Drs. Ryan, Hoffman, and Subramanian). In addition to its public health relevance, this proposal will recruit a unique school pediatric cohort that will facilitate future hypothesis testing. PUBLIC HEALTH RELEVANCE: Asthma is a disease that affects more than 12% of Americans under the age of 18 for over 14 million missed school days per year, and is the number one cause of school absences in America. Elementary school children spend 6 to 10 hours a day in school, and most of that time is spent in one classroom. The goals of this project are to provide an understanding of exposure risk factors specific to the classroom. This is critical, because the classroom environment could potentially be considered as an effective target for prevention of inner-city asthma morbidity by reducing exposures to many symptomatic children through an intervention in the school classrooms.; SICAS 2: Asthma is the most common chronic disease of childhood in the United States, causes significant morbidity, particularly in the inner-city, and accounts for billions of dollars in health care utilization, despite aggressive measures to identify remediable causes. Home environments are established sources of exposure that exacerbate symptoms and home-based interventions are proven effective. Prior to the inception of the School Inner-City Asthma Study (SICAS-1), no American study had comprehensively evaluated the relationship between urban exposures in school, classroom, and home environments and asthma morbidity. Nearly all elementary school children spend 6 to 10 hours a day in school, and most of that time is spent in one classroom. From SICAS-1, we learned that student classroom-specific mouse allergen, mold, and particulate pollutant exposure is associated with worsening symptoms. We also demonstrated our ability to reduce these exposures in a busy, school setting. Our proposal builds upon our established, successful school-based infrastructure to determine whether a school/classroom intervention will efficiently and effectively improve asthma morbidity by reducing these exposures. Our goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren. Our central hypothesis is that reducing classroom/school exposure to mouse allergen, mold, and particulate pollutants will decrease asthma morbidity in students with asthma. We plan to test this hypothesis in an intervention study of 300 elementary students with asthma from multiple classrooms in 40 Boston inner-city elementary schools. Our clinical trial aims are to determine the effectiveness of a school/classroom based environmental intervention (school integrated pest management and classroom air purifying filter units within these schools) to reduce asthma morbidity.This study is an unprecedented, high impact opportunity to test whether we can efficiently benefit a community of children in the school environment as opposed to individuals in single homes. It also adds a novel mechanistic application on health outcomes. It efficiently tackles a critical public health problem that affects a growing proportion of disadvantaged, urban U.S. children.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000708	http://dx.doi.org/10.21228/M8596T			Metabolic approaches reveal the role of CAR in energy metabolism	The constitutive androstane receptor (CAR; NR1I3) contributes important regulatory roles in biotransformation, xenobiotic transport function, energy metabolism and lipid homeostasis. In this investigation, global serum and liver tissue metabolomes were assessed analytically in wild type and CAR-null transgenic mice using NMR, GC/MS and UPLC/MS-MS-based metabolomics. Significantly, CAR activation increased serum levels of fatty acids, lactate, ketone bodies and tricarboxylic acid cycle products, whereas levels of phosphatidylcholine, sphingomyelin, amino acids and liver glucose were decreased following short-term activation of CAR. Mechanistically, quantitative mRNA analysis demonstrated significantly decreased expression of key gluconeogenic pathways, and increased expression of glucose utilization pathways, changes likely resulting from down-regulation of the hepatic glucose sensor and bi-directional transporter, Glut2. Short-term CAR activation also resulted in enhanced fatty acid synthesis and impaired ß-oxidation. In summary, CAR contributes an expansive role regulating energy metabolism, significantly impacting glucose, and monocarboxylic acid, as well as fatty acid metabolism and lipid homeostasis, through receptor-mediated regulation of several genes in multiple associated pathways.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000817	http://dx.doi.org/10.21228/M82X16			Wild type versus TRACK Mice on regular chow and Vitamin A deprived diet	Kidney cortex tissue from wild type mice and transgenic TRACK (TRAnsgenic Cancer of the Kidney) mice fed on a regular chow or vitamin A deprived diet were analyzed
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000866	http://dx.doi.org/10.21228/M8R963			Transgenic Parkinson's Mice Following Immunotherapy	An UHPLC-HRMS Metabolomics and Lipidomics Study of Stool from Transgenic Parkinson's disease Mice Following Immunotherapy. Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the brain as well as degeneration of motor and non-motor circuitry. The cause of neuronal death is currently unknown, although chronic neuroinflammation, aggregated a-synuclein, mitochondrial dysfunction and oxidative stress have all been implicated. Gliosis has been shown to exacerbate neuroinflammation via secretion of pro-inflammatory cytokines, and there is a subsequent infiltration of T lymphocytes (T-cells), into the brain of PD patients. Using liquid chromatography-high resolution mass spectrometry (LC-HRMS), we have observed metabolomic changes in stool samples, thought to be associated with the potential disease-modifying effect of an immunotherapy administered to transgenic Parkinsonian (A53T) mice. Significant elevations (p<0.05) in metabolites associated with immune response (taurine, histamine and its methylated product, 3-methylhistamine) are identified as being higher in the mice undergoing immunotherapy. Furthermore, a reduction in triacylglycerols (TG) and diacylglyceols (DG) expression in stool following immunotherapy suggests a regulation of lipid breakdown or biosynthesis with the vaccine. These “omics” markers (among others reported in this article) along with weight gain and increased life expectancy suggest that the immunotherapy is positively modifying the disease state.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000872	http://dx.doi.org/10.21228/M8ZT30			Lipidome Signatures of Metastasis in a Transgenic Mouse Model of Sonic Hedgehog Medulloblastoma.	Medulloblastoma (MB), the most common malignant pediatric brain tumor, has high propensity to metastasize. Currently, the standard treatment for MB patients includes radiation therapy administered to the entire brain and spine for the purpose of treating or preventing against metastasis. Due to this aggressive treatment, the majority of long-term survivors will be left with permanent and debilitating neurocognitive impairments and, for the 30-40% patients that fail to respond to radiation, all will relapse with terminal metastatic disease. An understanding of the underlying biology that drives MB metastasis is lacking, and is critically needed in order to develop targeted therapeutics for its prevention. To examine the metastatic biology of sonic hedgehog (SHH) MB, the human MB subgroup with the worst clinical outcome, we first generated a robust SmoA1-Math-GFP mouse model that reliably reproduces human SHH MB whereby metastases can be visualized under fluorescence microscopy. Lipidome alterations associated with metastasis were then investigated by applying Ultra-Performance Liquid Chromatography Mass Spectrometry (UPLC-MS) under both positive and negative ionization modes to primary tumor samples collected from mice with (n=18) and without (n=7) metastasis. This study provides the first insights into dysregulations of lipid metabolism associated with SHH MB metastatic progression, and thus serves as a guide toward novel targeted therapies.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000899	http://dx.doi.org/10.21228/M8GQ40			Maternal adiposity alters the human milk metabolome: a link between non-glucose monosaccharides and infant adiposity	An untargeted metabolomics analysis of human milk was performed to test the hypothesis that a unique human milk metabolome would emerge based on maternal adiposity (maternal fat mass and body mass index). This study also aimed to identify differentially expressed milk metabolites that are associated with fat mass in the infant. To our knowledge this study reports on the largest cohort to date examining the metabolomic differences in human milk composition between normal weight and obese women. Data generated from this study indicate the need for further research in the area of human milk metabolomics and the potential role for human milk small molecules in contributing to offspring growth and development.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000918	http://dx.doi.org/10.21228/M81H58			Metabolic dynamics and prediction of gestational age and time to delivery in pregnant women	Metabolism during pregnancy is a constantly changing yet precisely programmed process, the failure of which may have devastating consequences for the fetus. To capture in high resolution the sequence of metabolic events underlying the normal human pregnancy, we carried out an untargeted metabolome investigation on 784 weekly blood samples (3 outlier samples are removed) collected from 30 Danish pregnant women. The study revealed extensive metabolome alterations over the course of normal pregnancy: of 9,651 detected metabolic features, 4,995 were significantly changed (FDR < 0.05). Many metabolic changes were timed precisely according to pregnancy progression so that the overall metabolic profile demonstrated a highly choreographed pattern. Using machine-learning methods, we were able to build a linear models with five metabolites (four steroids and one phospholipid) that predicts gestational age with high accuracy (Pearson correlation coefficient, R = 0.95).
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR000945	http://dx.doi.org/10.21228/M8J967			Lipid profile Dataset of optogenetics induced optic nerve regeneration	The optic nerve transfers visual information from the retina to the brain through the axons of retinal ganglion cells (RGCs). In adult mammals, optic nerve injuries and progressive degenerative diseases lead to the irreversible loss of RGCs, resulting in blindness. Optogenetic models have proved useful in manipulating the growth of RGCs through expression of Channelrhodopsins (Chr2) and light stimulation. Using the transgenic Chr2 mouse (Thy1-ChR2-EYFP) as a model of regeneration, we present the profile the lipid changes that occur after optic nerve crush, light stimulation and RGC growth. Thy1-ChR2-EYFP mice and controls (C57BL/6) were divided in four groups each, no crush and no stimulation, no crush and stimulation, crush and no stimulation, crush and stimulation. After euthanasia, the optic nerves were collected for analysis. The Bligh and Dyer method was used for lipid extraction, followed by mass spectrometry lipid profiling on a high-resolution Q-Exactive instrument.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001007	http://dx.doi.org/10.21228/M8J106			Plasma lipidomic profiles after a low and high glycemic load dietary pattern in a randomized controlled cross over feeding study	Background: Dietary patterns low in glycemic load are associated with reduced risk of cardiometabolic diseases. Improvements in serum lipid concentrations may play a role in these observed associations. Objective: We investigated how dietary patterns differing in glycemic load affect a clinical lipid panel and plasma lipidomics profiles. Methods: In a crossover, controlled feeding study, 80 healthy participants (n=40 men, n=40 women), 18-45 y were randomized to receive low-glycemic load (LGL) or high glycemic load (HGL) diets for 28 days each with at least a 28-day washout period between controlled diets. Fasting plasma samples were collected at baseline and end of each diet period. A clinical lipid panel including total-, VLDL-, LDL-, and HDL-cholesterol and triglycerides were measured using an auto-analyzer. Lipidomics analysis using mass-spectrometry provided the concentrations of 863 species. Linear mixed models were used to test for a diet effect. Results: Lipids from the clinical panel were not significantly different between diets. Lipidomics analysis showed that 67 lipid species, predominantly in the triacylglycerol class, differed between diets (FDR<0.05). A majority of these were higher after the LGL diet compared to the HGL. Conclusion: While the clinical lipid measures did not differ between diets, some lipid species were higher after the LGL diet in the lipidomics analysis. The two diets were eucaloric and had similar percentage of energy from carbohydrate, protein and fat. Thus, the difference in macronutrient, particularly carbohydrate, quality of the LGL diet is likely affecting the composition of lipid species.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001017	http://dx.doi.org/10.21228/M87M4S			Hepatic [U-13C]Lactate tracing and metabolomics in young and old WT and SIRT6 overexpressing mice	Our previous data had suggested that gluconeogenesis capacity from the precursors lactate and glycerol declines in old C57BL/6 mice. This decline was rescued by whole body SIRT6 overexpression. Since the liver is the main gluconeogenic organ, we performed here liver metabolomics in young (6 months) versus old (20-24 months) WT and SIRT6-transgenic mice. We used liver tissues of 6h morning-fasted mice, either in naïve state or 15 minutes after intraperitoneal injection of [U-13C]Lactate.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001083	http://dx.doi.org/10.21228/M8Q98J			An overexpression of lipoprotein lipase leads to an alteration in the skeletal muscle metabolome in transgenic rabbits	-
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001134	http://dx.doi.org/10.21228/M8470J			Lipidomics on healthy blood donors	The study population includes 844 healthy volunteers of which 183 women and 661 men, with a median age of 43 ± 12 yrs and 40 ± 11 yrs, respectively. The participants in this study were selected from the Tus-cany section of the Italian Association of Blood Donors (AVIS) in the Transfusion Service of the Pistoia Hospital. Plasma samples were obtained according to the Italian guidelines for blood donations. How age and sex influence the human lipidome were investigated.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001144	http://dx.doi.org/10.21228/M8TQ3Q			Metabolomics-driven identification of biochemical mechanisms underlying the neuroprotective effects of pleiotrophin in a mouse model of Parkinson’s disease	Pleiotrophin (PTN) is a cytokine involved in nerve tissue repair processes, neuroinflammation and neuronal survival. PTN expression levels are upregulated in the nigrostriatal pathway of Parkinson’s Disease (PD) patients. We aimed to characterize the dopaminergic injury and glial activation in the nigrostriatal pathway of mice with transgenic Ptn overexpression in the brain (Ptn-Tg) after intrastriatal injection of the Parkinsonian toxin 6-hydroxydopamine (6-OHDA). The injection of 6-OHDA induced a significant decrease of the number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra and of the striatal TH contents in Wild type (Wt) mice. In contrast, these effects of 6-OHDA were blocked in Ptn-Tg mice. 6-OHDA injection did not cause robust changes in microglia but induced an exacerbated astrocytic response in Wt mice compared with Ptn-Tg mice. In metabolomics studies, we detected interesting metabolites that significantly discriminate the more injured 6-OHDA-injected Wt striatum and the more protected 6-OHDA-injected Ptn-Tg striatum. Particularly, we detected groups of metabolites, mostly corresponding to phospholipids, whose trends were opposite in both groups. In summary, the data confirm the neuroprotective effect of brain PTN overexpression in this mouse model of PD. New lipid-related PD drug candidates emerge from this study and the data presented here support the increasingly recognized “lipid cascade” in PD.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001154	http://dx.doi.org/10.21228/M8J97M			The pregnancy metabolome from a multi-ethnic pregnancy cohort	The PRogramming of Intergenerational Stress Mechanisms (PRISM) study is an urban, ethnically diverse pregnancy cohort that was designed to study a range of chemical and non-chemical stressors in relation to maternal health, pregnancy outcomes, and child development. Pregnant women were enrolled from Boston and New York City hospitals and affiliated prenatal clinics beginning in 2011. Eligibility criteria included English or Spanish-speaking, over 18 years of age at enrollment, and singleton pregnancy. Exclusion criteria included HIV+ status or self-reported drinking =7 alcoholic drinks per week before pregnancy or any alcohol after pregnancy recognition.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001155	http://dx.doi.org/10.21228/M8DH5P			Nested case–control study of environmental exposure within the ongoing Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) pregnancy cohort.	Preterm birth is the leading cause of infant mortality worldwide, and also greatly increases the risk of developing serious health complications in childhood and throughout life. Conditions that contribute to preterm birth remain largely unclear, though an influence by environmental exposures is suspected but poorly understood. In our preliminary work, we found that exposure to common chemicals, such as phthalates and bisphenol A (BPA), may contribute to this serious but understudied public health problem. We also observed strong associations between phthalates/BPA and general markers of oxidative stress, and in turn between these general markers of oxidative stress and risk of preterm birth. In this nested case-control study within an ongoing cohort of pregnant women in Puerto Rico (PROTECT), we will explore untargeted lipidomics, as well as levels of eicosanoids specific to arachidonic acid oxidation pathways, in relation to both environmental exposures and preterm birth.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001165	http://dx.doi.org/10.21228/M8411V			Untargeted mass spectrometry reveals impact of high fat diet on peripheral amino acid regulation in a mouse model of Alzheimer’s Disease	Recent research regarding amino acid metabolism has shown that there may be a link between obesity and Alzheimer’s Disease (AD). This work reports a metabolomics study using untargeted mass spectrometry-based metabolomic strategies to investigate the metabolic changes that occur in AD and obesity. APPSwe/PS1?E9 (APP/PSEN1) transgenic mice (to represent familial or early-onset AD) and wild-type litter mater controls were fed either a high-fat diet (HFD, 60% kcal from lard), low-fat diet (LFD, 10% kcal from lard) from 2 months of age, or reversal diet (REV, high-fat followed by low-fat from 9.5 months).
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001190	http://dx.doi.org/10.21228/M8WD84			Preeclampsia and plasma metabolomics	Longitudinal untargeted plasma metabolomics of pregnant women with preeclampsia
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001218	http://dx.doi.org/10.21228/M88H76			Metabolomics profiles of premenopausal women are different based on O-desmethylangolensin metabotype	Urinary O-desmethylangolensin (ODMA) concentrations provide a functional gut microbiome marker of dietary isoflavone daidzein metabolism to ODMA. Individuals who do not have gut microbial environments that produce ODMA have less favorable cardiometabolic and cancer risk profiles. Urinary metabolomics profiles were evaluated in relation to ODMA metabotypes within and between individuals over time. Secondary analysis was conducted of data from the BEAN2 trial, which was a cross-over study of premenopausal women consuming six months on a high- and a low-soy diet, each separated by a 1-month washout period. In all of the 672 samples in the study, 66 of the 84 women had the same ODMA metabotype at seven or all eight time points. Two or four urine samples per woman were selected based on temporal metabotypes in order to compare within and across individuals. Metabolomics assays for primary metabolism and biogenic amines were conducted in 60 urine samples from 20 women. Partial least-squares discriminant analysis was used to compare metabolomics profiles.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001235	http://dx.doi.org/10.21228/M82T49			Metabolites Associated with Gestational Diabetes in Plasma	Gestational diabetes mellitus (GDM) significantly increases maternal and fetal health risks, but factors predictive of GDM are poorly understood. Plasma metabolomics analyses were conducted in early pregnancy to identify potential biomarkers for early prediction of Gestational Diabetes Mellitus (GDM). Sixty-eight pregnant women with overweight/obesity from a clinical trial of a lifestyle intervention were included. Participants who developed GDM (n=34; GDM group) were matched on treatment group, age, body mass index, and ethnicity with those who did not develop GDM (n=34; Non-GDM group). Blood draws were completed early in pregnancy (10-16 weeks). Plasma samples were analyzed by UPLC-MS using three metabolomics assays.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001260	http://dx.doi.org/10.21228/M8V401			Metabolic adaptations in an endocrine-related breast cancer mouse model unveil potential markers of tumor response to hormonal therapy	Breast cancer (BC) is the most common type of cancer in women and, in most cases, it is hormone-dependent (HD), thus relying on ovarian hormone activation of intracellular receptors to stimulate tumor growth. Endocrine therapy (ET) aimed at preventing hormone receptor activation is the primary treatment strategy, however, about half of the patients, develop resistance in time. This involves the development of hormone independent tumors that initially are ET-responsive (HI), which may subsequently become resistant (HIR). The mechanisms that promote the conversion of HI to HIR tumors are varied and not completely understood. The aim of this work was to characterize the metabolic adaptations accompanying this conversion through the analysis of the polar metabolomes of tumor tissue and non-compromised mammary gland from mice implanted subcutaneously with HD, HI and HIR tumors from a medroxyprogesterone acetate (MPA)-induced BC mouse model. This was carried out by nuclear magnetic resonance (NMR) spectroscopy of tissue polar extracts and data mining through multivariate and univariate statistical analysis. Initial results unveiled marked changes between global tumor profiles and non-compromised mammary gland tissues, as expected. More importantly, specific metabolic signatures were found to accompany progression from HD, through HI and to HIR tumors, impacting on amino acids, nucleotides, membrane percursors and metabolites related to oxidative stress protection mechanisms. For each transition, sets of polar metabolites are advanced as potential markers of progression, including acquisition of resistance to ET. Putative biochemical interpretation of such signatures are proposed and discussed.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001282	http://dx.doi.org/10.21228/M80Q51			TIPs Metabolomics	Healthy omnivorous women underwent a short-term dietary intervention. Plasma and urine samples were collected before and after the 4-day vegetarian diet.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001287	http://dx.doi.org/10.21228/M8BX22			Metabolomics Analysis of Blood Plasma and Stool from Six Week Flaxseed Dietary Intervention in Postmenopausal Women	Samples were taken before and after 6 weeks of flaxseed dietary intervention. Serum and fecal metabolomics were performed to characterize the metabolomic profiles of serum and stool metabolites pre- and post-intervention.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001295	http://dx.doi.org/10.21228/M8B13G			Effects of Zika virus infection on the metabolome of pregnant women: a longitudinal study	Zika virus (ZIKV) is a mosquito-borne +ssRNA virus that can cause abnormal development in human fetal central neuron system and even lead to stillbirth. Despite the popularity of studies in this area recently, there is currently still no sufficient treatment for it. Knowledge on how ZIKV infection impact human metabolisms is still lacking. Untargeted metabolomics can profile the overall change in metabolites after infection, thus provide hypothesis for specific investigations. We here performed a Nuclear Magnetic Resonance spectroscopy (NMR)-based untargeted case-control metabolomics study on urine of ZIKV-infected pregnant women. We collected samples monthly from the first trimester till up to 6 months of ZIKV-infected and non-infected individuals and modelled the longitudinal data. We identified 3-aminoisobutyrate and trigonelline with significantly higher levels in the ZIKV-infected patients, while 11 metabolites (fucose, 2-hydroxyglutarate, N-acetyl-glutamine, dimethylamine, 4-hydroxyphenethyl alcohol, creatinine, lactate, threonine, histidine, pseudouridine, and 1-methylnicotinamide) had significantly lower levels. We also identified 2 metabolites, including glucose and 1-methylnicotinamide, where the trends over time of the intensity levels between the two groups were significantly different. These metabolites suggested further study on tryptophan, NAD+, pyrimidine, and glucose metabolisms. These metabolomic changes may lead us to a better understanding of mechanisms that cause poor fetal outcomes as well as effects of virus infection on human pregnancy.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001301	http://dx.doi.org/10.21228/M8JH7P			Integrated multilayer omics reveals the genomic, proteomic and metabolic influences of the histidyl dipeptides on heart	Histidyl dipeptides, such as carnosine, present in a micro-millimolar ranges in the heart, are synthesized via the enzyme carnosine synthase (Carns). These dipeptides facilitate glycolysis by proton buffering, form conjugates with reactive aldehydes, such as acrolein, and attenuate ischemia and reperfusion injury. While these dipeptides exhibit multifunctional properties, a composite understanding of their roles in myocardium is lacking. To identify the landscape of histidyl dipeptide mediated responses in the heart, we used a triomics approach of genome wide RNA sequencing, global proteomics and unbiased metabolomics in the cardio specific Carns transgenic (Tg) mice and integrated the three data sets. Our result show higher myocardial levels of histidyl dipeptides lead to extensive changes in several microRNAs, which could target the expression of contractile proteins, beta-fatty acid oxidation and citric acid cycle (TCA) enzymes. Global proteomics shows, expression of contractile proteins, enzymes of beta-fatty acid oxidation and TCA cycle, were enriched in the CarnsTg heart. Under aerobic conditions, the CarnsTg hearts had lower levels of short and long-chain fatty acids and TCA cycle intermediate-succinic acid, whereas, under ischemic conditions the accumulation of fatty acids and TCA cycle intermediates were significantly attenuated in the CarnsTg heart. Integration of multiple data sets suggests that beta-fatty acid oxidation and TCA cycle pathways exhibited correlative changes in the CarnsTg hearts at all three levels. Our triomics approach shows histidyl dipeptides are critical regulators of myocardial structure, function and energetics.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001337	http://dx.doi.org/10.21228/M8WM52			Metabolomics dataset of optogenetic axon regenerative mouse model post optic nerve crush	This metabolite dataset was collected from bacterial channel rhodopsin expressing transgenic mouse models subjected to optic nerve crush (ONC) with subsequent stimulation with light (promoting regeneration) or non-stimulation (lacking axon regeneration). ONC retains retinal ganglion cells within the retina, while degenerating axons. In transgenic bacterial channel rhodopsin expressing cells, light stimulation promotes regeneration. Genetically matched wild-type uninjured optic nerves, or control transgenic mice, were also analyzed. Metabolites were carefully extracted from finely minced optic nerve tissue using a solvent system (initial separation using 1:1 Methanol and H2O and second extraction using 8:1:1 of Acetonitrile:Acetone:Methanol). Untargeted liquid chromatography-mass spectrometry (LC-MS/MS) profiling was performed using fractionation on a Vanquish Horizon Binary UHPLC. Subsequent analyses were performed on an inline coupled Q-Exactive Orbitrap instrument. Metabolites were identified using Compound DiscovererTM software. Statistical analysis was performed using MetaboAnalyst 5.0.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001343	http://dx.doi.org/10.21228/M8439K			Exposures to Metals in Pregnant Women and the Impact on Fetal Development and Birth Outcomes in Suriname	The Caribbean Consortium for Environmental and Occupational Health, a NIH-funded integrated research and research training program, started in 2015. The research component is a population-based prospective longitudinal environmental epidemiologic cohort study addressing the potential adverse impact of chemical and non-chemical environmental exposures in mother/child dyads in Suriname. The study determines associations between exposures to neurotoxicants (metals and pesticides) and essential elements and non-chemical stressors in pregnant women and the impact on birth and neurodevelopmental outcomes. The study population consists of culturally diverse pregnant women (n=1143; ages: 16-49 years) and their babies/children (n=1069). Data collection takes place twice prenatally, at birth, 12, 36, and 48 months. Through HHEAR, targeted and untargeted (metabolomics) analyses will characterize exposure to metals in a sub-cohort of pregnant women for whom exposure data are not yet available. This expanded exposure analysis will enable a more comprehensive cumulative risk assessment of adverse birth and neurodevelopmental outcomes in the overall cohort.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001370	http://dx.doi.org/10.21228/M8N12W			Effect of long-term exposure to graphene on skin cell metabolism	Graphene-derived materials are a family of nanomaterials with multiple potential applications in different fields such as biomedicine. It is therefore essential to understand their interaction with cellular barriers such as skin. In this work we evaluated the metabolic changes in human skin cells (HaCaT) exposed to different GRMs for 7 and 30 days. Objectives Endogenous metabolic profiles of control and graphene-treated keratinocytes have been studied using ultra-high performance liquid chromatography – mass spectrometry (UHPLC-MS). Keratinocytes were treated with graphene oxide (GO) from two different suppliers and with few layer graphene (FLG). Samples were collected one week and one month after the start of the treatment. The general aim of the project was to evaluate potential metabolic differences between: 1) Graphene-treated keratinocytes and control keratinocytes at one week; 2) Graphene-treated keratinocytes and control keratinocytes at one month; 3) Control keratinocytes at 1 month and 1 week; 4) Graphene-treated keratinocytes at 1 month and 1 week. Experimental Procedures A successful metabolic profiling experiment relies on the ability to determine changes in an organism’s biofluid or tissue complement of metabolites. Mass spectrometry coupled to ultra-high performance liquid chromatography (UHPLC-MS) is well suited to such analyses due to its high sensitivity, large coverage over different classes of metabolites, high throughput capacity, and wide dynamic range. In this study, one UHPLC-MS based platform was used to analyse endogenous analytes for inclusion in subsequent statistical analysis procedures used to study metabolic differences between the groups of samples.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001382	http://dx.doi.org/10.21228/M8312X			Unveiling the mechanism of action of nature-inspired anti-cancer compounds using a multi-Omics approach	The 2020 global cancer registry has ranked breast cancer (BCa) as the most commonly diagnosed type of cancer and the most common cause of cancer-related deaths, especially in women worldwide. Increased resistance and significant side effects continue to limit the efficacy of anti-BCa drugs, hence the need to identify new drug targets and to develop novel compounds to overcome these limitations. Nature-inspired anti-cancer compounds are becoming increasingly popular since they often provide a relatively safe and effective alternative. In this study, we employed multi-omics techniques to gain insights into the novel and potentially relevant mechanism of action of two recently identified nature- inspired anti-cancer compounds (SIMR 3066 and SIMR 3058). Discovery proteomics analysis combined with LC-MS/MS-based untargeted metabolomics analysis was performed on compound-treated vs. DMSO-treated control MCF-7 cells. Downstream protein functional analysis showed that most of the responsive proteins were functionally associated with antigen processing and neutrophil degranulation, RNA catabolism and protein folding as well as cytoplasmic vesicle lumen and mitochondrial matrix formation. Consistent with the proteomics findings, metabolomic pathway analysis suggested that SIMR compounds could alter metabolic pathways such as glycolysis, the Krebs cycle and oxidative phosphorylation. Furthermore, metabolomics-based enriched-for-action pathway analysis showed that the of two SIMR compounds associate with mercaptopurine and thioguanine and azathiprine. Lastly, joint proteomics and metabolomics analysis revealed that treatment of BCa with SIMR3066 disrupts several signaling pathways including such p53-mediated apoptosis and the circadian entertainment pathway. Overall, the multi-omics we used in this study seems potent at probing the mechanism of action of novel anti-cancer agents.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001405	http://dx.doi.org/10.21228/M83T37			Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model	Untargeted Nuclear Magnetic Resonance (NMR) metabolomics of polar extracts from the pancreata of a caerulin-induced mouse model of pancreatitis (Pt) and of a transgenic mouse model of pancreatic cancer (PCa) were used to find metabolic markers of Pt and to characterize the metabolic changes accompanying PCa progression. Using multivariate analysis a 10-metabolite metabolic signature specific to Pt tissue was found to distinguish the benign condition from both normal tissue and precancerous tissue (low grade pancreatic intraepithelial neoplasia, PanIN, lesions).
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001473	http://dx.doi.org/10.21228/M8B40C			Characterizing the intrauterine environment via untargeted metabolomics profiling of maternal blood collected during pregnancy (Healthy Start Cohort)	This project is funded by the NIH Environmental influences on Child Health Outcomes (ECHO) program, and uses data from five cohorts: Healthy Start, Project Viva, Atlanta ECHO, Paneth Cohort, and PETALS. This project will generate new untargeted metabolomics profiling data at two time-points in pregnancy for all women in order to identify trimester-specific metabolomics signatures and longitudinal metabolomics trajectories associated with offspring birth size; identify the contribution of maternal sociodemographic and perinatal characteristics to the metabolomics signatures.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001483	http://dx.doi.org/10.21228/M81M72			Dietary inclusion of nitrite-containing frankfurter exacerbates colorectal cancer pathology, increases oxidative stress, alters metabolism and causes gut dybiosis in APCmin mice	This study investigated how the colorectal cancer pathology and metabolic status of adenomatous polyposis coli (APC) multiple intestinal neoplasia (min) mice was perturbed following 8 weeks of pork meat consumption.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001510	http://dx.doi.org/10.21228/M8HD93			Characterizing the intrauterine environment via untargeted metabolomics profiling of maternal blood collected during pregnancy (Atlanta ECHO Cohort)	This project is funded by the NIH Environmental influences on Child Health Outcomes (ECHO) program, and uses data from five cohorts: Healthy Start, Project Viva, Atlanta ECHO, Paneth Cohort, and PETALS. This project will generate new untargeted metabolomics profiling data at two time-points in pregnancy for all women in order to identify trimester-specific metabolomics signatures and longitudinal metabolomics trajectories associated with offspring birth size; identify the contribution of maternal sociodemographic and perinatal characteristics to the metabolomics signatures.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001554	http://dx.doi.org/10.21228/M8TM6T			Mass spectrometry dataset of LC-MS Lipidomics Analysis of Xenopus Laevis Optic Nerve	CNS injuries of the anuran amphibian, Xenopus laevis, are uniquely befitted for studying the molecular compositions of neuronal regeneration of retinal ganglion cells (RGC) due to a functional recovery of optic axons disparate to adult mammalian analogues. RGCs and their optic nerve axons undergo irreversible neurodegeneration in glaucoma and associated optic neuropathies, resulting in blindness in mammals. Conversely, Xenopus demonstrates RGC lifetime-spanning regenerative capabilities after optic nerve crush, inciting opportunities to compare de novo regeneration and develop efficient pharmaceutical approaches for vision restoration. Studies revealing lipidome alterations during optic nerve regeneration are sparse and could serve as a solid foundation for these underlying molecular changes. We profile the lipid changes in a transgenic line of 1 year old Xenopus laevis Tg(islet2b:gfp) frogs that were either left untreated (naïve) or had a monocular surgery of either a left optic crush injury (crush) or sham surgery (sham). Matching controls of uninjured right optic nerves were also collected (control). Tg(islet2b:gfp) frogs were allowed to recover for 7,12,18, and 27 days post optic nerve crush. Following euthanasia, the optic nerves were collected for lipidomic analysis. A modified Bligh and Dyer method [PMID: 13671378] was used for lipid extraction, followed by untargeted mass spectrometry lipid profiling with a Q-Exactive Orbitrap Liquid Chromatography-Mass Spectrometer (LC MS-MS) coupled with Vanquish Horizon Binary UHPLC LC-MS system.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001571	http://dx.doi.org/10.21228/M8MX49			Characterizing the intrauterine environment via untargeted metabolomics profiling of maternal blood collected during pregnancy (PETALS Cohort)	This project is funded by the NIH Environmental influences on Child Health Outcomes (ECHO) program, and uses data from five cohorts: Healthy Start, Project Viva, Atlanta ECHO, ARCH Cohort, and PETALS. This project will generate new untargeted metabolomics profiling data at two time-points in pregnancy for all women in order to identify trimester-specific metabolomics signatures and longitudinal metabolomics trajectories associated with offspring birth size; identify the contribution of maternal sociodemographic and perinatal characteristics to the metabolomics signatures.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001574	http://dx.doi.org/10.21228/M87Q6K			Characterizing the intrauterine environment via untargeted metabolomics profiling of maternal blood collected during pregnancy (ARCH Cohort)	This project is funded by the NIH Environmental influences on Child Health Outcomes (ECHO) program, and uses data from five cohorts: Healthy Start, Project Viva, Atlanta ECHO, ARCH Cohort, and PETALS. This project will generate new untargeted metabolomics profiling data at two time-points in pregnancy for all women in order to identify trimester-specific metabolomics signatures and longitudinal metabolomics trajectories associated with offspring birth size; identify the contribution of maternal sociodemographic and perinatal characteristics to the metabolomics signatures.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001610	http://dx.doi.org/10.21228/M8KT5B			Disrupted intestinal microbiota contributes to the pathogenesis of anorexia nervosa	Anorexia nervosa (AN) is an eating disorder with a high mortality affecting about 0.5% of women, where no evidence-based effective treatment exists. The pathogenesis likely involves genetic and environmental alterations. We hypothesized that a disrupted gut microbiota contributes to AN pathology. In analyses comparing 70 AN with 77 healthy females, we found multiple taxa, functional modules, structural variants and growth rates of bacterial gut microbiota, and viral gut microbiota that were altered in AN with parts of these perturbations linked to estimates of eating behavior and mental health. In silico, causal inference analyses implied bacterial metabolites mediated parts of the impact of altered gut microbiota on AN behavior, and in vivo, fecal microbiota transplantation from AN cases to germ-free mice induced a lower body weight and hypothalamic and adipose tissue gene expressions related to aberrant energy metabolism and eating and mental behavior.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001611	http://dx.doi.org/10.21228/M8G12B			Study of environmental toxicants and gut microbiome in relation to obesity and insulin resistance	Background & Aims: Environmental toxicants (ETs) associate with various adverse health outcomes. Here, we hypothesized that exposures to ETs are associated with obesity and insulin resistance via a dysbiotic gut microbiota and derived alterations in microbiome-mediated bile acid (BA) synthesis. Methods: Serum BAs, per- and polyfluoroalkyl substances (PFAS) and additional twenty-seven ETs were measured by mass spectrometry in 264 Danes (121 women and 143 men, age 56.6 ± 7.3 years, BMI 29.7 ± 6.0 kg/m2). Bacterial species were identified based on whole-genome shotgun (WGS) sequencing of DNA extracted from purified stool samples. Personalized genome-scale metabolic models (GEMs) of gut microbial communities were developed to elucidate regulation of BA pathways. Subsequently, we compared findings in the human study with metabolic implications of perfluorooctanoic acid (PFOA) exposure in a PPAR?-humanized murine model. Results: Fasting serum concentrations of twelve ETs associated directly with measures of obesity and insulin resistance. Several bacterial species including Dorea longicatena, Dorea formicigenerans, Subdoligranulum spp., Veillonella spp., and Roseburia intestinalis associated positively and in a sex-dimorphic manner, particularly in women, with high exposure to ETs. Moreover, high serum concentrations of ETs were linked with higher fasting serum levels of microbiome-synthesized secondary BAs such as lithocholic acid (LCA) and ursodeoxycholic acid (UDCA). These findings were substantiated by the outcome of a murine exposure study. Conclusion: Serum concentrations of ETs, particularly in women, were associated with an altered gut microbiome-mediated secondary BA biosynthesis, linked with obesity and insulin resistance.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001623	http://dx.doi.org/10.21228/M8X42D			Wide-Coverage Serum Metabolomic Profiling Reveals a Comprehensive Lipidome Signature of Ovarian Cancer.	Distinguishing ovarian cancer (OC) from other benign or cancerous gynecological malignancies remains a critical unmet medical need with significant implications on patient survival. Substantially better results are observed when women with OC are correctly diagnosed and ensured the right treatment. However, non-specific symptoms along with our lack of understanding of OC pathogenesis hinder its diagnosis, consequently leading to a very low survival rate. Accumulating evidence suggests the link between OC and deregulated lipid metabolism. Most studies, however, are limited by small sample sizes and metabolite coverage, thereby constraining the robustness of the results. Here, we performed a comprehensive serum lipidome profiling of OC and various other gynecological malignancies (non-OC). A relatively large patient cohort with 208 OC and 137 non-OC patients, including 93 OC patients with early-stage OC, was recruited from two independent clinical sites in South Korea. Samples were analyzed with high-coverage liquid chromatography high-resolution mass spectrometry, providing extensive lipidome coverage with 994 successfully annotated lipid features. Lipidome differences between OC and other gynecological malignancies were investigated via statistical and machine learning approaches. Our data suggest that lipidome alterations unique to OC can be detected as early as when the cancer is localized, and those changes amplify as the diseases progresses. Comparison of the relative lipid abundances revealed specific patterns based on lipid class with most lipid classes showing decreased abundance in ovarian cancer. This study provides a systemic analysis of lipidome alterations in OC, emphasizing the potential of circulating lipids as a complementary class of blood-based biomarkers for OC diagnosis.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001629	http://dx.doi.org/10.21228/M84M8C			Untargeted Metabolomics on First Trimester Serum Implicates Metabolic Perturbations Associated with BMI in Development of Hypertensive Disorders: A Discovery Study	Body mass index (BMI) in early pregnancy is a critical risk factor for hypertensive disorders of pregnancy (HDP). The pathobiology of the interplay between BMI and HDP is not fully understood and represents the focus of this investigation. BMI and 1st-trimester serum samples were obtained from the Global Alliance to Prevent Prematurity and Stillbirth repository for 154 women (105 without HDP and 49 with HDP). Metabotyping was conducted using ultra-high-performance liquid-chromatography high-resolution mass spectrometry (UHPLC HR-MS). Regression models were used to determine metabolites and pathway perturbations associated with BMI in women with and without HDP, and to determine metabolites and pathway perturbations associated with HDP for women in categories of obese, overweight, and normal weight based on the 1st trimester BMI. This study will lay the groundwork for larger studies of predictive markers and biological pathways leading to infant morbidity and mortality.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001645	http://dx.doi.org/10.21228/M82M7C			Exploring the Impact of Oral Arabic Gum Consumption on Sphingolipid Metabolism and human metabolites in Chronic Kidney Disease: A Mass Spectrometry Analysis	Globally, the incidence of chronic kidney disease is increasing, raising serious concerns about its impact on public health. It also poses significant difficulty in finding novel early diagnostics, understanding biochemical pathways, monitoring patients, and prognosis. Any metabolite found in a biofluid, or tissue may act as a driver, signal, or both in the emergence or spread of the disease. As a result, metabolomics is a very useful strategy in this therapeutic setting. Broad metabolite coverage is essential since it strives to offer a representative image of a biological system. An untargeted metabolomics-based method was used in this cross-sectional study to identify metabolomic changes and their relationship to pathways in the Arabic gum patient group and control participants. Plasma samples were collected from 88 participants who met the inclusion criteria, of whom 43 control patients were treated with a placebo and 45 intervention patients were treated with Arabic gum. Highly sensitive ultra-high-performance liquid chromatography with electrospray ionization and quadrupole time-of-flight mass spectrometry was used to analyze the plasma samples (UHPLC-ESI-QTOF-MS). We investigated the effect of Arabic gum on individual metabolites using a two-tailed independent student t-test. The results showed that 31 out of 92 identified metabolites were found to be statistically significant (p < 0.05). L-Leucine and 5'-Methylthioadenosine were the significantly increased metabolites in the Arabic gum group. Conversely, triethylamine, D-limonene, 4-methylphenylacetic acid, and sphingosine levels were significantly lower in the Arabic gum group compared to the control. Arabic gum primarily affected multiple metabolic pathways, including glycine and serine, arginine and proline, valine, leucine, and isoleucine degradation, phenylalanine and tyrosine, urea cycle, and sphingolipid. The results from this study provide insights into the potential diagnostic significance of different metabolites in chronic kidney disease and their impact on specific metabolic pathways. However, further research involving larger cohorts is necessary to validate the observed metabolite changes following Arabic gum intake and their diagnostic value for chronic kidney disease.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001647	http://dx.doi.org/10.21228/M8T413			Ethnicity-Specific Differences in Ovarian Cancer Metabolic Signatures	Ovarian cancer is a leading cause of cancer-related deaths among women worldwide. Cancer cell metabolism plays a critical role in tumor growth and progression, and metabolic alterations in cancer cells have been implicated in treatment resistance. In this study, we performed metabolomic analysis using ovarian cancer cells derived from patients in the United States and Korea. Our results reveal significant ethnic-specific differences in the metabolic signatures of ovarian cancer cells, with differential regulation of metabolites derived from glycolytic pathways, lipid metabolism, and microbiome modified metabolites. These findings have important therapeutic implications, as differences in ovarian cancer metabolism between ethnic groups may influence treatment response and resistance. Targeting the unique metabolic signatures of ovarian cancer cells based on ethnic specificity may improve the effectiveness of precision medicine approaches in the treatment of ovarian cancer. This study highlights the potential for personalized and targeted therapeutic options based on the tumor metabolome and ethnic background of the patient. Overall, our results suggest that investigating ethnic-specific differences in cancer metabolism is critical for developing effective and personalized cancer therapies. The identification of unique metabolic signatures in ovarian cancer cells based on ethnic specificity provides a promising avenue for improving treatment outcomes and advancing the field of precision medicine in ovarian cancer.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001667	http://dx.doi.org/10.21228/M87727			Per- and poly-fluoroalkyl substances (PFAS) Exposures and Child Health (PEACH) Study: Using targeted exposure assessment and untargeted metabolic profiling to characterize molecular pathways and mechanisms underlying PFAS toxicity on adverse birth and child health outcomes	The overarching goal of the Per- and poly-fluoroalkyl substances Exposures And Child Health (PEACH) Study is to apply an advanced untargeted metabolomics workflow to investigate associations between PFAS levels, perturbations in maternal and newborn metabolome and adverse birth outcomes. The Emory ECHO team has established a socio-economically diverse, exceptionally phenotyped African American (AA) maternal-child cohort that enrolls pregnant women in the early prenatal period and extends dyad follow-up through age five. PEACH draws from repeated metabolic profiling on a subset of 320 AA pregnant people within the Atlanta ECHO cohort, PFAS assessment, and untargeted metabolomics from newborn blood spots (n=279). Please contact Drs. Donghai Liang (Donghai.liang@emory.edu) and Anne Dunlop (amlang@emory.edu) via email for questions related to the subject characteristics and outcomes.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001696	http://dx.doi.org/10.21228/M8GM73			Impaired metabolism predicts coronary artery calcification in women with systemic lupus erythematosus	Background. Patients with systemic lupus erythematosus (SLE) exhibit a high risk for cardiovascular diseases (CVD) which is not fully explained by the classical Framingham risk factors. SLE is characterized by major metabolic alterations which can contribute to the elevated prevalence of CVD. In order to address this hypothesis, a comprehensive analysis of the circulating metabolome and lipidome was conducted in a large cohort of 211 women with SLE who underwent a multi-detector computed tomography scan for quantification of coronary artery calcium (CAC), a robust predictor of coronary heart disease (CHD). Results. Beyond traditional risk factors, including age and hypertension, disease activity and duration were independent risk factor for developing CAC in women with SLE. The presence of coronary calcium was associated with major alterations of circulating lipidome dominated by an elevated abundance of ceramides with very long chain fatty acids. Alterations in multiple metabolic pathways, including purine, arginine and proline metabolism, and microbiota-derived metabolites, were also associated with CAC in women with SLE. Backward stepwise logistic regression models of lipidomic and metabolomic variables were used to develop prognostic scores. Strikingly, combining metabolic and lipidomic variables with clinical and biological parameters markedly improved the prediction (area under the curve: 0.887, P<0.001) of the presence of coronary calcium in women with SLE. Conclusion. The present study uncovers the contribution of disturbed metabolism to the presence of coronary artery calcium and the prediction of CHD in SLE. Identification of novel lipid and metabolite biomarkers may help stratifying patients for reducing CVD morbidity and mortality in SLE.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001701	http://dx.doi.org/10.21228/M8TT5H			Characterizing the intrauterine environment via untargeted metabolomics profiling of maternal blood collected during pregnancy (Project Viva)	This project is funded by the NIH Environmental influences on Child Health Outcomes (ECHO) program, and uses data from five cohorts: Healthy Start, Project Viva, Atlanta ECHO, Paneth Cohort, and PETALS. This project will generate new untargeted metabolomics profiling data at two time-points in pregnancy for all women in order to identify trimester-specific metabolomics signatures and longitudinal metabolomics trajectories associated with offspring birth size; identify the contribution of maternal sociodemographic and perinatal characteristics to the metabolomics signatures.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001730	http://dx.doi.org/10.21228/M8371M			A nested case-control study of untargeted plasma metabolomics and lung cancer risk among never-smoking women in Shanghai Women’s Health Study	Background: The etiology of lung cancer among never smokers has not been fully elucidated despite 15% of cases in men and 53% in women worldwide are not smoking-related. Metabolomics provides a snapshot of dynamic biochemical activities, including those found to be driving tumor formation and progression. This study used untargeted metabolomics with network analysis to agnostically identify network modules and independent metabolites in pre-diagnostic blood samples among never-smokers to further understand the pathogenesis of lung cancer. Methods and Findings: Within the prospective Shanghai Women’s Health Study, we conducted a nested case-control study of 395 never-smoking incident lung cancer cases and 395 never-smoking controls matched on age. We performed liquid chromatography high-resolution mass spectrometry to quantify 20,348 metabolic features in plasma. We agnostically constructed 28 network modules using a weighted correlation network analysis approach and assessed associations for network modules and individual metabolites with lung cancer using conditional logistic regression models, adjusting for covariates. We accounted for multiple testing using a false discovery rate (FDR) &lt; 0.20. We identified a network module of 122 metabolic features enriched in lysophosphatidylethanolamines that was associated with all lung cancer combined (p = 0.001, FDR = 0.028) and lung adenocarcinoma (p = 0.002, FDR = 0.056) and another network module of 440 metabolic features that was associated with lung adenocarcinoma (p = 0.014, FDR = 0.196). Metabolic features were enriched in pathways associated with cell growth and proliferation, including oxidative stress, bile acid biosynthesis, and metabolism of nucleic acids, carbohydrates, and amino acids, including 1-carbon compounds. Conclusions: Our prospective study suggests that untargeted plasma metabolomics in pre-diagnostic samples could provide new insights into the etiology of lung cancer in never-smokers. Replication and further characterization of these associations are warranted.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001769	http://dx.doi.org/10.21228/M82130			Multi-assay nutritional metabolomics profiling of low vitamin A status versus adequacy is characterized by reduced plasma lipid mediators among lactating women in the Philippines: A pilot study	Low vitamin A (VA) status is common among lactating women in low-income countries. Lactation has substantial effects on mother’s metabolism and VA is required in multiple biological processes, including growth, vision, immunity, and reproduction. The objective of this pilot study was to utilize metabolomics profiling to conduct a broad, exploratory assessment of differences in plasma metabolites associated with low VA status versus VA adequacy in lactating women. Plasma samples from lactating women who participated in a survey in Samar, Philippines, were selected from a cross-sectional study based on plasma retinol concentrations indicating low (VA-; n=5) or adequate (VA+; n=5) VA status (plasma retinol <0.8 or >1.05 µmol/L). The plasma results collected from six metabolomics assays (oxylipins, endocannabinoids, bile acids, primary metabolomics, biogenic amines, and lipidomics) were compared by group using liquid chromatography mass spectrometry. Twenty-eight metabolites were altered in the VA- versus VA+ status groups, with 24 being lipid mediators (p<0.05). These lipid mediators included lower concentrations of arachidonic acid- and eicosapentaenoic acid-derived oxylipins, as well as lysophospholipids and sphingolipids, in the VA- group (p<0.05). Chemical similarity enrichment analysis identified HETEs, HEPEs, and DiHETEs as significantly altered oxylipin clusters (p<0.0001, false discovery rate (FDR) p<0.0001), as well as sphingomyelins, saturated lysophosphatidylcholines, phosphatidylcholines, and phosphatidylethanolamines (p<0.001, FDR p<0.01). The multi-assay nutritional metabolomics profiling of low VA status compared with adequacy in lactating women was characterized by reduced lipid mediator concentrations. Future studies with stronger study designs and larger sample size are needed to confirm and validate these preliminary results.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001828	http://dx.doi.org/10.21228/M8F14S			Role of PI3K in Atrial Myopathy: Insights from Transgenic Mouse Models and Identification of a Dysregulated PI3K Lipid Profile in Individuals with Atrial Fibrillation	In a serendipitous discovery, atrial enlargement, fibrosis and thrombi was identified in a subset of transgenic mice with reduced phosphoinositide 3-kinase (PI3K, class IA) in cardiac myocytes. Understanding mechanisms underlying atrial myopathy has important implications for understanding and preventing atrial fibrillation (AF). Prior work had shown that PI3K is an essential regulator of exercise-induced ventricular enlargement and protection, but the role in the atria was unknown. Further, while targeting IGF1-PI3K-Akt signaling has been considered a potential therapeutic strategy for the failing heart, growing evidence suggests fine-tuning IGF1-PI3K signaling would be necessary. Here, we undertook comprehensive physiological and molecular analyses in cardiac-specific transgenic mice with increased or decreased PI3K to assess the dose response impact of directly regulating PI3K. Elevated PI3K was associated with a dose-dependent increase in heart size, and preserved/enhanced function. In contrast, reduced PI3K led to cardiac dysfunction, fibrosis, arrhythmia, and increased susceptibility to atrial enlargement and thrombi. This phenotype was associated with dysregulation of a lipid species (GM3) that regulates the IGF1-PI3K pathway, cardiac stress and contractility genes. Proteomic profiling identified distinct signatures across atria with varying degrees of atrial dysfunction, enlargement, and presence of atrial thrombi. To assess the potential relevance in humans we assessed circulating PI3K-related lipids in plasma from athletes with/without AF. Dysregulation of GM3 and PI3K-related lipids were identified in athletes with AF. Collectively, this work advances our understanding of mechanisms underpinning atrial pathophysiology, offers new insights for therapeutic approaches targeting atrial myopathy and AF, and has identified potential new lipid markers for identifying individuals at risk of AF.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001832	http://dx.doi.org/10.21228/M8X144			A study of the physiological functions and impact of secretory protein Cgref1	Cell Growth Regulator with EF-Hand Domain 1 (Cgref1) is a secretory protein with limited information on its functions. Our group has performed an extensive study using both in-vitro and in-vivo models. Particularly, we used transgenic mice in which the Cgref1 gene is deleted to enable loss-of-function studies. Cgref1-knockout (KO) mice are generally leaner and metabolically healthier compared to wild type mice. To gain evidence of certain parameters, metabolomics studies have been performed for this project.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001852	http://dx.doi.org/10.21228/M8B424			Metabolomics Insights into Doxorubicin and 5-Fluorouracil Combination Therapy in Triple-Negative Breast Cancer: A Xenograft Model Study	Background: Breast cancer is one of the most prevalent malignancies and a leading cause of death among women worldwide. Among its subtypes, triple-negative breast cancer (TNBC), which poses significant clinical challenges due to its aggressive behavior and limited treatment options. Aim: This study explored the effects of doxorubicin (DOX) and 5-fluorouracil (5-FU) as monotherapies and in combination on MDA-MB-231 xenograft model. Employing advanced metabolomics analysis, the study was designed to investigate molecular alterations triggered by these treatments. Methods: State-of-the-art metabolomics analysis using Ultra-high-performance liquid chromatography-electrospray ionization quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS) was conducted including comprehensive plasma and tumor tissue sample profiling. Results: The study explored alterations induced by DOX, 5-FU, and their combination treatment. Each treatment group exhibited unique metabolic profiles in plasma and tumor analysis. Univariate and enrichment analyses identified alterations in metabolic pathways, including glycine and serine metabolism, spermidine and spermine biosynthesis, and purine and pyrimidine pathways. The combination of DOX and 5-FU significantly influenced plasma and tumor metabolites. The comprehensive metabolic profiling of both plasma and tumor samples shed light on the intricate changes within the tumor microenvironment and their systemic implications. Conclusion: The study findings offer insights into the metabolic vulnerabilities of TNBC in vivo induced by the studied chemotherapeutics. These findings highlight the involved metabolites and metabolic pathways in the response of MDA-MB-231 cells to DOX, 5-FU, and their combination which advance our understanding of TNBC treatment strategies, offering new possibilities for enhancing therapeutic outcomes.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001875	http://dx.doi.org/10.21228/M8BX4T			A High-Fat Eucaloric Diet Induces Reprometabolic Syndrome of Obesity in Normal Weight Women	Objective: We examined the effects of one month of a eucaloric, high-fat (48% of calories) diet (HFD) on gonadotropin secretion in normal weight women to interrogate the role of free fatty acids and insulin in mediating the relative hypogonadotropic hypogonadism of obesity. Methods: Eighteen eumenorrheic women (BMI 18-25 kg/m2) were studied in the early follicular phase of the menstrual cycle before and after exposure to a HFD with frequent blood sampling for LH and FSH, followed by an assessment of pituitary sensitivity to GnRH. Mass spectrometrybased plasma metabolomic analysis was also performed. Paired testing and time series analysis were performed as appropriate. Results: Mean endogenous LH (unstimulated) was significantly decreased after the HFD (4.3 ±1.0 vs 3.8 ± 1.0, P&lt;0.01); mean unstimulated FSH was not changed. Both LH (10.1 ± 1.0 vs 7.2 ± 1.0, P&lt;0.01), and FSH (9.5 ± 1.0 vs 8.8 ± 1.0, P&lt;0.01) response to 75 ng/kg of GnRH were reduced after the HFD. Mean LH pulse amplitude and LH interpulse interval were unaffected by the dietary exposure. Eucaloric HFD exposure did not cause weight change. Plasma metabolomics confirmed adherence with elevation of fasting free fatty acids (especially long-chain mono-, poly- and highly-unsaturated fatty acids) by the last day of the HFD. Conclusion: One-month exposure to a HFD successfully induced key reproductive and metabolic features of Reprometabolic Syndrome in normal weight women. Dietary factors may underly the gonadotrope compromise seen in obesity related subfertility and that therapeutic dietary interventions, independent of weight loss, may be possible.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001880	http://dx.doi.org/10.21228/M8Q72K			Untargeted Metabolomics Reveals Unique Biomolecular Signatures in Overweight and Obesity Using UHPLC-ESI-QTOF-MS Analysis	Obesity poses a multifaceted challenge to global public health, impacting individuals and society in various ways. Apart from the heightened susceptibility to chronic conditions such as diabetes, cardiovascular diseases, obesity significantly escalates healthcare costs. Effective public health strategies are essential for addressing issues related to early detection, diagnosis, and personalized treatment plans. This emphasizes the crucial need for a deep understanding of biochemical pathways, patient monitoring, and prognosis. In this context, metabolomics has become a valuable approach, focusing on the identification of metabolites in biofluids and tissues.In this study, an untargeted metabolomics-based method was employed to investigate metabolomic changes and their relationship to pathways in overweight and obese individuals. Plasma samples were collected from 29 healthy individuals with normal weight, 17 overweight individuals, and 28 obese individuals who met the inclusion criteria for the study. The plasma samples were analyzed using highly sensitive ultra-high-performance liquid chromatography electrospray ionization quadrupole time-of-flight mass spectrometry. Pantothenic acid and L-proline showed increased levels in the overweight group, whereas phenylacetaldehyde and glycerophosphocholine were notably decreased compared to the normal weight group. Conversely, the obese group exhibited elevated levels of specific metabolites, including L-leucine, L-tryptophan, phenylalanine, and tyrosine. On the contrary, the obese group demonstrated decreased levels of other metabolites such as 2,3-Diaminopropionic acid, and phenylacetaldehyde. Additionally, significant changes in metabolic pathways, such as pantothenate and CoA biosynthesis, and beta-alanine metabolism, were observed in the overweight group. In contrast, the obese group displayed significant alterations in phenylalanine and tyrosine metabolism, tryptophan metabolism, and beta oxidation of very long-chain fatty acids. The present investigation sheds light on the potential diagnostic significance of certain metabolites in obesity and the impact of their level changes on specific metabolic pathways. Additional studies are necessary to confirm the association of these metabolites in obesity and to confirm their diagnostic value.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001898	http://dx.doi.org/10.21228/M8CQ76			Identification and validation of serum metabolite biomarkers for endometrial cancer diagnosis	Endometrial cancer (EC) stands as the most prevalent gynecological tumor in women worldwide. Notably, differentiation diagnosis of abnormity detected by ultrasound findings (e.g., thickened endometrium or mass in the uterine cavity) is essential and remains challenging in clinical practice. Herein, we identified a metabolic biomarker panel for differentiation diagnosis of EC using machine learning of high-performance serum metabolic fingerprints (SMFs) and validated the biological function. We first recorded the high-performance SMFs of 191 EC and 204 Non-EC subjects via particle-enhanced laser desorption/ionization mass spectrometry (PELDI-MS). Then, we achieved an area-under-the-curve (AUC) of 0.957-0.968 for EC diagnosis through machine learning of high-performance SMFs, outperforming the clinical biomarker of cancer antigen 125 (CA-125, AUC of 0.610-0.684, P &lt; 0.05). Finally, we identified a metabolic biomarker panel of glutamine, glucose, and cholesterol linoleate with an AUC of 0.901-0.902 and validated the biological function in vitro. Therefore, our work would facilitate the development of novel diagnostic biomarkers for EC in clinics.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR001980	http://dx.doi.org/10.21228/M8SJ0J			Depression symptoms modifies differently plasma metabolites in pre- and post-menopausal women	Depression will be the disease with the highest incidence worldwide by 2030. Data indicate that postmenopausal women have a higher incidence of mood disorders, and this high vulnerability seems to be related to hormonal changes and weight gain. Although research evaluating the profile of metabolites in mood disorders is advancing, further research, maintaining consistent methodology, is necessary to reach a consensus. Therefore, the objective of the present study was to carry out an exploratory analysis of the plasma polar metabolites and lipids of pre- and postmenopausal women to explore whether the profile is affected by depression. The study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Human Research Ethics Committee of the Universidade Federal de São Paulo (nº 0624/2019) and all participants signed the informed consent. 42 premenopausal and 67 postmenopausal women had the depression symptoms assessed by the Beck Depression's Inventory (BDI). Lipids and polar metabolites were extracted from plasma and analyzed in an ultra-performance liquid chromatography system (UHPLC) coupled to a spectrometer with a triple-quadrupole analyzer operating with an electrospray ionization source (ESI) in positive and negative mode. Lipids and polar metabolites analyses was performed using MetaboAnalyst 5.0. Ten metabolites were significantly affected by depression symptoms in postmenopause, including Adenosine, Guanosine, Proline, Citrulline, Lysine, and Carnitine, which were down-regulated, and Dimethylglycine, Glutathione, Creatine, and Methionine that were up-regulated. In premenopausal women with depression, Oxidized Glutathione was down-regulated, and Dimethylglycine and 4-hydroxyproline were up-regulated. Seven lipids were were significantly affected by depression symptoms in pre-menopausal women PC(36:1)/PC(18:1(9Z)/18:0), PC(19:0/19:0), and LTB4 were up-regulated and PC(18:0/14:0)/GPCho(18:0/14:0), SM(d18:1/16:0), LysoPC(18:1(9z))/LPC 18:1, and Azelaoyl-PAF were down-regulated. In post-menopausal women PC(16:1(9z)/16:1(9z)) and 14,15-DHET were down-regulated and acetylcarnitine was up-regulated. Though there seems to be a relationship in the occurrence of obesity and depression in women the hormonal status influenced the effect of depression in women and that this status may be taken into account when searching for a marker for depression.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002005	http://dx.doi.org/10.21228/M8FJ9V			Protein restriction slows the development and progression of Alzheimer's disease in mice	Dietary protein is a critical regulator of metabolic health and aging. Low protein diets are associated with healthy aging in humans, and many independent groups of researchers have shown that dietary protein restriction (PR) extends the lifespan and healthspan of mice. Here, we examined the effect of PR on metabolic health and the development and progression of Alzheimer’s disease (AD) in the 3xTg mouse model of AD. We found that PR has metabolic benefits for 3xTg mice and non-transgenic controls of both sexes, promoting leanness and glycemic control in 3xTg mice and rescuing the glucose intolerance of 3xTg females. We found that PR induces sex-specific alterations in circulating metabolites and in the brain lipidome, downregulating sphingolipid subclasses including ceramides, glucosylceramides, and sphingomyelins in 3xTg females. Consumption of a PR diet starting at 6 months of age reduced AD pathology in conjunction with reduced mTORC1 activity, increased autophagy, and had cognitive benefits for 3xTg mice. Finally, PR improved the survival of 3xTg mice. Our results demonstrate that PR slows the progression of AD at molecular and pathological levels, preserves cognition in this mouse model of AD, and suggests that PR or pharmaceutical interventions that mimic the effects of this diet may hold promise as a treatment for AD.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002011	http://dx.doi.org/10.21228/M8P23X			Lipidomic analysis of Axon Regeneration in Xenopus laevis Chiasm	CNS injuries of the anuran amphibian, Xenopus laevis, are uniquely befitted for studying the molecular compositions of neuronal regeneration of retinal ganglion cells (RGC) due to a functional recovery of optic axons disparate to adult mammalian analogues. RGCs and their optic nerve axons undergo irreversible neurodegeneration in glaucoma and associated optic neuropathies, resulting in blindness in mammals. Conversely, Xenopus demonstrates RGC lifetime-spanning regenerative capabilities after optic nerve crush, inciting opportunities to compare de novo regeneration and develop efficient pharmaceutical approaches for vision restoration. Studies revealing lipidome alterations during optic nerve regeneration are sparse and could serve as a solid foundation for these underlying molecular changes. We profile the lipid changes in a transgenic line of 1 year old Xenopus laevis Tg(islet2b:gfp) frogs that were either had a monocular surgery of either a left optic crush injury (crush) or sham surgery (sham). The matching controls of uninjured right optic nerves were also collected (control). Tg(islet2b:gfp) frogs were allowed to recover for 12 and 27 days post optic nerve crush. Following euthanasia, the optic nerves were collected for lipidomic analysis. A modified Bligh and Dyer method was used for lipid extraction, followed by untargeted mass spectrometry lipid profiling with a Q-Exactive Orbitrap Liquid Chromatography-Mass Spectrometer (LC MS-MS) coupled with Vanquish Horizon Binary UHPLC LC-MS system.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002032	http://dx.doi.org/10.21228/M8ZC0C			Metabolomic Analysis of Axon Regeneration in Xenopus laevis	CNS injuries of the anuran amphibian, Xenopus laevis, are uniquely befitted for studying the molecular compositions of neuronal regeneration of retinal ganglion cells (RGC) due to a functional recovery of optic axons disparate to adult mammalian analogues. RGCs and their optic nerve axons undergo irreversible neurodegeneration in glaucoma and associated optic neuropathies, resulting in blindness in mammals. Conversely, Xenopus demonstrates RGC lifetime-spanning regenerative capabilities after optic nerve crush, inciting opportunities to compare de novo regeneration and develop efficient pharmaceutical approaches for vision restoration. Studies revealing metabolome alterations during optic nerve regeneration are sparse and could serve as a solid foundation for these underlying molecular changes. We profile the metabolite changes in the optic tissues of a transgenic line of 1 year old Xenopus laevis Tg(islet2b:gfp) frogs that either had a monocular surgery of either a left optic crush injury (crush) or sham surgery (sham). The matching controls of uninjured right optic nerves were also collected (control). Tg(islet2b:gfp) frogs were allowed to recover for 12 and 27 days post optic nerve crush. Following euthanasia, the tissues were collected for metabolomic analysis. Samples were pooled for each category (crush, sham, and control) at n =3 to obtain sufficient metabolite concentrations for analysis. Metabolites were extracted using a Precellys Homogenizer and a serial extraction method: (1) 1:1 Methanol/Water and (2) 8:1:1 Acetonitrile/Methanol/Acetone. Metabolites were analyzed by untargeted liquid chromatography-mass spectrometry (LC MS-MS) profiling using a Q-Exactive Orbitrap instrument coupled with Vanquish Horizon Binary UHPLC LC-MS system. Metabolites were identified and quantified using Compound Discoverer 3.3 and isotopic internal metabolites standards.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002055	http://dx.doi.org/10.21228/M8052C			Comparative analysis of breast cancer metabolomes highlights fascin's central role in regulating key pathways related to disease progression	Omics technologies provide useful tools for the identification of novel biomarkers in many diseases, including breast cancer, which is the most diagnosed cancer in women worldwide. We and others have reported a central role for the actin-bundling protein (fascin) in regulating breast cancer disease progression at different levels. However, whether fascin expression promotes metabolic molecules that could predict disease progression has not been fully elucidated. Here, fascin expression was manipulated via knockdown (fascinKD+NORF) and rescue (fascinKD+FORF) in the naturally fascin-positive (fascinpos+NORF) MDA-MB-231 breast cancer cells. Whether fascin dysregulates metabolic profiles that are associated with disease progression was assessed using untargeted metabolomics analyses via liquid chromatography-mass spectrometry. An overall of 12,226 metabolites were detected in the tested cell pellets. Fascinpos+NORF cell pellets showed 2,510 and 3,804 significantly dysregulated metabolites compared to their fascinKD+NORF counterparts. Fascin rescue (fascinKD+FORF) revealed 2,710 significantly dysregulated cellular metabolites compared to fascinKD+NORF counterparts. 101 overlapped cellular metabolites between fascinKD+FORF and fascinpos+NORF were significantly dysregulated in the fascinKD+NORF cells. Analysis of the significantly dysregulated metabolites by fascin expression revealed their involvement in the metabolism of sphingolipid, phenylalanine, tyrosine and tryptophan biosynthesis, and pantothenate and CoA biosynthesis, which are critical pathways for breast cancer progression. Our findings of fascin-mediated alteration of metabolic pathways could be used as putative poor prognostic biomarkers and highlight other underlying mechanisms of fascin contribution to breast cancer progression.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002062	http://dx.doi.org/10.21228/M82Z4P			Randomized phase II trial of pre-operative fulvestrant with or without enzalutamide for ER+/Her2- primary breast cancer: effects on tumor immune microenvironment and clinical outcomes.	Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether the addition of AR blockade to Fulv would limit residual tumor at time of surgery, as measured by modified preoperative endocrine predictive index (PEPI) score. Eligible patients were women with ER+/HER2- primary BC cT2 or greater. Stratification factors were clinical node and T-stage. Fresh tumor biopsies were required at study entry, after 4 weeks on therapy (W5), and at surgery (W17). Laboratory analyses on tumors included immunochemistry (IHC) for ER/PR/AR/GR and Ki67 protein, evaluation of gene expression, multiplex for myeloid lineage immune cells, reverse phase protein array, and plasma metabolomic analyses. 59 out of 69 consented patients were evaluable. Toxicity was as expected with endocrine therapy. Combo achieved PEPI=0 more frequently (24%: 8/33) than Fulv (8%: 2/26). Ki67 was &lt;10% across arms by W5 or surgery in most patients (23/33 (70%) on Combo, 21/26 (81%) on Fulv). mTOR activation was elevated in tumors with poor Ki67 response. Tumors in both arms showed decreased estrogen-regulated and cell division gene sets, while Combo uniquely exhibited enrichment of immune activation genes sets, including interferon gamma, complement, inflammation, antigen processing, and B and T cell activation. Multiplex IHC showed significantly reduced tumor-associated macrophages and CD14+/HLADR-/CD68- MDSCs with Combo at W5. In summary, Combo achieved a higher PEPI=0 response, Ki67 response, and more activated tumor immune microenvironment than Fulv. The odds of response were 4.6-fold higher for patients with ILC versus IDC.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002063	http://dx.doi.org/10.21228/M8Z823			Effects of LDAH on the lipidome of oxLDL-treated mouse peritoneal macrophages	Lipid droplet-associated hydrolase (LDAH) has a lipase structure and high affinity for lipid droplets of macrophages/foam cells. However, LDAH's functions and lipid substrates remain poorly understood. In this project we treated mouse peritoneal macrophages isolated from LDAH-transgenic mice and wild-type littermate controls with oxidized low-density lipoprotein (oxLDL) and analyzed the effects of LDAH overexpression on their lipidome.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002073	http://dx.doi.org/10.21228/M8NR71			Impact of partial body shielding from very high dose rates on untargeted metabolomics in biodosimetry	A realistic exposure to ionizing radiation (IR) from an improvised nuclear device will likely include individuals that are partially shielded from the initial blast delivered at a very high-dose rate (VHDR). As different tissues have varying levels of radiosensitivity, e.g. hematopoietic vs. gastrointestinal tissues, the effects of shielding on radiation biomarkers needs to be addressed. Here, we explore how biofluid (urine and serum) metabolite signatures from male and female C57BL/6 mice exposed to VHDR (5 – 10 Gy/sec) total body irradiation (TBI, 0, 4, and 8 Gy) compare to individuals exposed to partial body irradiation (PBI) (lower body irradiated [LBI] or upper body irradiated [UBI] at an 8 Gy dose) using a data-independent acquisition untargeted metabolomics approach. Although sex differences were observed in the spatial groupings of urine signatures from TBI and PBI mice, a metabolite signature (N6,N6,N6-trimethyllysine, carnitine, propionylcarnitine, hexosamine-valine-isoleucine, taurine, and creatine) previously developed from variable dose rate experiments was able to identify individuals with high sensitivity and specificity irrespective of radiation shielding. A panel of serum metabolites composed from previous untargeted studies on nonhuman primates had excellent performance for separating irradiated cohorts; however, a multi-omic approach to complement the metabolome could increase dose estimation confidence intervals. Overall, these results support the inclusion of small molecule markers in biodosimetry assays without substantial interference from upper or lower body shielding.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002080	http://dx.doi.org/10.21228/M8RJ9N			Fast Targeted Metabolomics for Analyzing Metabolic Diversity of Bacterial Indole Derivatives	Disruptions in microbial metabolite interactions due to gut microbiome dysbiosis and metabolomic shifts may contribute to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and other immune-related conditions. The aryl hydrocarbon receptor (AhR), activated upon binding various tryptophan metabolites, modulates host immune responses. This study investigates whether the metabolic intrinsic variation—the concentration distribution—of bacterial indole pathway metabolites can differentiate bacterial strains and classify ME/CFS samples. A fast-targeted liquid chromatography-parallel reaction monitoring method with a 4-minute cycle time was developed for large-scale analysis. This method revealed significant metabolic intrinsic variation in indole derivatives among B. uniformis strains cultured from human isolates. Principal component analysis identified two major components (PC1, 68.9%; PC2, 18.7%), accounting for 87.6% of the variance and distinguishing two distinct B. uniformis clusters. The metabolic intrinsic variation between clusters was particularly evident in the contributions of indole-3-acrylate and indole-3-aldehyde. We explored the metabolic intrinsic variation of indole derivatives as potential biomarkers for ME/CFS by analyzing fecal samples from patients and healthy controls using the fast-targeted metabolomics method. An AdaBoost-LOOCV model achieved moderate classification success. Our findings suggest that the local indole intrinsic variation of tryptophan degradation is a promising biomarker for differentiating bacterial strains and classifying ME/CFS samples. The fast-targeted metabolomics method and data analysis enable accurate and precise quantitative measurements of metabolic intrinsic variation in indole derivatives, facilitating the study of microbial contributions to ME/CFS and other immune-related conditions.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002089	http://dx.doi.org/10.21228/M8KR7D			Human milk microbiome across lactation stages and free glutamate concentrations in healthy Ecuadorian women	Project Summary: To examine the differences in microbiome and glutamate concentrations in human breast milk among different lactation stages (colostrum-, transition-, and mature-milk), a longitudinal cohort study for healthy Ecuadorian women was conducted. This deposition is for the glutamate analysis.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002132	http://dx.doi.org/10.21228/M81N7D			1H NMR metabolomics applied to assess the direct and transgenerational effects of simvastatin on the metabolism of the amphipod Gammarus locusta	Pharmaceutical compounds (PhACs) and their metabolites are considered contaminants of emerging concern (CECs) to public and environmental health, due to their high stability, bioactivity, and persistence in conventional wastewater treatment plants. Aquatic organisms can be chronically exposed to PhACs during critical periods of their life or even through multi-generations. This may result in severe physiological/metabolic/endocrine disturbances, not only through direct exposure but also through inter- and transgenerational inheritance (in the absence of the insult). Special attention is given to simvastatin, one of the PhACs most prescribed to humans for the primary treatment of hypercholesterolemia, known to affect endocrine functions and disrupt reproduction, development, neuronal processes and/or other important physiological responses; not only in exposed individuals, but also in subsequent non-exposed generations. Previous studies observed that direct exposure and transgenerational exposure to simvastatin has been found to impact severely on crustaceans’ reproduction, growth and development, although the underlying mechanism remains partially unclear. NMR metabolomic approaches may provide crucial complementary mechanistic information about the cascade of metabolic events occurring with exposure. In this study a comprehensive untargetd 1H NMR metabolomics study was applied to measure the metabolic effects of direct exposure to environmentally relevant concentrations of simvastatin (F0) and transgenerational exposure (F3, where only the F0 generation was exposed) on the keystone marine amphipod species Gammarus locusta. Furthermore, NMR is here employed for the first time to address G. locusta metabolic behavior. The obtained data added important knowledge, paving the way to an improved understanding of the metabolic events cascade associated with simvastatin exposure.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002143	http://dx.doi.org/10.21228/M8MF9C			Repeated urinary VOC and PAH metabolites during pregnancy in the context of the Ghana Randomized Air Pollution and Health Study (GRAPHS)	This study will use untargeted metabolomics data acquired from 300 women at 3 timepoints during pregnancy whose urine samples were stored in the GRAPHS biorepository for discovery of new biomarkers of household air pollution exposure and to explore associations with health outcomes. Researchers interested in learning more about the cohort and available data should reach out to Alison Lee: Alison.Lee@mssm.edu.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002147	http://dx.doi.org/10.21228/M83F9Q			TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism	Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial activity and sequence variants are major risk factors for late onset Alzheimer’s disease (LOAD). To better understand the molecular and functional changes associated with TREM2 signalling, we generated a TREM2 reporter mouse model and observed a gradual upregulation of reporter expression with increasing plaque proximity. Isolated microglia were sorted based on reporter expression and their transcriptomic profiles acquired in both wildtype and APP transgenic animals, allowing us to disentangle TREM2 versus pathology-specific effects. Bulk RNA sequencing highlighted TREM2 level-dependent changes in major immunometabolic pathways, with enrichment of genes in oxidative phosphorylation and cholesterol metabolism in microglia with increased TREM2 expression. To confirm these findings, we next analysed uptake of fluorodeoxyglucose (FDG) and examined metabolomic and lipidomic profiles. Again, independent of Aβ pathology, TREM2 expression correlated with uptake of FDG as well as increased cellular redox, energetics, and cholesterol homeostasis. Finally, we performed chronic treatment with a brain penetrant TREM2 agonist and identified a window of TREM2 expression where microglia are most responsive. Thus, our data provide novel insights into TREM2-mediated regulation of microglial metabolic function and informs current efforts to bring TREM2 agonists into clinical application.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002153	http://dx.doi.org/10.21228/M89Z57			A NRF2/β3-adrenoreceptor axis drives a sustained antioxidant and metabolic rewiring through the pentose-phosphate pathway to alleviate cardiac stress	Background Cardiac β3-adrenergic receptors (β3AR) are upregulated in diseased hearts and mediate antithetic effects to those of β1AR and β2AR. β3AR agonists were recently shown to protect from myocardial remodeling in preclinical studies and to improve systolic function in patients with severe heart failure. The underlying mechanisms, however, remain elusive. Methods To dissect functional, transcriptional and metabolic effects, hearts and isolated ventricular myocytes from mice harboring a moderate, cardiac-specific expression of a human ADRB3 transgene (β3AR-Tg) and subjected to transverse aortic constriction (TAC) were assessed using echocardiography, RNAseq, PET scan, metabolomics, seahorse and metabolic flux analysis. Subsequently, signaling and metabolic pathways were investigated further in vivo in β3AR-Tg and in vitro in neonatal rat ventricular myocytes adenovirally infected to express β3AR and subjected to neurohormonal stress. These results were completed with an analysis of single nucleus RNAseq data from human cardiac myocytes from heart failure patients. Results Compared with WT littermate, β3AR-Tg mice were protected from hypertrophy after transaortic constriction (TAC), while systolic function was preserved. β3AR-expressing hearts displayed enhanced myocardial glucose uptake under stress in absence of increased lactate levels. Instead, metabolomic and metabolic flux analyses in stressed hearts revealed an increase in intermediates of the Pentose-Phosphate Pathway (PPP) in β3AR-Tg, an alternative route of glucose utilization, paralleled with increased transcript levels of NADPH-producing and rate-limiting enzymes of the PPP, without fueling the hexosamine metabolism. The ensuing increased content of NADPH and of reduced glutathione decreased myocyte oxidant stress, while downstream oxidative metabolism assessed by oxygen consumption was preserved with higher glucose oxidation in β3AR-Tg post-TAC compared to WT, together with increased mitochondrial biogenesis. Unbiased transcriptomics and pathway analysis identified NRF2 (NFE2L2) as upstream transcription factor which was functionally verified in β3AR-expressing cardiac myocytes where its translocation and nuclear activity was dependent on β3AR activation of nitric-oxide synthase (NOS) NO production. Conclusion Moderate expression of cardiac β3AR, at levels observed in human cardiac myocardium, exerts antioxidant effects through activation of the PPP and NRF2 pathway, thereby preserving myocardial oxidative metabolism, function and integrity under pathophysiological stress.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002154	http://dx.doi.org/10.21228/M8681W			Associations Between Maternal Microbiome, Metabolome and Incidence of Low-Birth Weight in Guatemalan Participants from the Women First Trial	Low birth weight (babies born at less than 2,500 grams) affects approximately 15 to 20 percent of global births annually and is associated with poor child development. The goal of this study was to examine relationships between maternal microbial taxa, fecal metabolites, and maternal anthropometry on incidence of LBW in resource-limited settings. This was a secondary analysis of the Women First trial conducted in a semi-rural region of Guatemala. Maternal weight was measured at 12 and 34 weeks (wk) of gestation. Infant anthropometry measures were collected within 48 h of delivery. Maternal fecal samples at 12 and 34 wk were used for microbiome (16S rRNA gene amplicon sequencing) and metabolomics analysis (34 wk only). Linear mixed models using the MaAslin2 package were utilized to assess changes in microbiome associated with LBW. Predictive models using gradient boosted machines (XGBoost) were developed using the H2o.ai engine. No differences in β-intrinsic variation were observed at either time point between mothers with LBW infants relative to normal weight (NW) infants. Simpson intrinsic variation at 12 and 34 wk was lower in mothers with LBW infants. Notable differences in genus-level abundance between LBW and NW mothers (p&lt; 0.05) were observed at 12 weeks with increasing abundances of Barnesiella, Faecalibacterium, Sutterella, and Bacterioides. At 34 weeks, there were lower abundances of Magasphaera, Phascolarctobacterium, and Turicibacter and higher abundances of Bacteriodes, and Fusobacterium in mothers with LBW infants. Fecal metabolites related to bile acids, tryptophan metabolism and fatty acid related metabolites changed in mothers with LBW infants. Classification models to predict LBW based on maternal anthropometry and predicted microbial functions showed moderate performance. Collectively, the findings indicate that less beneficial gut microbes and circulating metabolites of the mother is associated with low birth weight infants compared to normal weight. Future research should target functional and predictive roles of the maternal gut microbiome in infant birth outcomes including birthweight.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002168	http://dx.doi.org/10.21228/M8CR8X			Arachidonic acid fuels inflammation by unlocking 5-LOX in macrophages after myocardial infarction to promote cardiac dysfunction	An overactive inflammatory response and immune cell infiltration in myocardial infarction (MI) impairs tissue repair. Arachidonic acid (AA) metabolites act as important sources of inflammatory mediators in cardiac tissue. We investigated the mechanisms underlying the AA cascade-mediated inflammatory response after MI. Metabolomics analyses revealed that the 5-lipoxygenase (5-LOX)-dependent AA metabolic pathway derivative leukotriene B4 (LTB4) accumulated in large quantities after MI. Elevated levels of AA in vivo after MI facilitated the recruitment of protein phosphatase 5 (PP5) into the nucleus by binding PP5 to its nuclear transporter receptor karyopherin subunit alpha 1. On entering the nucleus, PP5 directly dephosphorylated 5-LOX at Thr218, promoting the production of the proinflammatory mediator LTB4 by macrophages. Transgenic mice were created with a population of cardiac resident macrophages with a mutation at 5-LOX Thr218. Single-cell transcriptomics showed that these cells overexpressed CXC-chemokine ligand 13 and actively recruited B cells to the heart, exacerbating tissue inflammation. In a UK Biobank cohort, the PP5 E76D mutation was found to be associated with complications after acute MI. Overall, our results have elucidated a conserved role for 5-LOX-phosphorylation-regulated LTB4 levels in MI and identified PP5 as a potential therapeutic target for the treatment of MI.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002178	http://dx.doi.org/10.21228/M83C2C			Dysregulated Follicular Fluid Metabolism in Women with Unexplained Infertility	Research Question: Are there specific metabolomic alterations in the Follicular fluid (FF) of women with unexplained infertility (UI)? Study Design: This case-control study included 20 women undergoing in-vitro fertilization (IVF), comparing 10 women diagnosed with UI to 10 control women whose male partners had abnormal semen parameters. FF samples were collected during oocyte retrieval and analysed using hydrophilic interaction liquid chromatography and reversed-phase liquid chromatography, coupled with tandem mass spectrometry (MS/MS) on a Q-TOF mass spectrometer. Metabolites were identified using XCMS Online and MetaboAnalyst, followed by pathway enrichment analysis via the KEGG database. Statistical analyses including OPLS-DA and ROC analysis assessed their diagnostic potential. Metabolite levels were correlated with clinical parameters, including embryo development rates, oocyte maturation, and IVF outcomes. Results: In women with UI, 12 metabolites, including Diacylglycerols, Phosphatidic acids, Vitamin D3 glucosiduronate, 1α-hydroxy-2β-(5-hydroxypentoxy) vitamin D3, Asparginyl-Asparagine, Lithocholic acid, Leu-Pro-Ala-Ser-Phe, Triacylglycerols, Phosphatidyl choline, Phosphatidylethanolamine and Lactosyl ceramide were significantly decreased, while Ile-Lys-Val-Val was significantly increased compared to controls. These metabolites were linked to glycerophospholipid metabolism, glycerolipid metabolism, and steroid synthesis pathways. PLS-DA, OPLS-DA, and ROC analysis indicated high diagnostic performance, with AUC values exceeding 0.8. Additionally, Vitamin D3 glucosiduronate levels negatively correlated with embryo development rates, while Asparginyl-Asparagine levels demonstrated a positive correlation with the MII oocyte rate. Conclusion: This study constitutes the first comprehensive characterization of metabolic dysregulation in the FF of women with UI, offering novel insights into the underlying mechanisms contributing to this condition and advocates for routine assessment of vitamin D3 levels in serum/FF of these women.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002198	http://dx.doi.org/10.21228/M8HC23			Metabolomics of Papanicolaou Tests for the Discovery of Ovarian Cancer Biomarkers	Ovarian cancer (OC) remains one of the most lethal cancers among female populations due to the vast majority of cases going undiagnosed until later stages (stage III, IV). Early detection and treatment of this malignancy provides the best prognosis, but the lack of accurate and sensitive screening tools combined with the presence of ambiguous symptoms hinders these diagnoses. In contrast, screening for cervical cancer via Papanicolaou (Pap) tests is a widespread practice with use spanning the past several decades, reducing this cancer’s morbidity and mortality rates. Two types of Pap smear tests exist: a conventional method where cells from the ectocervix are stained on a glass slide and a liquid-based cytology method. Interestingly, previous studies show evidence of OC cells in Pap tests, suggesting that lipids shed from ovarian tumors may end up in the cervix. The goal of this study is to evaluate the practicality of using liquid-based Pap tests as biospecimens for OC screening-related metabolic studies. Cell pellets from liquid-based Pap tests from 29 healthy women were analyzed via ultra-high performance liquid chromatography mass spectrometry (UHPLC-MS). This approach facilitated the detection and annotation of 453 unique lipids across 20 lipid subclasses, including ceramides, triacylglycerols, and hexosylceramides. These results demonstrated the feasibility of using an MS-based approach to analyze residual Pap test samples for the discovery of OC-related lipid biomarkers with the goal of detecting OC at early stages of the disease.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002235	http://dx.doi.org/10.21228/M8QR7N			An insight into the chemical exposome during pregnancy	This project focuses on the non-targeted analysis of serum and placenta samples from pregnant women to identify exogenous chemicals.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002245	http://dx.doi.org/10.21228/M8F83T			Untargeted Lipidomics of African American women at 8-10 months postpartum	Lipid dysregulation is hallmark of CMCPreg, specifically polyunsaturated fatty acids (PUFA) metabolism and downstream lipid mediators. To investigate whether this lipid dysregulation is prolonged after delivery, we performed untargeted lipidomics on serum collected 8-10 months postpartum from African American women who were diagnosed with cardiometabolic complications of pregnancy and from those with uncomplicated, term deliveries. We identified 11 lipids that were significantly increased in the postpartum serum of African American women who experienced cardiometabolic complications of pregnancy. These species belonged to sphingolipid, glycerolipid, and cholesteryl ester lipid classes and reveal dysregulated activity of glycerophospholipid metabolism, sphingolipid metabolism, sphingolipid signaling pathways, ferroptosis, and others by lipid enrichment pathway analysis. We also observed increases in Resolvin D3, 13 HpODE, AEA, OEA, and LEA suggesting dysregulated endocannabinoid signaling and increased phospholipaseA2 activity. Combined, these findings demonstrate that African American women who experienced cardiometabolic complications of pregnancy may have dysregulated lipid metabolism that extends as long as 8-10 months postpartum.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002256	http://dx.doi.org/10.21228/M8125S			Multi-Omic Analysis Links Neighborhood Disadvantage to Elevated Cortisol Metabolites and Tumorigenic Markers in ER+ Breast Cancer Patient Plasma and Tumor Samples	Intro: Estrogen receptor positive (ER+) breast cancer (BC) patients living in disadvantaged neighborhoods experience worse survival compared with patients in advantaged neighborhoods. Chronic stress, indicated by elevated cortisol levels, may mediate this disparity by dysregulating inflammatory responses driving BC tumorigenesis. However, the role of cortisol in ER+ BC remains underexplored. Objective: To explore associations between pre-treatment plasma cortisol, inflammatory proteins, tumoral gene expression changes, and neighborhood disadvantage in women with primary ER+ BC compared to cancer-free controls. Methods: Pretreatment plasma samples were collected from women with primary ER+ BC (n=98) and cancer-free controls (n=144). Tumor samples were obtained from a subset of cases (n=77). Samples were obtained from three Chicago hospitals serving disadvantaged or advantaged neighborhoods. Plasma samples were analyzed via a steroid hormone metabolomics assay and Olink Proteomic’s inflammatory proteins panel. Gene expression in tumor samples was analyzed via the Breast Cancer 360 Nanostring panel. Univariate single -omics analysis was performed using a mixed model and multi-omics data integration was performed using the mixOmics R package. Results: Among all cases vs. controls, cortisol-related metabolites were elevated in cases (p&lt;0.05), with the cortisol/cortisone ratio remained significantly elevated in disadvantaged cases vs. controls (p&lt;0.01) but not advantaged cases vs. controls. In disadvantaged individuals, 62 inflammatory proteins were elevated (p&lt;0.05), including five weakly correlated with the cortisol/cortisone ratio (p&lt;0.05). Genes upregulated in disadvantaged vs. advantaged cases were those involved in inflammation and cell cycle regulation, while downregulated genes were those involved in anti-inflammation (p&lt;0.05). Motif analyses showed NFKB as a top motif (p&lt;0.01), suggesting dysregulated immune/inflammation and cortisol signaling. Integrative multi-omics analysis further supported dysregulation in inflammatory signaling correlated with altered cortisol metabolism. Conclusion: BC diagnosis in disadvantaged individuals is associated with elevated cortisol, potentially contributing to elevated circulating inflammatory proteins and tumoral gene expression changes that promote tumor progression.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002271	http://dx.doi.org/10.21228/M82V6D			Metabolome trajectory of exercise physiology- a comprehensive study of healthy male and female athletes	BACKGROUND. Integrating metabolomics in sports science provides valuable insights into the biochemistry during physical activity. However, due to their invasiveness, traditional blood sampling methods present challenges in sports settings. The study investigated sex-specific metabolic responses, addressing a significant gap in exercise research, where female participation remains underrepresented. METHODS. To address this, we explored volumetrically accurate microsampling (VAMS) as a dried blood spot (DBS) technique for assessing metabolomic changes in response to acute exercise in more than 130 participants. This study employed a targeted quantitative approach using isotopically-labeled internal standards to measure over 100 metabolites in DBS, providing accurate and traceable results. An accuracy assessment using standard reference material and stability testing over 90 days further evaluated the suitability of DBS for sports metabolomics. RESULTS. Our findings confirm that DBS offers a valid approach to capturing metabolic changes during exercise, reporting a wide panel of metabolites including key metabolites of energy pathways, which correlate well with plasma-derived data but also less studied classes such as pyrimidines. Implementing a straightforward standardization concept established metabolic perturbations upon bout exercise as differences of absolute concentrations. CONCLUSIONS. While metabolic regulations upon exercise are similar in both sexes, differences in the correlation with fitness-related metadata such as peak volitional oxygen consumption (V̇O2peak) and performance, indicate a higher complexity in women and a limitation of previous knowledge to men only. The quantification approach together with the simplicity of the sampling paves the way to expand this type of research towards other fields of personalized medical services.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002276	http://dx.doi.org/10.21228/M8F53S			Discovery of Metabolic Biomarkers for Gestational Diabetes Mellitus: An In-Depth Metabolomics Investigation Utilizing Mass Spectrometry	Gestational diabetes mellitus (GDM) is a predominant medical complication Aims: Gestational diabetes mellitus (GDM) is a predominant medical complication during pregnancy, which is characterized by a glucose intolerance identified during pregnancy and generally resolved after childbirth. Women with a GDM history are 7 times more subject to develop type 2 diabetes compared to healthy pregnant women. Metabolic alteration during pregnancy has been suggested as an underlying cause of GDM. Metabolomics of collected blood from GDM pregnant women indicate that GDM is associated with alteration of amino acids, fatty acids, and glycolysis. However, deep metabolomics analysis to identify complicated and unique pathways that can guide prognosis and treatment are not fully determined particularly with Middle Eastern women. Developing such data in comparison to published data will help to provide more understanding of the disease progression and for target treatment. Methods: In this research, we utilized metabolomics-assisted technology to identify dysregulated metabolic pathways and metabolites in pregnant women with GDM compared to healthy pregnant women. Trapped ion mobility spectrometry time-of-flight TIMS-QTOF MS was employed on blood samples collected from 32 GDM pregnant women in comparison to 20 healthy pregnant women. This was followed by significant statistical analysis including two-tailed independent Student's t-test, P&lt;0.05 will be considered significant. These findings facilitate clear understanding of underlying metabolic pathways and early detection of GDM and hence will enable effective targeting treatment. Results: The student t-test analysis was used, 33 of the 108 metabolites that were discovered had statistical significance (p&lt;0.05) when compared between the two groups. When compared to the control group, which consists of normal pregnant women, the gestational diabetes group had significantly lower levels of citramalic acid, creatinine, D-arginine, and glutamine, while the group with gestational diabetes had higher levels of 4-aminohippuric acid, homovanillic acid, alpha-aspartyl-lysine, L-aspartyl-L-phenvlalanine, L-valine, L-leucine, and normetanepherine. Conclusion: Understanding specific metabolic interactions aids pregnant GDM patients in comprehending many factors affecting their metabolic environment. In addition to enhancing our understanding of the molecular mechanisms underlying GDM, this knowledge makes it possible to explore targeted therapeutics for its management or prevention by altering unusual metabolomic pathways.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002466	http://dx.doi.org/10.21228/M8W82G			Metabolomic analysis of breast cancer in Colombian patients: Exploring molecular signatures in different subtypes and stages	Breast cancer is a neoplasm characterized by high heterogeneity, influenced by intrinsic molecular subtypes and clinical stage, aspects that remain underexplored in the Colombian population. This study aimed to characterize the metabolic alterations associated with subtypes and disease pro-gression using an untargeted metabolomics approach in a cohort of newly diagnosed, treat-ment-naive Colombian women. Samples were analyzed using LC-QTOF-MS and GC-QTOF-MS, along with amino acid profiling to improve metabolite coverage. Alterations consistent with previous studies were identified; however, the Luminal B subtype showed elevated levels of long-chain acylcarnitines, along with higher concentrations of free fatty acids compared to other subtypes. It also presented elevated levels of carbohydrates and essential glycolytic intermediates, suggesting that this subtype may adopt a hybrid metabolic phenotype characterized by increased glycolytic flux as well as enhanced fatty acid catabolism. TNM (Tumor, Node, Metastasis) staging analysis showed progres-sive metabolic reprogramming of breast cancer. In advanced stages, a sustained increase in phosphatidylcholines and a decrease in lysophosphatidylcholines were observed, reflecting lipid alterations associated with key roles in tumor progression. In early stages (I-II), plasma metabo-lites with high discriminatory power were identified, such as pyrrolidone glutamic acid, ribose, and glycerol, which are associated with dysfunctions in energy and carbohydrate metabolism. These results highlight metabolomics as a promising tool for early diagnosis, clinical follow-up, and molecular characterization in breast cancer.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002493	http://dx.doi.org/10.21228/M8D54V			Metabolome analysis as a potential source of endometriosis biomarkers	This project aims to analyse the metabolomic profiles of plasma and peritoneal fluid samples obtained from women with endometriosis and compare them to those of the control group. It involves the collection of samples from women undergoing laparoscopic surgery in several medical centres.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002527	http://dx.doi.org/10.21228/M80R9W			Serum Metabolites at Defined Stages of Liver Disease	The present dataset comprises a total of 978 compounds of known identity (named biochemicals). Following log transformation and imputation of missing values, if any, with the minimum observed value for each compound, ANOVA contrasts were used to identify biochemicals that differed significantly between experimental groups. A summary of the numbers of biochemicals that achieved statistical significance (p≤0.05), as well as those approaching significance (0.05&lt;p&lt;0.10), is shown below. Analysis by two-way ANOVA identified biochemicals exhibiting significant interaction and main effects for experimental parameters of time and treatment. An estimate of the false discovery rate (q-value) is calculated to take into account the multiple comparisons that normally occur in metabolomic-based studies. For example, when analyzing 200 compounds, we would expect to see about 10 compounds meeting the p≤0.05 cut-off by random chance. The q-value describes the false discovery rate; a low q-value (q&lt;0.10) is an indication of high confidence in a result. While a higher q-value indicates diminished confidence, it does not necessarily rule out the significance of a result. Other lines of evidence may be taken into consideration when determining whether a result merits further scrutiny. Such evidence may include a) significance in another dimension of the study, b) inclusion in a common pathway with a highly significant compound, or c) residing in a similar functional biochemical family with other significant compounds. Refer to the Appendix for general definitions and further descriptions of false discovery rate and other statistical tests used at Metabolon.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002574	http://dx.doi.org/10.21228/M8XP05			Metabolic-Immuno-Hormonal Crosstalk in Breast Cancer	Breast cancer (BC) remains the leading cause of cancer-related death among women in the Middle East and North Africa, with particularly high mortality in the United Arab Emirates (UAE), mainly due to delayed diagnosis. This study aimed to identify metabolic biomarkers associated with BC progression in the UAE population. A total of 135 metabolites were detected using LC/MS-MS, of which 15 were significantly different between the two groups (q-value &lt; 0.05). Notably, 4 metabolites including hypoxanthine, allantoic acid, 2-phenylbutyric acid, and uridine were significantly upregulated in BC patients (FC &gt; 1.5, q-value &lt; 0.05). However, 11 metabolites including vitamin D3, N-acetylputrescine, 9-methyluric acid, thyroxine, indoleacetic acid, guanidine, L-arginine, guanidinosuccinic acid, androstenedione, L-homocysteic acid, and PC (18:1(9Z)/18:1(9Z)) were significantly downregulated in BC patients relative to HC (FC=0.2-0.6, q-value &lt; 0.05). Further analysis was conducted to identify specific biomarkers between early and late-stage BC. Compared to HC, L-arginine, guanidine, isocitric acid, guanidinosuccinic acid, indoleacetic acid, ethanolamine, diethanolamine, and thyroxine levels were significantly (q-value &lt; 0.05) downregulated only in early BC patients reflecting altered metabolic pathways critical to early tumor development particularly those involved in amino acid and energy metabolism. In late stage BC, pipecolic acid and estradiol were found to be significantly (q-value &lt; 0.05) increased only in patients with late-stage BC compared to HC (healhty control), indicating an enhanced lysine degradation and hormonal dysregulation. However, PC (18:1(9Z)/18:1(9Z)), urea, androstenedione, 9-methyluric acid were significantly (q-value &lt; 0.05) reduced in late BC patients compared to HC indicating metabolic reprogramming that favor tumor progression. Hypoxanthine and allantoic acid were significantly upregulated in both early- and late-stage BC. Vitamin D3, N-acetylputrescine, urocanic acid, L-homocysteic acid were significantly downregulated in both early- and late-stage BC. Further, significant increase (FC=4.75, q-value &lt; 0.05) in biotin levels was observed in patients with high proliferative tumor (Ki-67 &gt; 14%) compared to patients with low proliferative (Ki-67 &lt; 14%), indicating that this metabolite is important for cancer cell proliferation and further investigations are warranted to identify its role in BC cells proliferation. All these alterations indicates that the tumor is in increased demand for specific metabolites to support rapid proliferation and survival, highlighting potential opportunity for biomarker development and therapeutic intervention. Collectively, the metabolomics analysis revealed significant metabolic alterations between BC patients and HC, with distinct upregulation and downregulation of key metabolites linked to tumor progression, proliferation, and stage-specific metabolic reprogramming. The main metabolic pathway altered in BC patients is amino acid metabolism, particularly arginine metabolism, tryptophan metabolism, and lysine metabolism. These pathways are critical for providing biosynthetic precursors, supporting energy demands, and facilitating tumor proliferation and progression, making them potential targets for biomarker development and therapeutic intervention.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002609	http://dx.doi.org/10.21228/M8DG1T			Urinary Multi-Omics Signatures of Preterm Premature Rupture of Membranes: Insights into Microbial and Metabolic Biomarkers	Preterm premature rupture of membranes (PPROM) is a significant obstetric complication, often associated with infection-related processes. However, the underlying mechanisms remain poorly understood, particularly regarding the interplay between microbial dysbiosis and host metabolism. To address this, urine samples from women with PPROM and healthy controls were analyzed using 16S rRNA gene sequencing and ¹H NMR-based metabolomics. Microbiota analysis revealed increased abundance of Hoylesella, Escherichia, Pseudomonas, and Enterococcus in the PPROM group, whereas Lactobacillus and Limosilactobacillus dominated in controls. Metabolomics identified key metabolites with diagnostic potential. Receiver operating characteristic (ROC) analysis showed that hippurate, formate, citrate, glycolate, serine, valine, and isoleucine had high discriminatory accuracy (AUC &gt; 0.7), while β-glucose, asparagine, pyroglutarate, 2-hydroxyglutarate, tyrosine, creatinine, and imidazole had moderate predictive power. The PPROM group exhibited increased valine, isoleucine, asparagine, and β-glucose, while others decreased compared to controls. Multi-omics integration revealed robust correlations between specific bacterial species and urinary metabolites, suggesting interactions between microbial dysbiosis and host metabolic pathways. These findings demonstrate distinct microbial and metabolic signatures in the urine of women with PPROM and support the utility of urinary multi-omics analysis in advancing understanding of PPROM pathophysiology.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002701	http://dx.doi.org/10.21228/M8HR9J			Cardiometabolic and molecular adaptations to 6-month intermittent fasting in middle-aged men and women with overweight: secondary outcomes of a randomized controlled trial	ABSTRACT Intermittent fasting (IF) has gained attention as a potential intervention for cardiometabolic health, though its long-term effects remain unclear. In this randomized clinical trial (ClinicalTrials.gov NCT01964118), we assessed the impact of 6 months of IF on body composition, cardiovascular risk factors, and related molecular pathways in middle-aged (30-65 years) men and women with overweight (BMI 24.8–35 kg/m²). In this trial, 41 participants were randomized to either an intermittent fasting (IF) intervention or to maintain their habitual diet. The primary outcome (circulating CRP concentration) was previously reported; here, we present secondary analyses focusing on metabolomic and transcriptomic responses. IF led to an 8% reduction in body weight, a 16% decrease in body fat, and significant improvements in lipid profile, including substantial reductions in plasma LDL-cholesterol, non-HDL-cholesterol, and triglycerides (p=0.001). However, no significant changes were observed in other cardiometabolic risk factors. To investigate the underlying molecular mechanisms, we performed untargeted plasma metabolomics and transcriptomic analysis of colon mucosa biopsies. Significant multi-omic changes were identified, particularly in lipid metabolism, bile acid signaling, and enteroendocrine regulation. Notably, there was a downregulation of transcripts related to glucagon-like peptide 1 (GLP-1) and related enteroendocrine hormones. Correlation analysis highlighted key molecular pathways, with PPAR-α and B-cell-mediated immune processes significantly associated with changes in non-HDL cholesterol. Our findings extend the understanding of IF in humans beyond weight loss, providing key mechanistic insights to inform targeted therapies for improving cardiometabolic health.
ingest/c2m2s/Metabolomics/MW_submission_packet_20251214/MW_submission_packet_20251214/project.tsv:https://www.metabolomicsworkbench.org/	PR002716	http://dx.doi.org/10.21228/M8KK1D			Integrated liver and brain lipidomics reveal tissue-specific alcohol effects and systemic intervention of fat-1 gene in mice with alcohol-associated liver disease	Alcohol-associated liver disease (ALD) involves profound systemic lipid disruption. Using comprehensive 2DLC-MS-based untargeted lipidomics, we characterized the hepatic and cerebral lipidomes in wild-type and fat-1 transgenic (endogenous omega-3 PUFA-producing) mice subjected to a chronic-plus-binge ethanol model. Compared to fat-1 gene, ethanol intake was the dominant factor that induced 228 lipids in the liver and 316 in the brain with significant abundance changes. . Those significantly changed lipids were consistent across wild-type and fat-1 genotypes but highly tissue-specific. Furthermore, fat-1 genotype significantly modulated ethanol's impact and even reversed the regulation of some lipids, including sphingolipids and monosaturated and saturated fatty acyl-containing lipids. Four lipids in the liver and seven lipids in the brain were co-regulated by ethanol, genotype, and their interaction, with excellent discriminatory power in linear discriminant analysis. The odd-chain lipids of those 11 lipids suggest gut microbiome contributions. While ethanol effects were tissue-specific, fat-1 induced consistent responses in the two tissues, indicating conserved protective pathways. Our findings revealed complex lipid network remodeling in ALD through a multi-factorial affecting the liver-brain axis, highlighting the potential of fat-1 gene to mitigate tissue-specific metabolic dysfunction and informing future therapeutic strategies.
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion08.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion08.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion08.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file_in_collection.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac-pass1b-06-metabolomics-untargeted
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	e0452370-214f-5385-8468-37290cdb829a		358022436		e8b49f66e15d0efe6291a76fb00872a3f07c7c0fc75b2c69a32a71a06bf4aba2		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	52d11b7e-7189-5705-aa2e-6815ce673cdc		359751817		b4ac9a05ed920a05913885e8f40f97d0dc84122648da6e080b6968fa08f23a81		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	bfaf559a-ca4c-5577-8e75-4a019b5c1b0f		353848227		61b5ad23d6d0c51a9f14912f8f51661b1511c7ed502db769ea2ad2ef4ddc88df		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	6d874c08-10ae-5219-9835-a813a8587dce		354800868		b0e824d7fb2ed1ab7993a361fd46d914767b02156767579f32457317e706ab04		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	0051d0e2-fd1b-5cdb-a985-de784982228d		162237654		1c941134a5f734dd841fc33f106cc65ad04783d5727283d325ddf3d478db123f		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	d5f268a1-3ac5-5e57-826e-59465f57c989		160977095		285aa28164f86116eb8b109f412628d97ede7bcbaf4157f15c8c92304b4333ce		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	f54791ef-13e5-5d51-8241-66fe7b277331		163118611		943ba65aefe8655ab6e44b6688e39001348803f9cd292ace88ea5d048af077c6		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	e8997910-dd65-5254-8b84-270309ead7f0		158182622		fafb13e9a113efb01691703cd7cbe4683dce0b1d470715c719658b8d2cf6ed48		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	b4d63e68-46bc-5062-929b-422318be3814		159256887		1923f211d8b93eaf9e7e74d60157786f65c630408119f6ccd12ae1d2fb2632ff		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac	8c0a67b6-c8da-576e-9bca-ca06b2954195		159089789		9465ca9f713da3def57f04bcbef7a9137519565a3086235e8e9bb6ea9053fc59		DDA_Inclusion06.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac	1abcb872-f4c6-5f6b-b88f-f49ce65c52fe		160653077		75101d8f8b95ebcc2281f88a3682fa75a117f27128e37ed9d2186ba8083454b4		DDA_Inclusion07.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t31-plasma/metab-u-lrppos/DDA_Inclusion08.raw	tag:motrpac-data.org,2023:	motrpac	e0c4e7c6-6520-599d-bee6-28889bb095db		158667055		6f9809a82b985a288f66616e60b287af3767f3711bd818bff1096c29a3486620		DDA_Inclusion08.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	aa775df4-6399-517f-9cfc-c26c5e1daa53		354436117		8535a653ecf9a6a536ce1c7dc8abd262fcc0ebb89507bb723f951beea720b0cc		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	70db7e96-dbae-5880-a1e1-442a7eaf9b2a		358376416		42fa7263192343f8700021e8e44fc44bbd33f373f6b62f29310bd94a6301eb35		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	2cc5681f-d2e2-5101-939c-9b023c10e488		356170572		0d09494a423545cb5a5b81e282a887c8472bbc797bb62b7cef1c49b10e9fb1cb		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	199c5129-6bd2-5925-8165-f886611b9802		352916055		da66a4238a0f952be7a1b968a62fcfc1bcfcf86fb31ba17c473096d4e822be2b		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	97459326-46f9-5be2-b7ab-0ac43d367ccb		175678391		54127bd5964d655eb3cfabbe2dfdbf66e6d887d4fe3c6cb0fe906f93364af7e0		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	d270f451-7bb5-5cce-8fac-228432a802e5		173847394		d1ebc38f2226b06e1408bd2f5105a3733b9a2fd8e99b2f7ecba6630bc0262d39		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	d8dec18d-48aa-5d3d-982c-e6aab8d7d9cf		171240690		a969c52ccaccfcc8b1772b67b66452f527fd4d3f4a8ce9e027d0f33baae4c23e		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	7d840530-0372-50d2-81cd-40a23929b0b9		174126278		377693e0f1da5bb3dc9013c49872553b47a8b8b347b4c0a70dbcb7517d8f5b8d		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	3b9f2b4d-817e-53bd-92df-f6e11279703f		171277051		65bbe3a67865769a015e9f59b9af662e9720e987e2d47ad69e39a1dee829f9fb		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t52-hippocampus/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac	aa7230f6-ede4-5ba0-9c40-b8cb4bfbc4a9		173586222		4b7002c53af5254b708dcdfeac694cbdf50922abea287590985b350656d0d50e		DDA_Inclusion06.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	53b0a122-7c22-5226-b9dc-efdb5a7c5a6d		373417731		b0f96cf5d8ac9ec44f264a8b7fe4f77f232512b5537b6b745dab6027a8b0dbf9		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	167750fa-b463-51f5-bc3a-e5e2812ac78d		374328581		6ae468dca08589c0d0452d6b5ddad4f0453a294885a4ceebdc181b855c07d753		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	e00d3f4a-1e03-5b16-acdd-9d454dc2f468		375253214		0fcb3374c83eaffbf3dfa847431a68581d173474cfc70415ceb7d80aad42e7c4		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	2cf06283-1b30-573b-8e08-61a5da5252e7		369031306		6da9a6d789317955d802b177c780d56a3402dc840427dc5757c1a08632b4816f		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	c2ce1fbb-af1d-56f2-aa82-bc2356a717b7		182422994		92d032a9a7d9fe53ff3a2e4c4c3a69808bc94ec2437ef9876477332aa3296397		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	e767af42-fc28-5bfc-902c-8a257dadf8ff		178502622		a30c8320cb7c4382767238a617a697becca399d473e48405c1e1c951961f426e		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	34687d57-4b20-5714-985a-1901f0984432		180330471		bb330db2487d1c024f195616f2cefec29dee910719044c1b9b8f67cc5d91aec1		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	5ff321cb-3930-5b1e-85e6-cf811fdb3ed0		180358406		9992a09e39350307a9f0d933eed23e59caed0b68568d90fdc4aee3d8dad42bc2		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t55-gastrocnemius/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	f6d20e0f-9597-5d86-91c1-9dee0191768a		101029985		d2845e1b7a112fa3d9d653b78112f24e0299f1ca92d86ed0b92f35aab6747ada		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	28dc9e27-a79a-5060-a477-08fd616ace3c		355332327		f48480dc45c12475e5fa724cb40e8ae78c548f189f62327c9d9c1613962b05e3		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	e2b4b47e-e714-5cbe-91e4-2fe86338ad22		359461297		edb13d3a46f91590676da90e2f8c2a2c201fc886b354bb622e5c65d5c81d5f90		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	05f491d2-8c40-51d2-b4f6-272c9e90fd24		165496794		fbdeae4f93912c5381f130dab3d034bbcc941c79f165b8194a3fb80645a26647		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	8d07d3d9-7841-5bd0-88aa-6ee49c9007c9		166976029		849cd753b82ea82e8d75dff5bfc6cc905235f213f89866f9f3a437edcc9c255f		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	4f7cd1ed-29d9-5132-b15a-b7d1ae61a44f		96251284		0b14f6bbf8ec1554eb527c63e19fca14271451364e5478d45dfe793303ca435b		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	2efce349-bbe3-59be-82bb-7a9ee95e2ac2		167403846		83f4ed6e7b1ca41d5475bf3672d82790eaf975e4b81448c70811aa7eab095572		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t58-heart/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	782d1c6a-fdf9-5998-bf64-2a69783d5094		166516690		4bebffe032d197dbeb2c47751f3af4ac70f43d2d26f544abf5f34bbf48e55a34		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	6d5d815b-1ef3-5997-9a7a-1aaf04054984		361597229		142f6ada33800888f8ea656709ebaa122df8d7f2476ca1411a193f582ba79ea8		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	e84d9f3b-0b30-5fe8-acbd-f842f1101e58		357915252		fc8b9ac83cf77a520fd33f1e03507525beaf320b955d25aa8b12fcd3bc9a6e23		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	64a10df7-05b5-55bd-b7ba-c9193c49745c		362739655		293dc8a180818f5a33bc92266509b0ab4e44fda232cff9f911e8c365c892742b		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	49eae0c7-085c-584c-900d-cf1e8cd4ed35		170456980		bdb32e7d8bf8b28e3f7106b667995c859fd5145214baedbbb3060487c08e2ecc		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	3f7b3d33-b85c-5590-a087-fe70ef0d5a16		168284553		6883ca4650b22831be9373b94d3cc63b3fc7cc2ad690d5b7d8865a1639ba4423		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	dac37970-6705-5a79-822a-9dfa5d05d9a8		167365804		d0d452dd102f0671317ac22a759212e6f04fbad6ae6f2e07936286fc97be49db		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	cf660874-1e7c-5506-bfb5-c505101eaf04		164957182		c6e3b01bface918ac6494ccc40e73f031041caae651a2e0f418883b361e6c521		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	28f2a92a-4925-5c73-ad1c-1e4ab1cb6ef5		167722833		2a6b17e71dbdfedb7feda230a160b44f305ccfd1f6f875b4326faf45b05da7da		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac	09ad5991-ad48-5704-aa73-ad740c5a1577		169654840		0b24dfdc47d0fded836c193f3c95a8cfe4c1716a0d999918486f03b7d438df76		DDA_Inclusion06.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac	fc4eb35a-fbd9-5eac-856f-655d1e171a2a		168923902		598d473e77303abbaa5c80d25705c47d6b2c4a93d81d0bbb6a7b9bf10f06a629		DDA_Inclusion07.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t59-kidney/metab-u-lrppos/DDA_Inclusion08.raw	tag:motrpac-data.org,2023:	motrpac	9d05fb06-e704-5778-868f-421706fbfa15		167516868		985a1d2f3f8733fe5203610f9c5849691da1c2746a7b27402c1447372304cba2		DDA_Inclusion08.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	202c516d-71e3-51a2-a708-38c0348b071d		357861629		35fdbc93d7616ea8e1983207599b3266c2007b12840cffc4c3e537259de29126		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	20048080-ce42-5547-8db3-12c61eb9fa17		356661371		cfd733791b72b12682a49db7384d50174c63831d38915296ce1f3f8eccd1f04a		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	d1620041-f072-5faf-ae73-47076ffe5750		352538102		5ae47ba02993d2dd90eb26affc2beec8d9a8fa7b9cf53e8629a42313fe8c66a4		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrpneg/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	3db906e9-269a-5665-b2fd-2e8cd9db6c73		354068546		d3911ac1b5ea806af41ae73d2c9556514928c8bc6cb44c6e1a06e92713266a63		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	d4634574-c339-5c54-8003-76ac522c20d2		202021146		941ad013572774864d0975068cbd1f1a21d153c7068a6551d1a3b893afdb8e4f		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	9d621341-133a-55f8-ad1f-42c12a8a9d02		197857031		999942ed0383529366c1ab167e8feeaa143c6b22355ad07e485cd7345aeec81e		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	22814eae-6393-5216-98ac-96159050ddbb		200956232		df9d1c9f120c569d1d5e00026d23466a73cb2f15e61647dae2b1f5960bdece55		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	b3a9ccb2-3f3e-5824-9328-4e98a6cec183		199963253		b146f4ade5099d7405bef24ff0c47233d201a92328c2e4771f88394c2485ef2a		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	3482fba7-8e66-5e8e-9103-d5802ea147e7		199240539		240d5a970029260fa6af2ecf437fb8f2538073c6be206ad7bba1a8394eb1d87c		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac	2b20ef76-631f-5fb9-9722-dec9729c4b4d		201839521		43ea2272698fe942d16014ad62373a82d89410241450b99f2ac22a0f09056e08		DDA_Inclusion06.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t66-lung/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac	866979b1-63ee-5c45-8c65-e32be0383910		200305060		68e068c3c3a4cc0be6cc54777cc08c3de47f5469d611ca6306d168effddb2866		DDA_Inclusion07.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	7c535b1f-19ae-5d17-b6d6-aa11434324da		353513508		280da4a83fccb133c482afa9f9b7048488f71aa40a5ef20f778ff1fd4f75d5bf		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	ae99e909-f2ee-56d6-8ae5-fec73171aedd		354397110		7bb9247721b9aad5fd11bf86640ca8a9d3226ce1b83e90b05babc711b0e59506		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	bf8f9655-fa1e-5bdc-a9d1-a2190ee9b422		170234458		87bc77df6996142a7f8e8994dc12c468d5a9aaaeff2bc9342c6b0610f23468a8		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	1cbed08b-150b-5c14-9517-a1b0641854da		172979087		e965459db0df83632df6b083e696b193f6c915e0f6fe5a45bdc214fa3a176915		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	6ca540a6-b1c8-5265-89cc-a8720946eca3		170551321		c4113822d9eb9ba4c47e9a2284ecdac813677635336f279fcd26d35b80f1bc38		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	bb5b3249-fdf2-5d72-afa3-3117347fa5f0		171775406		7101e9f7bbdcd667b850d07eaf88f4027789a9db828ca6f9d66916ad43a32981		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	17a9e54d-f6e2-5093-b4ff-7d85a6ceaa64		172315666		99a282493be5fbdf4f3322f1597418322a95e3f7785487ef46458c58eae211ce		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac	f4673797-e374-5cd9-9725-7346745d6ae6		171853757		8c0ab303979bece9974984e4b8834c05647ac6190f30487f6d713bb9d50d5585		DDA_Inclusion06.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac	45fe54f7-71b2-5393-b503-3cae17d63536		172579360		e24f2f8f1463bec9221b0d17dc46b916af18edd88e10934e36f7e7bb9e341f34		DDA_Inclusion07.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t68-liver/metab-u-lrppos/DDA_Inclusion08.raw	tag:motrpac-data.org,2023:	motrpac	dccba3e3-bb80-547b-a80e-c6273a4058cb		173700712		fcc527fc065a1fe182c9958ee2900241c513291bee4d3c0a01b35d8c24cd8e83		DDA_Inclusion08.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	027dbf94-69f3-5738-b4d1-68ad63a59cce		377582986		f35185f00bc45b23bcbf4daddfe7d8f8577874f81acf9ea5dffc28446b9b5a6f		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	5658e175-b1eb-5456-91b1-1d4843f07e80		376520910		a6932da9b8c925ce59974442e3ab290e7f7a9ec5f175aacd31579643a760b3b0		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	735d8bf1-6b62-5449-8f06-2aabde3ff2f6		161113250		123021f01914bdadf63fc5c3f866a0c20a02a095767855370573782fedf517f7		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	5f816f7e-a501-5051-8b22-bca4cbc74507		159947819		49c59f0f3814c430516659140342c31e53f6382a4467f97a6a8626061fc54311		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	e7c424de-a5ef-5c77-89a4-2b423e9aa82e		158933308		da42977c62c120aa8cb882c1f8b07add7e84f3359da355020c55f09db35b5e2b		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	c60af9c2-7a7f-546d-a020-373fcc35514e		163934029		642b8dbf3b9db928272886128148ee958a0e904fd531b6a11138a906865c6dcf		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	e8d73be6-1057-5cb7-9836-598065686f47		162732594		84196ee1a64715ca6fb2800dfa158565ae91cba53210c1173308294a809908ce		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t69-brown-adipose/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac	9d2f8032-4f61-54fc-b53a-2f877e1f4827		163606411		6b20cedb191e74438560426ce94d7603ad4065b9f494c15e67ca37945f757472		DDA_Inclusion06.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrpneg/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	069ee303-6251-5c93-9c84-d23e9eed4032		386262638		fb75898e5d39787348d9cd77a81d5bc477c57f104ced25434592e3ad805bd80d		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrpneg/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	1c05b905-1007-5e5c-beeb-5151421f7e33		385641552		34adaca2d338045d8253e053b151ac65454afdc3f3afb49db97c82097c72792a		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrpneg/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	363fae39-c260-54be-a63f-06536c6a4d37		389111245		f07647db51eea13a1230c990479bb061c24742b55903f60204d656e060a99534		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion01.raw	tag:motrpac-data.org,2023:	motrpac	8c2a09de-5ec8-5396-b379-a37b59d74c00		209196730		02582ffaca2f7bca5e3852321e4d2e0efc5f0d2e85a482bc2e407d5ec6dd2203		DDA_Inclusion01.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion02.raw	tag:motrpac-data.org,2023:	motrpac	ce06ce04-390d-5a4f-b48b-5e693de4c28c		211663643		32d60829ff1088d8b062b0695b379f35e598b876c97336ff656faa8e5b587809		DDA_Inclusion02.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion03.raw	tag:motrpac-data.org,2023:	motrpac	6c651669-494f-5c3a-983e-72b719e61056		207323679		0b01f1aa6e0f269164317abc866207b7f2cf37fb343d1ca262e57873932c727c		DDA_Inclusion03.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion04.raw	tag:motrpac-data.org,2023:	motrpac	9588575c-31ab-589f-a629-611f2e7f263e		209031714		ab11967a82e9753c09f3b8ed0cfcf2f636b6abdf8a1972b310df1b6e305daca7		DDA_Inclusion04.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion05.raw	tag:motrpac-data.org,2023:	motrpac	4d2fa2e3-01ec-548f-bc5c-e251a23feb18		209117047		3970494301f31e639a5c8e8257bcf6a82c2d1dd2e2d0f59a0e002484e90f9644		DDA_Inclusion05.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion06.raw	tag:motrpac-data.org,2023:	motrpac	fd30dca8-3ecc-5bea-be9f-bc2f50631911		210609918		8facbd3b649df4703facd6c09d0b05026d28bf9239cbf0bba32ee36b2595678f		DDA_Inclusion06.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/MoTrPAC/datapackage/submit_03_15_2024/data/file.tsv:tag:motrpac-data.org,2023:	pass1b-06/metabolomics-untargeted/t70-white-adipose/metab-u-lrppos/DDA_Inclusion07.raw	tag:motrpac-data.org,2023:	motrpac	0392c149-c720-5516-bc1a-26e1e33bffc3		211846428		01a1ed9693e7d9db41806a51c6e017dbfd31cec1e929c4a41fcfe51f891efab5		DDA_Inclusion07.raw				OBI:0000366		application/octet-stream			
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/file.tsv:SPARC.file:	package:707c987a-6323-48df-8942-522c21794018	SPARC.project:	OT2OD023848	sparc.drs:package/707c987a-6323-48df-8942-522c21794018	2022-12-13T15:43:03+0000	253124	253124	6fda50827b5e15ae34e9d290df28c34048a0461f31b5bed3a628893b45468b7d		derivative__DiffExp_Gender.pdf	format:3547		data:2968	OBI:0002119		image/jpx				https://services.scicrunch.io/sparc/drs/v1/package/707c987a-6323-48df-8942-522c21794018
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/project.tsv:SPARC.project:	OT2OD024899	https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=OT2OD024899		SPARC_OT2OD024899	Comprehensive structural and functional mapping of mammalian colonic nervous system	"The colon is the site of a multitude of disorders which are leading causes of morbidity and mortality and of significant financial burden. The colonic intrinsic (enteric) and extrinsic innervation play crucial role in regulating the secreto-motor, endocrine, immune functions and pain sensation. There has been increasing understanding of the neurochemical and electrophysiological properties, cell physiology, and functional roles of colonic enteric neurons and their interaction with the parasympathetic, sympathetic and sensory systems during the past decades. However, these data are derived largely from small animal studies and relevant knowledge in large animals and humans is lagging, which has hampered the development of effective therapies. Recent advances in cutting edge approaches including 3-D mapping, innovative viral tracing tools, and neuroimaging provide a means to obtain detailed information on neural circuits and related functions in large animals and human tissues, which has never been achieved before. The overall objective of the proposal is to provide a comprehensive and detailed structural and functional mapping of the intrinsic and extrinsic innervation of various regions of the colon in humans and the pig, as a relevant large animal model based on its structural and physiological similarities to humans. Mice will be utilized for studies involving transgenic, optogenetics and viral tracing approaches. This objective will be achieved by a concerted effort of world expert investigators who developed state-of-the art neuroanatomical, molecular, electrophysiological and functional approaches. Preliminary data obtained by the consortium team showed the feasibility to use CLARITY, high resolution confocal microscopy, viral tracing and optogenetics to provide detailed mapping of extrinsic nerve fibers, enteric circuitries and the expertise to probe human colonic enteric neurons electrophysiologically by fast and high resolution neuroimaging. In addition, the design of new microelectrode array and fiber optic technology has allowed quantifying motor patterns in response to nerve stimulation at a resolution level not attained before. The combined effort and multidisciplinary approaches will fill the gaps in current knowledge on colonic intrinsic and extrinsic neuronal circuits and cell-cell communication, especially in human tissues and pig, a large animal model ideally suited for translational applicability to patients. These findings will set the foundation for understanding neurocircuitry in this organ and will be critical for potential electroceutical interventions to treat colonic disorders."
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/project.tsv:SPARC.project:	OT2OD023853	https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=OT2OD023853		SPARC_OT2OD023853	Foundational tools to study the impacts of sympathetic activity on the neuroanatomy and function of brown adipose tissue	"A growing body of evidence supports the idea that brown/beige adipose tissue (BAT) contributes to basal metabolism in adult humans, and that diminished BAT activity can lead to obesity. Sympathetic nerve stimulation increases BAT activity in rodents. Reports that signaling from the stellate ganglion (SG) modulates thermogenesis in humans, raises the possibility that minimally-invasive approaches to stimulate sympathetic projections from the SG to supraclavicular BAT (scBAT) have potential as an anti-obesity therapy. The neuroanatomy of the SG is complex, because sympathetic and sensory neuronal axons leave the ganglion through 6-8 different exit points to reach a wide variety of targets in the periphery. For neuromodulation of SG projections to BAT to have clinical applications, it is essential that stimulation protocols avoid projections from the SG to the heart and upper extremities. In theory, this can be achieved by physically focusing the electrical stimulus to SG neurons as they exit the SG or enter the scBAT depot. Alternatively, genetic approaches could be used restrict pharmacological manipulations to the subpopulation of SG neurons that innervates BAT. These complementary studies in mouse models and human tissue samples will serve as the basis for deciding which of these strategies are viable therapeutic options. The proposed studies are designed to fill critical information gaps and to develop tools needed for comprehensive mapping of neural circuits regulating BAT and to explore the potential use of BAT neuromodulation as an anti- obesity therapy. Studies in Aim 1 will use combinations of transgenic mouse models and fluorescent neuronal tracers to determine whether there is any physical overlap between BAT and forelimb-projecting soma within the SG or their exit points out of the SG. In parallel, we will perform the first mapping studies of the projections from the SG to scBAT in human autopsy specimens. A major obstacle to studies to modulate or record neural activity in the SG is that this ganglion contains many different types of afferent and efferent neurons that regulate a wide range of physiological functions. Studies in Aim 2 will define molecular markers for distinct subpopulations of SG neurons that project to BAT and heart. Then we will determine whether any of these markers are conserved in human surgical samples. Finally, studies in Aim 3 will establish systems to evaluate the impact of neuromodulation on the organization of sympathetic fibers in conjunction with well-established assays to measure BAT oxidative capacity and activity. To aid these efforts, we will develop techniques to image sympathetic projections in an intact BAT depot. In addition, we will validate key in vivo assays needed to assess the impacts of neuromodulation on BAT function that can be readily translated to humans. In addition to impacts on the BAT field, these studies will also provide a strong foundation for future efforts to understand how existing SG neuromodulation therapies have beneficial effects on a wide range of conditions that are refractory to other treatments, including ventricular tachycardia, chronic regional pain syndrome and post-traumatic stress disorder."
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/project.tsv:SPARC.project:	U01NS113871	https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=U01NS113871		SPARC_U01NS113871	Structural and functional mapping of visceral pain afferent neurocircuitries of the colorectum and bladder in preclinical models	"Irritable Bowel Syndrome (IBS) and interstitial cystitis/painful bladder syndrome (IC/PBS) are common chronic visceral pain disorders that affect the colon and bladder respectively. Both conditions pose significant health and financial burden. Notably, IBS and IC/PBS present with considerable overlapping symptoms, whilst individual patients can suffer from both disorders concurrently. The colon and bladder cross-sensitize and share spinal innervations. However, despite increased understanding of their symptomatology and the role of pain afferents in their pathophysiology, there are no effective therapies. The few pharmacological drugs including opioids have significant adverse effects. Current barriers to the development of effective therapies for IBS and IC/PBS include: a) Inadequate structural and functional knowledge on the dichotomizing dorsal root ganglia (DRG) neurons of the distal colon and bladder. b) The lack of adequate investigation on sex differences in cross-organ sensitization, despite the prevalence of both conditions being higher in women than in men (female to male ratio: 2:1 for IBS, 5-10:1 for IC/PBS) c) Lack of knowledge of the sensory afferent innervation and cross-organ sensitization in species with higher translational relevance to humans. We propose to address these gaps through concurrent monitoring of the colon and bladder pain circuitries in two pre-clinical models and under 3 specific aims. 1): Structural mapping of colon and bladder pain afferent neurocircuits: Dichotomizing and non-dichotomizing neurons, their spatial distribution and connectivity. 2): Functional characterization of colon and bladder afferents in acute and chronic models of cross-organ sensitization and 3): Map spinal sites of colon and bladder pain and cross-organ sensitization through neuromodulation. We will use acute and chronic cross-organ sensitization models, state-of-the-art high- resolution imaging, 3D mapping, dual retrograde tracing of bladder and colon sensory neurons, CLARITY, ex vivo DRG Ca2+ imaging of dichotomizing neurons, ex vivo electrophysiological recordings from bladder and colon afferents and transcutaneous spinal stimulation (TSCS) approaches. The murine model will unravel the classes of pain afferents/neurons and their functional circuits in bowel-to-bladder and bladder-to-bowel acute and chronic pain cross sensitization. The porcine studies will provide novel information on the structural map of the colon and bladder dichotomizing neurons and their connections as well as cross sensitization of pain responses. It will also allow us to gain insight on the use of TSCS to map spinal cord circuits and backtrack colon and bladder pain circuits and its translational feasibility for human use. The combined multidisciplinary approaches will fill the gaps in current knowledge on the colon/bladder dichotomizing DRG neurons, spatial distribution and connections as well as the plasticity in the pain circuitries post sensitization. Our findings will contribute to the foundation for understanding colon and bladder neurocircuitries that will be critical for urgently needed drugs and/or neuromodulator therapies for chronic visceral pain syndromes such as IBS and IC/PBS."
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/project.tsv:SPARC.project:	OT2OD024909	https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=OT2OD024909		SPARC_OT2OD024909	Optical Nanosensors Detect Neurotransmitter Release in the Peripheral Nervous System	"Recent converging evidence suggests that communication between the immune system and the brain is critical for controlling inflammation. The brain receives information in response to injury induced inflammation in the periphery which in turn initiates a reflex mechanism to suppress immune responses. The resulting neuroendocrine reflex plays an important regulatory role in the immune system. These bidirectional brain-peripheral immune communications operate reflexively, in a closed feedback loop whereby neural circuits can exert significant influence to modulate inflammation. However, the specific mechanisms underlying this brain-immune signaling are largely unknown. Therefore, understanding the distinct molecular and neurophysiological mechanisms that govern these complex pathways is critical, which motivates us to develop new approaches to accurately detect and monitor these changes. We will develop nanosensors for the detection of neurotransmitter release in the peripheral nervous system of axolotls (regenerating salamanders). Our nanosensors are based on a modular platform that can easily be tuned to an appropriate dynamic range, wavelengths for tissue penetration, and size to be compatible with the in vivo environment. The juvenile axolotl is highly transparent and nanosensors injected into the nervous system or organs will be imaged using light sheet fluorescence microscopy. In addition, we have the ability to genetically modify the system to develop a transgenic model that can be stimulated with light to target neuronal excitations, while simultaneously measuring neurotransmitter levels via the fluorescence emitted from the injected nanosensors. Combined, we will image volumetric release of acetylcholine in the peripheral nervous system and spleen of the axolotl, and will translate these results to a mammalian model by the end of the project period."
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/project.tsv:SPARC.project:	U01NS113869	https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=U01NS113869		SPARC_U01NS113869	Mapping gut-spinal cord connections in visceral pain	"Project Summary/Abstract Our current understanding of mechanisms underlying visceral pain, including that associated with irritable bowel syndrome, remains rudimentary. Importantly, opiates are ineffective at treating visceral pain syndromes, and only exacerbate discomfort by producing constipation, reflecting a clear need for alternative treatment options. The goal of this proposal is to bring greater mechanistic insight to this underserved area of pain research, and to approach the problem in a multifaceted strategy designed to maximize the relevance of our basic research discoveries to future pain treatments. Here, we will ask how enterochromaffin (EC) cells transmit noxious signals from the gut lumen to the spinal cord. EC cells are key sensory cells in the intestinal epithelium that release serotonin onto primary sensory nerve fibers, thereby evoking a sensation of discomfort and pain in response to luminal irritants, such as bacterial metabolites, inflammatory agents, or ingested chemicals. The goals of this collaborative effort are to use activating and silencing approaches to examine functional connections between EC cells and sensory nerve fibers. We will couple these methods with transcriptome profiling, viral tracing, and electrophysiological methods to gain insights into the molecular and functional identity of these fibers. Another key goal is to determine whether EC cell signaling pathways exhibit sex-specific differences, an important question that may relate to the higher prevalence of GI visceral pain syndromes experienced by women. Our team brings an unusually wide ranging and innovative approach to this area of pain research that includes expertise in the neurophysiology, pharmacology, and anatomy of nociceptive and pain circuits, visceral tissue anatomy and development, and relevant clinical experience. This knowledge base is supported by complementary technological approaches that will enable us to connect molecular and mechanistic insights to physiology, visceral nociception, and disease. Our focus on the epithelial-nociceptor connectome highlights EC and other enteroendocrine cell types as potentially powerful control points for neuromodulation of visceral discomfort and pain. A comprehensive functional, pharmacological, genetic and anatomical characterization of EC-primary afferent-spinal circuits is an essential first step toward achieving this important goal. As such, our research program fits squarely within the SPARC mandate to transform our understanding of peripheral nerve-organ interactions and advance strategies for controlling organ system function."
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/project.tsv:SPARC.project:	OT2OD24899	https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=OT2OD024899		SPARC_OT2OD24899	Comprehensive structural and functional mapping of mammalian colonic nervous system OT2OD24899	"The colon is the site of a multitude of disorders which are leading causes of morbidity and mortality and of significant financial burden. The colonic intrinsic (enteric) and extrinsic innervation play crucial role in regulating the secreto-motor, endocrine, immune functions and pain sensation. There has been increasing understanding of the neurochemical and electrophysiological properties, cell physiology, and functional roles of colonic enteric neurons and their interaction with the parasympathetic, sympathetic and sensory systems during the past decades. However, these data are derived largely from small animal studies and relevant knowledge in large animals and humans is lagging, which has hampered the development of effective therapies. Recent advances in cutting edge approaches including 3-D mapping, innovative viral tracing tools, and neuroimaging provide a means to obtain detailed information on neural circuits and related functions in large animals and human tissues, which has never been achieved before. The overall objective of the proposal is to provide a comprehensive and detailed structural and functional mapping of the intrinsic and extrinsic innervation of various regions of the colon in humans and the pig, as a relevant large animal model based on its structural and physiological similarities to humans. Mice will be utilized for studies involving transgenic, optogenetics and viral tracing approaches. This objective will be achieved by a concerted effort of world expert investigators who developed state-of-the art neuroanatomical, molecular, electrophysiological and functional approaches. Preliminary data obtained by the consortium team showed the feasibility to use CLARITY, high resolution confocal microscopy, viral tracing and optogenetics to provide detailed mapping of extrinsic nerve fibers, enteric circuitries and the expertise to probe human colonic enteric neurons electrophysiologically by fast and high resolution neuroimaging. In addition, the design of new microelectrode array and fiber optic technology has allowed quantifying motor patterns in response to nerve stimulation at a resolution level not attained before. The combined effort and multidisciplinary approaches will fill the gaps in current knowledge on colonic intrinsic and extrinsic neuronal circuits and cell-cell communication, especially in human tissues and pig, a large animal model ideally suited for translational applicability to patients. These findings will set the foundation for understanding neurocircuitry in this organ and will be critical for potential electroceutical interventions to treat colonic disorders."
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/project.tsv:SPARC.project:	U01NS113868	https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=U01NS113868		SPARC_U01NS113868	Comparative mapping of functionally distinct visceral afferent nociceptive pathways	"Visceral pain is a common, often debilitating and treatment-resistant condition. In order to overcome major obstacles hampering the study of visceral pain, we have devised an alternative approach to identify the pain pathways using novel transgenic and viral vector tracing strategies. We expect that our findings will spur the development of more effective therapies for visceral pain."
ingest/c2m2s/SPARC/C2M2_datapackage_20251215/collection.tsv:SPARC.collection:	N:dataset:21957eae-0824-4fb5-b18f-04d6ed12ce18	https://doi.org/10.26275/advv-1awo		advv_1awo	Spatially tracked single-neuron transcriptomics of a male porcine right atrial ganglionic plexus (RAGP)	Animal study (C57BL/6J background transgenic mice) to determine the involvement of the superior mesenteric ganglion in the cholinergic anti-inflammatory pathway using optogenetic activation or blockade.	
ingest/c2m2s/4DN/251215_4dn_c2m2_submission/251215_4dn_c2m2_submission/project.tsv:https://data.4dnucleome.org	ef637c2d-7e48-4e26-aad2-eac1f680d4e8				1U01DK127422-01 - Andrew Belmont	IDENTIFICATION OF THE ACTIVE NUCLEAR NICHE(S) USING NOVEL PROTEOMIC, GENOMIC, TRANSGENIC, AND LIVE-CELL MICROSCOPY TECHNOLOGIES
ingest/c2m2s/4DN/251215_4dn_c2m2_submission/251215_4dn_c2m2_submission/file.tsv:https://data.4dnucleome.org	97b6e4d6-59dd-4fb5-936f-ad295e77a80a	https://data.4dnucleome.org	12a92962-8265-4fc0-b2f8-cf14f05db58b	https://data.4dnucleome.org/4DNFID4LGBT1	2019-10-11	122396429			67ed7d92e0c672b443bdfc425c1db78f	4DNFID4LGBT1.fastq.gz	format:1930		data:2887	OBI:0003306		application/gzip				drs://data.4dnucleome.org/4DNFID4LGBT1
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_readCounts_gencode_antisense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		9342	c9513779af7a75b00f586089a632b71f2ee2569f083fc6704b2ce6391eab9bb6		readCounts_gencode_antisense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_endogenousAlignments_genomeMapped_transcriptome_Aligned.out.sorted.bam.coverage.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		408550	af3f79fb46d946d9467cb6a0a68a826a4667c9a62a9a7ef9f7f02bee0d5dd914		endogenousAlignments_genomeMapped_transcriptome_Aligned.out.sorted.bam.coverage.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_ExogenousGenomicAlignments.result.taxaAnnotated.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		29557	8a1837e125b4c25960a4f265b412a636889b9d1b93d9848643d62bba12da32af		ExogenousGenomicAlignments.result.taxaAnnotated.txt	format:3475		data:2048	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_readCounts_miRNAmature_sense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		284	d2b609c569c41257e444fb165a04125f512928637c904c893af1b72b19452ac1		readCounts_miRNAmature_sense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_endogenousAlignments_genome_Aligned.out.bam.CIGARstats.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		2074	eae3b75fbabed7bdfe5ef364cc47925489084ea2c3c9ddf0458cde602ea5f5e4		endogenousAlignments_genome_Aligned.out.bam.CIGARstats.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_sample_IG_S48_M_R1_001_fastq.adapterSeq	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		34	efc40cccfd4ccd250826d9c8029e39f3289081d4c568482260f28bbcad239076		sample_IG_S48_M_R1_001_fastq.adapterSeq	format:3475		data:2048	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_readCounts_tRNA_sense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		2810	7d57715530a37db22637341407252592cf91da53a11836594a9b3ba2dc3fbdc0		readCounts_tRNA_sense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_ExogenousRibosomalAlignments.result.taxaAnnotated.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		3689	675f813e5c0f3d55c452db0f862ad362a45e2e695e0480e7940bbfffd8c49dc1		ExogenousRibosomalAlignments.result.taxaAnnotated.txt	format:3475		data:2048	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_readCounts_gencode_antisense_geneLevel.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		1129	71a8414fe79181fb8c8489bd2a1776d708bac30dc1bfe197c403a2a283ccb712		readCounts_gencode_antisense_geneLevel.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_readCounts_gencode_sense_geneLevel.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		8668	3f15cf4301589bd053200b936e5b42244ab26018d010b9abd3315055216848b3		readCounts_gencode_sense_geneLevel.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_readCounts_gencode_sense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		55414	709495f19d21761f3e2844f99b242e8377b3074872947d59c68b8e661a3b8803		readCounts_gencode_sense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_endogenousAlignments_genomeMapped_transcriptome_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		11556	8dbd99d4956c29ae4990b83232b788012412b363eeffc739e474d8df409a32de		endogenousAlignments_genomeMapped_transcriptome_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_filteringAlignments_rRNA_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		2900	8f36cd219beaf66f3fe4a8276535d2882525e49ac01cbb7745720e375aaa7afb		filteringAlignments_rRNA_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_endogenousAlignments_genomeUnmapped_transcriptome_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		2732	f3b816db324662bba6e06840d153174f7e1ba962f06ea2da37dacc8038b0c08a		endogenousAlignments_genomeUnmapped_transcriptome_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_endogenousAlignments_genome_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		5852	9184b85ab2ae2895257bb2b68b66a079991dc4d8ab700526f46d5ac06f2aa82c		endogenousAlignments_genome_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS_endogenousAlignments_genome_Aligned.bedgraph.intersect_RBP_all_combined.bed.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		7624248	24a52c5e944663e2a2c14c8d29436b894d26827ad073ea55f95fc86542d4a57b		endogenousAlignments_genome_Aligned.bedgraph.intersect_RBP_all_combined.bed.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_readCounts_miRNAmature_sense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		722	c9dd190a0768a7d458892964c14364c9acd2eb63f668b154de317adaa10c2f51		readCounts_miRNAmature_sense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_ExogenousRibosomalAlignments.result.taxaAnnotated.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		4913	eb506852abc64e60982fac601d8d14bdab0ef6d3516dcfffec8622c6b691ceac		ExogenousRibosomalAlignments.result.taxaAnnotated.txt	format:3475		data:2048	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_readCounts_gencode_antisense_geneLevel.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		1283	8133c410d80c2deefaf8943946adbae587d3785a6ea6ec80aa80152f5e2d72b0		readCounts_gencode_antisense_geneLevel.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_endogenousAlignments_genome_Aligned.out.bam.CIGARstats.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		2087	aaa49b6fa3619f541cf9944ec1fc38d28fe91a95b7df8d930a1844b1d883c5eb		endogenousAlignments_genome_Aligned.out.bam.CIGARstats.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_readCounts_gencode_antisense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		7478	32efcf3ca486646c8483f2a0ed68f50dad2fe868bb7c75dcb649028369ed1d64		readCounts_gencode_antisense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_endogenousAlignments_genomeMapped_transcriptome_Aligned.out.sorted.bam.coverage.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		300628	524f5e263fa37c488e6d22d5fd052c0c0875d823d747d6ff2f89b2ee41950553		endogenousAlignments_genomeMapped_transcriptome_Aligned.out.sorted.bam.coverage.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_readCounts_piRNA_sense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		182	f8a6bc2c1c8a711e76b88f4408ec1c60dfa55a1c24cb4cfaee9f87b59cf9c45c		readCounts_piRNA_sense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_sample_IG_S47_F_R1_001_fastq.adapterSeq	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		34	efc40cccfd4ccd250826d9c8029e39f3289081d4c568482260f28bbcad239076		sample_IG_S47_F_R1_001_fastq.adapterSeq	format:3475		data:2048	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_readCounts_tRNA_sense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		1660	5f4cf5b24eabe8dd88e5ae9a564701a017f92195e3dda1883fed0deb041c62af		readCounts_tRNA_sense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_readCounts_gencode_sense_geneLevel.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		9737	5f50f127c74f52893b655d68a96fc2060f49220bb0a639ab61360a18a374a4e5		readCounts_gencode_sense_geneLevel.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_ExogenousGenomicAlignments.result.taxaAnnotated.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		29989	5a96839eb86900d973f84d0798d4789f41a77d894e1f635ae53027946db961ec		ExogenousGenomicAlignments.result.taxaAnnotated.txt	format:3475		data:2048	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_readCounts_gencode_sense.txt	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		48318	d0b4956c4b291242a475465cd5b4d798832b20641386f6acb1748cceddc969de		readCounts_gencode_sense.txt	format:3475		data:2082	OBI:0002112	OBI:0001872	text/plain				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_endogenousAlignments_genomeMapped_transcriptome_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		13296	8d86f6a202e7fe8d0786489725d11969800a6d69d6cc56afcaffb2992f8adda3		endogenousAlignments_genomeMapped_transcriptome_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_filteringAlignments_rRNA_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		3300	42e3ca0fd74166fc1f9534f8c21de959e0c76e45bedc745f47d909e5f3a1dc01		filteringAlignments_rRNA_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_endogenousAlignments_genomeUnmapped_transcriptome_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		3128	7943a6d4fb1281b808cb408dd26ec097c09b41e78dda12723f8e65f7baaafcbd		endogenousAlignments_genomeUnmapped_transcriptome_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_endogenousAlignments_genome_Aligned.bedgraph.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		9416	485acb27a9335bf92263efe708cb5ddf48173ba02c6b9343190bc5a420c728a5		endogenousAlignments_genome_Aligned.bedgraph.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/file.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS_endogenousAlignments_genome_Aligned.bedgraph.intersect_RBP_all_combined.bed.xz	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20		7632868	ad02639a9026ace73e795442323affa34fc0bc8f9fdd0a1a50e5ebfc7ff18297		endogenousAlignments_genome_Aligned.bedgraph.intersect_RBP_all_combined.bed.xz	format:3475	format:2333	data:2082	OBI:0002112	OBI:0001872	application/xz				
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/collection_defined_by_project.tsv:ERCC-exRNA	EXR-IGHIR1GUqJ5l-AN	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/project.tsv:ERCC-exRNA	EXR-DERLE1LLAURPLATCOMP-ST		9/4/20	DERLE1LLAURPLATCOMP	Small RNA-sequencing of maternal and non-maternal plasma	"Given the increasing interest in their use as disease biomarkers, establishment of reproducible, accurate, sensitive, and specific platforms for microRNA (miRNA) quantification in biofluids is of high priority. We compared four platforms for these characteristics: small RNA-seq, FirePlex, EdgeSeq, and nCounter. Using a pool of synthetic miRNAs, coefficients of variation for technical replicates for EdgeSeq (6.9%) and RNA-seq (8.2%) were lower than FirePlex (22.4%); nCounter replicates were not performed. Receiver operating characteristic analysis for distinguishing present versus absent miRNAs showed small RNA-seq (area under curve 0.99) was superior to EdgeSeq (0.97), nCounter (0.94), and FirePlex (0.81). Expected differences in expression of placenta-associated miRNAs in plasma from pregnant and non-pregnant women were observed with RNA-seq and EdgeSeq, but not FirePlex or nCounter. These results indicate that differences in performance among miRNA profiling platforms impact ability to detect biological differences among samples, and thus their relative utility for research and clinical use."
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/project.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20	IGHIR1IGHIRANGenderPool1	Feb2017_GenderPoolPlasmaRNA	exRNAs profiles by sex in healthy individuals
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/biosample.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPM02032017-BS	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20	OBI:0001902	UBERON:0004535	UBERON:0006530
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/biosample.tsv:ERCC-exRNA	EXR-IGHIR1IGHIRANGPF02032017-BS	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST		4/20/20	OBI:0001902	UBERON:0004535	UBERON:0006530
Binary file ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/C2M2_datapackage.sqlite matches
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/disease.tsv:DOID:12217	Lewy body dementia	"A dementia that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities that has_material_basis_in accumulation of alpha-synuclein, SCNA, (protein). The causal mutation might be in SCNA or SCNB or some other gene(s) but the end result is always accumulation of SCNA in Lewy bodies."	"[""Dementia with Lewy bodies"", ""Diffuse Lewy body disease"", ""Lewy body disease"", ""Senile dementia of the Lewy body type""]"
ingest/c2m2s/ExRNA/exRNA_CFDE_102025/exRNA_CFDE_102025/project_in_project.tsv:ERCC-exRNA	exRNA_Atlas	ERCC-exRNA	EXR-IGHIR1IGHIRANGenderPool1-ST
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000007	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000007		SCGE18000000007	Testing AAV5 for activation of tdTomato in HEK293T cells (SCGE:18000000007)	AAV shuttle plasmids expressing SpCas9 and guide RNAs targeting the Ai9 transgene were tested in HEK293T cells by transient transfection. Both delivery and gene editing were detected by fluorescence.
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000011	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000011		SCGE18000000011	Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain. (SCGE:18000000011)	Nanocapusules carrying CRISPR Cas9 RNP with guide RNA targeting the stop sequence in the Ai14 transgene are intracerebrally delivered to Ai14 mice and gene editing is measured by gain of tdTomato protein expression.
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000012	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000012		SCGE18000000012	Testing AAV5 for activation of tdTomato in mouse airway (SCGE:18000000012)	AAV2/5 mediated gene editing in the mouse airway was tested by deliverying SpCas9 and guide RNAs targeting the Ai9 transgene in Ai9 transgenic mice. Viral delivery was detected by GFP expression and gene editing quantified by tdTomato activation
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000017	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000017		SCGE18000000017	Testing newly chemically modified crRNA and tracrRNA to activate the TLR reporter in human cells (SCGE:18000000017)	Chemically modified crRNA and tracrRNA were delivered by electroporation in presence of amphiphilic peptide to transgenic human HEK-293T cells harboring the TLR-MCV1 reporter. Gene editing was determined by reporter activation.
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000019	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000019		SCGE18000000019	Testing newly chemically modified crRNA and tracrRNA to activate the TLR1 reporter in human cells (SCGE:18000000019)	Chemically modified crRNA and tracrRNA were delivered by electroporation to transgenic human HEK-293T cells harboring the TLR1 reporter. Gene editing was determined by reporter activation.
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000022	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000022		SCGE18000000022	Selection of gRNA sequences and gRNA scaffold modification lead to improved editing of the Ai9 locus in vitro (SCGE:18000000022)	Reporter transgene activation by SaCas9 gRNA target and modified scaffold sequences by transient transfection in immortalized Ai9 mouse fibroblasts
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000069	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000069		SCGE18000000069	Testing AAV5 for activation of tdTomato in mouse airway club and ciliated cells (SCGE:18000000069)	AAV2/5 mediated gene editing in the mouse airway was tested by deliverying SpCas9 and guide RNAs targeting the Ai9 transgene in Ai9 transgenic mice. Gene editing quantified by tdTomato activation and cell specific markers for club and ciliated cell types.
ingest/c2m2s/SCGE/scge_cfde_submission_20251016_143304/project.tsv:scge.mcw.edu	SCGE:18000000097	https://scge.mcw.edu/toolkit/data/experiments/experiment/18000000097		SCGE18000000097	Delivery of saCas9 and gRNAs to nephron epithelia by AAV2 in kidney organoids. (SCGE:18000000097)	An AAV2 viral vector carrying SaCas9 and AAV2 vector expressing mCherry and carrying two gRNAs against the DMD gene were used in human kidney organoids to assess transgene delivery to nephron epithelia. Organoids were treated with both AAVs at MOI 10^5 for one week. Delivery of Cas9 and gRNA vectors to nephron cell types were evaluted by immunohistochemistry.  Note: additional data not shown demonstrated mCherry and SaCas9 were not detectable in non-transduced cells.
